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Introduction 
Despite tremendous recent advances in the clinical neurology, neurobiology and 
epidemiology of Alzheimer's disease, the cause as well as its treatment remains as 
much a mystery today as when it was first described in 1907 by Alois Alzheimer.' 
Alzheimer's disease, the most common type of dementia in the elderlf and already 
referred to as the disease of the century, is one of the major social and medical 
challenges for clinical practice as well as for scientific medicine, especially since the 
number of Alzheimer patients is predicted to rise strongly into the next century.3 
Studies presented in this thesis deal with issues that confront patients suffering 
from Alzheimer's disease and their families and caregivers every day: the uncertainty 
of the clinical diagnosis and the lack of adequate treatment The focus will be on 
single photon emission computed tomography (SPECT) as a method to assess 
regional cerebral blood flow (rCBF), its methods of analysis and the contribution to 
the clinical diagnosis. In addition, aspects of two therapeutic strategies will be 
explored: stimulation of neuronal metabolism and modulation of neurotransmitter 
dependent processes. Much of the work presented is guided by epidemiological 
principles and methods. This coincides with the clinical neurological point of view 
that is a leading thread running through this thesis. 
Chapter 2 presents an overview of SPECT in aging and dementia. In chapter 3.1 
different methods of analysis of SPECT and the consequences for research studies of 
Alzheimer's disease are evaluated. Chapter 3.2 examines the contribution of SPECT 
to the clinical diagnosis of Alzheimer's disease with emphasis on dementia severity 
and decision analysis. In chapter 3.3, age, risk factors for atherosclerotic vessel 
disease as well as indicators for atherosclerosis are studied in relation to rCBF in a 
sample from a population-based study, the Rotterdam Elderly Study4 
A review of current therapeutic strategies for Alzheimer's disease and future 
possibilities is given in chapter 4. One of the methodological aspects in clinical trials, 
the occurrence of learning effects with repeated neuropsychological testing, receives 
attention in chapter 5.1. Treatment of Alzheimer patients with the nootropic 
compound pramiracetam, a putative enhancer of neuronal metabolism, is evaluated in 
13 
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a two-phase trial design with dose-finding over a broad range of doses (chapter 5.2). 
In chapter 5.3 the effects of lisuride on cognitive and non-cognitive functions are 
studied in a preliminary trial with 16 Alzheimer patients. Finally, the limitations of 
the studies in this thesis are discussed from a methodological point of view, the 
results are reviewed in the context of the present knowledge of Alzheimer's disease 
and future possibilities for research are suggested (chapter 6). 
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Brain imaging with SPECT in aging and dementia 
Introduction 
Brain imaging techniques play an important role in the evaluation of the patient 
presenting with a dementia syndrome. Structural imaging techniques that visualize the 
brain, such as computed tomography (CT) or magnetic resonance imaging (MRI), are 
used to detect lesions that may cause dementia, which may lead to effective treatment 
in some cases. Their role is limited in the diagnosis of Alzheimer's disease, however, 
since some of the observed changes, including ventricular enlargement and cortical 
atrophy, are also found in other dementias and in the aged non-demented population. 
Recent interest has focused on the contribution of physiological imaging techniques, 
such as single photon emission computed tomography (SPECT) and positron emission 
tomography (PET), to the understanding of functional correlates of the biological and 
structural changes observed in the elderly. Areas of research include their role in the 
differential diagnosis of dementia and the exploration of disease-specific impairments 
in various dementing disorders. In this chapter, we describe several techniques for 
measurement of cerebral blood flow (CBF) and address the methods of data analysis 
in SPECT studies. Finally, results of SPECT and PET studies in normal aging and 
dementia will be summarized. 
Measurement of cerebral blood flow 
Several methods have been developed for measurement of CBF. The first method 
for measurement of global cerebral perfusion and metabolism was developed in 1945 
by Kety and Schmidt1 This technique employed the inert diffusible gas nitrous oxide 
and measured an average value of blood flow per minute per unit weight for the 
brain as a whole2 Cerebral metabolic oxygen consumption (CMR02) and cerebral 
glucose utilization (CMRGlc) could be calculated from arteriovenous oxygen and 
glucose differences, respectively. In 1963, the 133Xenon (133Xe) clearance technique 
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with intracarotid injection of 133Xe was introduced for measurement of CBF.3 The 
principle was similar to the Kety-Schmidt technique: measurement of the uptake and 
clearance in the brain of an inert diffusible gas. Later, non-invasive administration of 
133Xe was developed by 133Xe inhalation. Inhalation of 133Xe or intravenous injection 
of 133Xe was combined with the monitoring of radioactivity with multiple collimated 
scintillation detectors over each hemisphere permitting assessment of regional CBF 
(rCBF).'·' The 133Xe method has the advantage that, due to the rapid wash-out, 
studies can be repeated after as little as 20 minutes. A problem is that rCBF changes 
in the deep regions of the brain, such as the medial temporal cortex, can not be 
reliably detected with this method.6 In addition, the 133Xe inhalation method has a 
poor resolution,? and due to the short half-life, the method is not well suited for 
tomographic imaging.' 
The need for radioisotope rCBF tracers suitable for tomographic imaging led to 
the development of new tracers. These tracers should cross the intact blood-brain-
barrier (BBB), distribute proportionally to blood flow and retain a fixed regional 
distribution for a certain period to permit tomographic acquisition-' In 1980, iodine-
123 labeled isopropyl-iodoamphetamine (123!-!MP) was introduced as a 
radiopharmaceutical that crossed the BBB and was retained in the brain 
proportionally to rCBF.10 Imaging with IMP has several drawbacks, however, 
including the relatively long half-life, the cost, the unfavorable dosimetry, and the 
redistribution11.13 The better dosimetry characteristics and general availability of 
technetium-99M initiated the search for an appropriate pharmaceutical to link this 
radionuclide into a lipophilic complex that meets the criteria above. In 1985, 
Neirinckx and coworkers synthesized the 99mTc labeled hexamethyl-propylene amine 
oxime (HM-PA0),14 a lipid soluble molecule that is readily converted to a secondary 
hydrophillic form in brain cells and that is retained in the brain for several hours 
proportionally to rCBF without redistribution15 Images with IMP give a poorer 
quality than those with HM-PAO, but more lesions were seen with IMP than with 
HM-PAO in Alzheimer patients but not in multi-infarct dementia16 Especially when 
using high resolution cameras, and given the better image quality and availability of 
HM-PAO, this agent is preferred for imaging rCBF in dementia.16 Comparable results 
were obtained in patients with various neurological disorders when HM-PAO imaging 
was compared to the 133Xe clearance method.' The introduction of HM-PAO 
provided the opportunity to use rCBF tomography on a wide clinical scale with the 
use of a conventional slowly-rotating gamma camera.17 
20 
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In the 1970's Sokoloff and associates developed the 14C-deoxyglucose technique 
with PET to measure regional cerebral metabolism and blood flow. 18 Extension of 
this method was made possible with the synthesis of [18F]-fluoro-deoxyglucose (F-18-
FDG), fulfilling the requirements of a pharmaceutical for measuring regional cerebral 
glucose metabolism in humans. PET is now a well established technique to measure 
physiological parameters in the brain such as rCMRGic, rCMRO, and rCBF. The 
advantage of PET, in contrast to SPECT, is that quantitative estimates of these 
parameters are provided and that the resolution is relatively high. Extensive research 
has been performed with PET in several degenerative neurological disorders and PET 
studies continue to add to the scientific knowledge of these diseases. The high costs of 
PET and the limitation to centers with on-site cyclotrons led to renewed interest in 
SPECT imaging and to the development of the tracers IMP and HM-PAO. Cameras 
for SPECT imaging are widely available and the finding that rCBF is coupled to both 
rCMRGlc and rCMR02 in normal subjects and in patients with Alzheimer's 
disease,19•20 possibly through both chemical and neuronal mechanisms,21 suggests that 
SPECT may be a good clinical alternative for PET. 
Comparison of SPECT imaging with PET for the measurement of rCBF has been 
performed in several studies. HM-PAO images were shown to reflect rCBF as 
measured by C150 2 PET." In a rCBF comparison study of HM-PAO SPECT with 
fluoromethane PET in cerebrovascular disease, it was found that HM-PAO images 
showed less contrast between high and low activity regions than PET.' The 
application of the Lassen correction logarithm did not improve the correspondence of 
SPECT data with PET rCBF because this procedure increased the variance in the 
high flow areas.' In another study, FOG PET was superior in the detection of mildly 
affected areas as compared to SPECT, but IMP and HM-PAO SPECT were 
considered useful in the detection of abnormal regions in dementia including 
Alzheimer's disease and Pick's disease.23 
Methods of analysis in SPECT studies 
In general, two methods are used to analyze SPECT images: the semi-quantitative 
analysis and the qualitative analysis. The data sampling in the semi-quantitative 
analysis requires the construction of a region of interest (ROI) to measure rCBF in a 
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particular area of the brain. Since SPEer does not yield quantitative data, the mean 
activity (average counts per pixel) in this ROI is then divided by that of a defined 
reference area, for example the cerebellum. In qualitative analysis the data set is 
rated by visual inspection on a classification scale. Both methods of analysis will be 
discussed in the following section. 
Semi-quantitative analysis: the ROI definition 
The need for ROI's comes from the necessity to have an anatontical reference area 
and to reduce the enormous amount of information contained by the 3 dimensional 
data set comprising thousands of pixels. In most studies of Alzheimer's disease the 
ROI location is with reference to the normal anatomy of the brain and guided by the 
underlying assumption that structure and function are related. Defined regions usually 
include the areas of frontal, temporal, parietal, and occipital cortex. 
For ROI definitions, variations occur across studies in shape, size and location, and 
different reference areas are used. Geometrically shaped ROI's range from 
rectangular regions of 2x4 pixels (13x25 mm),24 to square regions of 4x4 pixels (2.5x2.5 
cm),25 or 3x3 pixels (18x18 mm).26 Regions are also drawn by hand with reference to a 
standard CT brain atlas to optimally conform to the anatomical configuration of the 
region.27•28 Waldemar and colleagues" used a computerized method with semi-fixed 
ROI templates from an anatomical atlas that could be individually adjusted and 
redrawn only for the outer contour of the brain. In the method described by Gemmell 
et al, an operator gives an outline of the outer brain contour after which a computer 
inscribes a second ROI within the first outline at a fixed distance of 7 pixels (22.4 
mm).22 
The number of slices per cortical region included in the analysis shows 
considerable variation, ranging from one to six.24-30 The choice of the reference area 
is the cerebellum in most studies,26'29'30 but also the occipital cortex is used,28,31 as well 
as the activity in the whole tomographic slice.27 The results of rCBF measurements 
with SPECT will be dependent on the way an RO! is defined. 
Potential sources of bias for the ROI construction are discussed by Fox32 in relation 
to PET studies, and the issues raised by the author may well translate to the ROI 
definition in SPECT studies. The a priori selection for "interest" of a brain structure 
may be a source of sampling bias, because detection of changes outside the defined 
region is not possible. The sensitivity for this change depends on the anatomical 
precision of the ROJ placement in the affected brain area, which is referred to as the 
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"small signal problem"." The dimensions of the ROI pose another problem. It is 
argued by Fox that the more closely the dimensions of the ROI conform to the area 
of change, the more sensitive is the ROI for the magnitude of this change. Small 
ROI's may be more sensitive but have less anatomical precision, and geometrically 
shaped ROI's may not optimally conform to the affected brain area. 
Qualitative analysis 
Qualitative rating of tomographic images is another possibility to analyze SPECT 
images. Rating procedures by one or more raters blind to the clinical diagnosis 
include dichotomous ratings of images, e.g. as normal or abnormal, or on an ordinal 
rating scale. If an absolute scaling method is employed for analysis of SPECT images, 
the reference area chosen will determine the relative count activity in a certain area 
and thereby the appearance of the particular regions. Several qualitative rating 
methods have been used. In a study by Johnson et al,33 only the parietal cortex was 
taken into account, and an Alzheimer patient was classified as abnormal when the 
parietal activity was lower than 60% of the maximum of the slice. Employing the 
same rating procedure, patterns of hypoperfusion were identified in all cortical areas, 
including bilateral posterior temporal and/or parietal cortex and multiple small 
cortical defects.34 In a study by Neary et al35 two individuals independently rated 
cerebral activity as normal or abnormal. Cerebral regions were defined as anterior, 
posterior, left and right, but no information was given on the scaling method of the 
image display in this study. With another method employed by Sharp et al,36 the brain 
was divided in 5 equal-sized sections, and regions did not follow internal anatomical 
borders. The decrease in average count density in focal regions was expressed as 
percentage reduction from visually appearing normal tissue. 
SPECT and PET studies in normal aging 
Several studies have been reported in healthy elderly individuals from the 2nd to 
the 8th decade of life, assessing rCBF, rCMRG!c or rCMR02, or combinations of 
these variables. Most studies have been conducted with PET, but recently also a 
SPECT study addressed this subject. The first studies measuring global CBF and 
oxygen and glucose utilization in normal aging were conducted by Kety and 
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coworkers. They found that CBF, CMR02 and CMRGJc show a gradual decrease 
with advancing age, possibly secondary to neuronal cell loss37 Dastur and colleagues 
selected healthy elderly control subjects with and without hypertension and 
arteriosclerosis.38 In contrast to the findings by Kety et al, CBF and CMR02 were not 
significantly different between the young and old healthy groups in this study and 
appeared to be age invariant, although CMRGJc was significantly decreased in the 
elderly subjects. In a selected sample of elderly subjects with subclinical vascular 
disease, CBF showed a significant decline of 10-16% compared to the young group, 
suggesting a role of vascular factors in CBF decline.38 The role of cerebrovascular 
disease in CBF decrements and oxygen and glucose consumption of the brain was 
also suggested in another study.39 Other studies with PET in healthy individuals have 
suggested a decrease with aging of rCBF,40•41 with the exception of a study by 
Yamaguchi et al.42 Martin and associates performed a pixel by pixel analysis in a PET 
rCBF study of normal aging, because variability in methods and limited precision of 
ROI placement could have affected results in previous reports.43 They reported an 
age related decline in adjusted rCBF in limbic and association cortices and suggested 
that the decrease with age of rCBF could be due to structural changes, to decreases 
in the activity of individual neurons independent of structural change, or to a 
combination of the two.43 
SPECT studies of normal aging have been sparse. In a single study by Waldemar 
and colleagues 53 healthy elderly subjects aged 21-83 years were assessed with HM-
PAO SPECT and'"' 133Xe inhalation technique.29 An age related decline in rCBF was 
observed in the frontal cortex, and an area of subcortical low-flow increased with age. 
In addition, the side-to-side asymmetry of several regions increased with age. 
PET studies investigating rCMR02 and rCMRGJc have not yielded consistent 
results. The first studies found reductions in rCMRGlc and rCMR02,4446 with a faster 
rate for CMRGlc with advancing age than for rCMR02.'5•47•48 A decrease in rCMR02 
and rCMRGJc was also observed in later reports.4042•49 However, no age related 
changes in parameters of brain metabolism were observed in other studies.50·55 In a 
reanalysis of their former study Frackowiak et al could not confirm the decline in 
rCMR02 while the effect of age on rCBF was reproduced. 56 Varying selection criteria, 
in particular those involving inclusion of subjects with cerebrovascular disease, could 
possibly account for study differences.'1~0 
The effect of cerebral atrophy has been demonstrated in several studies. When 
corrections for cerebral atrophy are made, global CMRG!c increased in Alzheimer 
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patients and elderly controls with 16.9% and 9.0%, respectively." Yoshii and 
coworkers found a significantly lower CMRGlc in the elderly compared to young 
subjects, that disappeared after correcting for brain volume and atrophy." Brain 
volume explained 17%, brain atrophy 8%, and the combination of these two factors 
21% of the variance in CMRG!c. Cerebrovascular risk factors were not related to 
CMRG!c measures, leaving almost 80% of the variance in CMRG!c unexplained." 
The oxygen extraction ratio (OER) showed no statistically significant age effect, 
although a small upward trend has been observed, and it is suggested that OER is not 
determined by CMR02 but compensates reciprocally for different values of CBF.41 
The trend to increased OER with a decline in CBF could reflect a maintenance of 
metabolism,43 compensating for a falling CBF, to maintain CMR02 at higher levels 
than would be expected if CMR02 fell in parallel with CBF, or if the fall in CBF 
were a consequence of a primary fall in CMR02•59 
SPECT and PET studies in dementia 
Alzheimer's disease 
A large number of studies have been performed with both SPEer and PET 
imaging to examine rCMRGlc and rCBF changes in Alzheimer's disease. The earliest 
studies in the 1970s with the 133Xe method in patients with presumptive Alzheimer's 
disease showed reductions in overall CBF.60 The conclusions of these studies in 
dementia are limited, mainly because selection criteria for patients were not rigorous. 
In PET research, a general finding is that metabolic reductions appear in Alzheimer's 
disease. Association cortices are predominantly involved and most studies show a 
relation of rCMRGlc and rCBF reductions and dementia severity. In one of the first 
PET studies using 150 to estimate oxygen utilization, defects were observed in parietal 
and temporal lobes of patients with mild Alzheimer's disease whereas in severe 
dementia also the frontal lobe was found to be profoundly impaired with relative 
sparing of the occipitallobe.61 Other studies also showed relative decreases in cortical 
glucose metabolism in the temporo-parietal association cortex, as well as in the 
frontal cortex.62-64 In mild and moderate Alzheimer's disease reductions in rCMRGlc 
were reported in parietal cortex whereas severe Alzheimer patients demonstrated 
both parietal and temporal metabolic decreases,65 and in another study the number of 
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regions involved in Alzheimer patients increased with dementia severity.66 In mildly 
impaired patients with Alzheimer's disease neocortical abnormalities in rCMRGlc 
may precede the appearance of non-memory cognitive deficits.67 Longitudinal study of 
these patients showed that the heterogeneous nonmemory language and visuospatial 
impairment was related to and predicted by these early metabolic abnormalities in 
the neocortex, and that asymmetry indices were directionally stable and became more 
pronounced over time.68 
SPECT investigations have largely confirmed results obtained in PET studies. The 
most consistent finding in these studies is a reduction in rCBF in Alzheimer's disease 
compared to healthy controls in temporo-parietal and parietal cortex.26•28•33•36•69 Results 
of frontal and occipital cortex are not consistent, however. Several studies found a 
rCBF decrease in occipital cortex'6 ~3 and frontal cortex,26-"~3 while other studies 
reported no changes in frontal cortex,27'68 in superior frontal cortex,28 and occipital 
cortex?0 In studies using a qualitative analysis, some investigators make a distinction 
between "anterior" and "posterior" deficits. The heterogeneity of metabolic 
disturbances in Alzheimer patients reported with PET71 was confirmed by these 
studies. The percentage of Alzheimer patients with decreased rCBF in both anterior 
and posterior areas was 46% in one study72 and 33% in another study.35 Reduction in 
only posterior areas was found in 33%35 and 29%75 of Alzheimer patients and in only 
anterior areas this was 14%.35 The percentage of Alzheimer patients with no 
abnormalities was reported to be 19%.35 
Dementia severity correlates with rCBF values measured with SPECT in 
Alzheimer's disease, most strongly with rCBF decreases in posterior cortical areas in 
patients with severe dementia.73 In a study with the 133Xe inhalation method a 
temporo-parietal rCBF deficit was consistently found in early Alzheimer patients, and 
it was concluded that rCBF procedures provide an accurate and sensitive marker for 
early Alzheimer's disease." The diagnostic value of SPECT in early Alzheimer 
patients before structural abnormalities are present on CT or MRI was demonstrated 
in a study by Perani et al.25 They found globally decreased cortical rCBF with largest 
reductions in frontal and temporo-parietal regions and uptake asymmetries 
corresponded to lateralized neuropsychologic deficits in selected patients. Temporal 
as well as parietal reductions of rCBF were found in groups of mild, moderate, and 
severe Alzheimer's disease?1,33 In addition, occipital rCBF was decreased in patients 
with dementia severity ranging from mild to moderate.33 Regional CBF in 
dorsolateral frontal cortex in mild and moderate Alzheimer's disease was reported 
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normal compared to controls,31 and 33% of mild and 50% of moderate Alzheimer 
patients in this study had values beyond the 95% confidence interval of the control 
group means. 
Vascular dementia 
Vascular dementia (VaD) is a broad term that encompasses all patients with 
dementia associated with ischemic and hemorrhagic cerebrovascular disease, 
according to recent diagnostic criteria for research studies.75 Several underlying 
illnesses include small vessel disease with dementia such as in Binswanger's disease 
(subcortical atherosclerotic encephalopathy) and multiple lacunar strokes, and multi-
infarct dementia (MID) and strategic single-infarct dementia, terms used to describe 
the dementia resulting from multiple cerebral infarcts or localized ischemic damage. 
The prevalence of VaD increases with advancing age76 and VaD is, after Alzheimer's 
disease, the second most common type of dementia and may account for 15-20% of 
all dementia cases, in addition to another 15-20% that may suffer from a combination 
of VaD and Alzheimer's disease." 
Several studies have searched for characteristic patterns of rCMRGlc and rCBF 
deficits in VaD, but results are not consistent. With PET and SPECT hypometabolism 
and hypoperfusion were found to be multiple, focal and asymmetric in VaD.78 Some 
studies found no differences between MID patients and controls.27•68 Gemmell et a! 
studied 15 patients with MID and found no characteristic pattern, with images ranging 
from fairly normal to multiple rCBF deficits, while in 13% bilateral temporo-parietal 
deficits were observed.36•72 
More extensive areas of hypoperfusion than observed on structural imaging may be 
present, illustrating the value of SPECT to establish the functional significance of 
vascular lesions." Deficits in rCBF were seen in MID patients that did not match 
infarcts on MRI or CT scan.80 Cortical metabolism is dependent on afferent and 
efferent pathways as was demonstrated in a patient with multiple cerebral infarcts.81 
The degeneration of fiber tracts may result in disconnection of remote structures that 
is reflected by distant metabolic defects81 In the study by Jagust et a!, MID patients 
showed a propensity for frontal involvement." The patients in this study had multiple 
lacunar infarcts and deep white matter involvement and it was suggested that frontal 
rCBF decrease may be characteristic for these patients, representing distant flow 
effects.27 
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Other dementias 
SPECT studies have also been conducted in other, less common dementing 
disorders, that are to be excluded when making the diagnosis of probable Alzheimer's 
disease. Patients with "frontal lobe type dementia" showed selective anterior 
hypoperfusion.82,83 In patients with Parkinson's disease no specific pattern was 
demonstrated in the basal ganglia but those parkinsonians with dementia showed 
parietal and frontal cortical uptake abnormalities compared to those without 
dementia.26 In progressive supranuclear palsy frontal areas of hypoperfusion were 
present with SPECT'"' and reduced metabolic values were found with FDG PET in all 
cortical and subcortical areas investigated." Another SPECT study of progressive 
supranuclear palsy patients demonstrated significant rCBF reductions in basal ganglia, 
frontal and parietal regions.86 In early Huntington's disease PET studies have shown 
decreased glucose metabolism in the basal ganglia before the appearance of 
abnormalities on CT and it was shown that patients with Huntington's disease have a 
diffuse decrease in cortical metabolism with early involvement of the frontallobe.87 
The role of SPECT in the diagnosis of Alzheimer's disease 
SPECT imaging as a valuable aid in the diagnostic evaluation of dementing 
disorders is suggested by some studies that show distinctive rCBF patterns in different 
types of dementia. SPECT as a diagnostic tool is only useful when sufficient sensitivity 
and specificity is demonstrated, in particular for the diagnosis of early Alzheimer's 
disease. Various studies have investigated sensitivity and specificity of SPECT in 
Alzheimer's disease. Johnson and associates used a cut-off score of 0.66 below which 
the parietal to cerebellar activity ratio was defined abnormal. This semi-quantitative 
method was 76% sensitive and 78% specific in 37 Alzheimer patients and 9 controls.88 
The investigators tried to improve diagnostic accuracy by examining all image data in 
each subject with a qualitative rating method. A data set was classified as abnormal 
when activity in the parietal lobe was reduced. In 58 mildly to severely affected 
Alzheimer patients, this method yielded a sensitivity of 88% and specificity of 87%.33 
J agust and coworkers were able to differentiate all Alzheimer patients from both 
controls and MID patients with the activity ratio of bilateral temporo-parietal cortex 
to the whole slice.27 With a grading scale from 0 (normal) to 5 (severely abnormal) 
for the whole data set, Duara and colleagues defined an optimal cut-off as 2 or more 
in a group of 40 patients with probable or possible Alzheimer's disease and 30 
controls. They found sensitivity and specificity 58% and 77% with SPECT, and 75% 
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and 78% with PET, respectively." Powers et al used a blinded clinical evaluation of 
bilateral temporo-parietal rCBF reduction in patients with probable Alzheimer's 
disease in a PET study and reported sensitivity 38% and specificity 88%, while these 
figures were 92% and 85%, respectively, when diagnostic criteria were liberalized.90 
The correct identification of Alzheimer patients in an early stage of the disease is 
clinically important, but poses most difficulties. In almost all studies the temporal, 
parietal or temporo-parietal cortex is used to differentiate between Alzheimer 
patients and controls, and sensitivity is reportedly lower in early Alzheimer's disease 
compared to more severe patients. For example, Johnson et al found that the 
sensitivity was lowest (80%) in the mild Alzheimer's disease group compared to the 
severe patients (95%).33 Gemmell et al found that a bilateral temporo-parietal rCBF 
deficit was not present in 25% of their least impaired Alzheimer patients.72 Reed et al 
defined SPECT abnormalities as values beyond the 95% confidence interval of the 
control group means. They reported in 9 patients with probable and possible 
Alzheimer's disease a sensitivity of 56%, whereas this value was 83o/o in 12 moderate 
Alzheimer patients.31 Prohovnik and associates used the 133Xe inhalation technique 
and reported sensitivity and specificity 88% and 75%, respectively, in a subgroup of 
mild Alzheimer patients74 In a recent study of 132 patients evaluated for memory loss 
it was reported that the probability of Alzheimer's disease is 82% when bilateral 
temporo-parietal defects are present.34 
No characteristic patterns of hypoperfusion or hypometabolism in SPECT and PET 
studies have been found to separate patients with Alzheimer's disease and VaD. The 
presence of a bilateral temporo-parietal deficit has been described in VaD patients, 
while focal rCBF reductions were found in Alzheimer patients.68·72 The co-occurrence 
of these disorders in some patients provides the diagnostic evaluation with an extra 
challenge and complicates the interpretation of results in SPECT studies of 
Alzheimer's disease and VaD. 
Conclusion 
SPECT with 99mTc HM-PAO has gained recent interest in research studies of aging 
and dementia, based on reported distinctive patterns of hypoperfusion in different 
dementing illnesses. Similar results were reported for rCBF abnormalities with 
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SPECT and PET, and SPEer may therefore provide a clinical alternative for PET. 
Encouraging results of sensitivity and specificity of SPEer in Alzheimer's disease and 
normal controls have been reported and some authors have suggested the use of 
SPEer as an adjunct for the clinical diagnosis of Alzheimer's disease. Some studies 
also show that considerable overlap may exist in rCBF values between Alzheimer 
patients, VaD patients, patients with other dementing illnesses and normal controls. 
For their methods of analysis, various SPEer studies use different definitions of 
regions of interest. It is unclear how these differences affect study results. Most 
studies report a decrease in rCBF with advancing age, possibly related to the 
presence of vascular risk factors and indicators of atherosclerosis, while inconsistent 
results were reported for CMR02 and CMRG!c. 
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Chapter 3 
Studies of diagnosis 

Chapter 3.1 
Comparison of different methods for rCBF measurements 
with SPECT in normal controls and in patients with 
Alzheimer's disease 
Introduction 
Regional cerebral blood flow (rCBF) measurements by means of single photon 
emission computed tomography (SPECT) studies is widely applied in research regarding 
Alzheimer's disease (AD).1"'1n contrast to positron emission tomography (PET), it is not 
possible to obtain quantitative rCBF with SPECT. In SPECT studies, semi-quantitative 
rCBF values are calculated by dividing the mean activity (counts per pixel) in a given 
region of interest (ROI) by that of a defined reference area (for example the 
cerebellum). Consequently, the results of rCBF measurements with SPECT will vary 
depending on the criteria used to define the ROI's and the reference area. 
Various definitions of an ROI have been employed in SPECT studies. ROI's vary 
between studies in shape, size, and location, and in the number of slices included in the 
analysis. Some investigators drew RO!'s by hand with reference to a CT or anatomical 
atlas,'·' others employed geometrically shaped RO!'s, such as rectangular and square 
regions of varying sizes and localization,1·2·6·7 or included either one single-slice1•3•4•7 or 
multi-slices in their analysis.2•6•8·9 However, it is not known whether variations in methods 
of defining the ROI's will have different results. In this study, we compared the 
discriminative ability of 3 different methods of semi-quantitative rCBF measurement with 
technetium-99M labeled hexamethyl-propylene amine oxime (99mTc HM-PAO) SPECT 
in normal controls and AD patients. 
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Subjects and methods 
Patients 
Forty-eight patients referred from the metropolitan area of Rotterdam to the 
outpatient clinic of the Departments of Neurology and Geriatric Medicine, University 
Hospital Rotterdam Dijkzigt, for the evaluation of memory complaints in the period 1989 
to 1991, fulfilled NINCDS-ADRDA criteria for probable AD10 and were included in this 
study. Mean age was 72.2 years (range 50 to 89) and dementia severity was assessed with 
the Global Deterioration Scale (GDS)." Patients with scores of 3 on the GDS were 
classified as having mild dementia (n=12), patients with the score 4 as moderate 
dementia (n=20), and patients with scores 5 or higher as severe dementia (n= 16). The 
mean Mini Mental State Examination (MMSE)12 score was 19.9 and ranged from 9 to 
25 (Table 3.1.1). 
Table 3.1.1 Entry characteristics of 60 controls and 48 Alzheimer patients 
Sex 
male 
female 
Age 
mean (in years) 
range (in years) 
GDS 
range 
MMSE 
mean 
range 
*SEM in parentheses 
Controls 
(n=60)' 
27 
33 
74.1 (0.8) 
62-86 
28.3 (0.2) 
25-30 
tSignificantly different from controls by t-test (p < 0.01) 
Controls 
Alzheimer patients 
(n=48)* 
22 
26 
72.2 (1.2) 
50-89 
4.1 ± 0.1 
3-7 
19.9 (0.7)t 
9-25 
Controls for the SPECT study were recruited from a random sample of 111 persons 
from the Rotterdam Elderly Study that participated in an additional magnetic resonance 
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imaging (MRI) study (response rate for the MRI study: 87%) and were matched for age 
and sex to the AD patients (Table 3.1.1). The Rotterdam Elderly Study is an ongoing 
single center prospective follow-up study of the total population aged 55 years and over 
from the suburb Ommoord in Rotterdam. The total eligible population of this study 
comprises 11,854 persons and the refusal rate in those aged 65 to 84 years was 18 
percent. Rationale and design of the Rotterdam Elderly Study have been described 
elsewhereP A careful screening procedure for dementia was employed.14 Written 
informed consent was obtained from all subjects (controls and patients). Twenty-one of 
the 111 persons were excluded on the basis of a neurologic disease, such as history of 
stroke or transient ischemic attacks, Parkinson's disease and AD. The remaining 90 
subjects were eligible for the SPECT study. Twenty-four of these 90 refused participation 
and one died before the SPECT study could be performed. SPECT was performed in the 
remaining 65 persons, 5 of these scans were not available for analysis because of 
technical reasons. The remaining 60 persons were included in the control group. 
SPECT 
Regional CBF studies were performed with 99mTc HM-PAO. Technetium-99M labeled 
HM-PAO was prepared by adding 1,110 megabecquerel (MBq) freshly eluted sodium 
pertechnate to a vial containing freeze dried 0.5 mg d,l-HM-PAO, 7.6 microgram 
stannous chloride dihydrate, and 4.5 mg sodium chloride (Ceretec). From this mixture, 
740 MBq was intravenously administered within 30 minutes after preparation. SPECT 
was carried out 10 to 20 minutes later to avoid possible interference from cerebral 
uptake of free sodium pertechnate. Data acquisition was performed with either a single-
head rotating gamma-camera (model Siemens) with a low energy all purpose collimator 
or a 3-headed rotating gamma camera (model Picker). Total acquisition angle was 360°, 
60 projections of 30 seconds each, with a 64x64 matrix and spatial resolution of 
approximately 12 mm for the Siemens camera, and 128x128 matrix and approximately 
7 mm spatial resolution for the Picker camera. Transversal (parallel to orbito-meatal 
line) slices were reconstructed with a ramp filter, after correction for attenuation, by 
calculation of the geometric means. 
Regions of interest 
Analysis of the results of rCBF measurements was performed on a personal computer 
with GAMMAPC 1.41 (Dr 0. Nickel, Department of Nuclear Medicine, University of 
Mainz, Germany). The matrix of images acquired with the Picker camera was reduced 
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from 128x128 to 64x64. ROI's were drawo blinded to the clinical diagnosis by the 
following standardized procedure. The reference slice included one cerebellar 
hemisphere that contained a pixel with the highest counts of the entire cerebellum. After 
drawing a region by hand roughly around this hemisphere, the computer defined the 
reference region by activity higher than 70% of the maximum value in this slice (Figure 
3.1.1). The boundary of this reference region corresponds to the anatomical boundary 
of the cerebellum. The mean activity of this region of interest in counts per pixel was 
regarded as a reference value. All other slices were displayed in a color scale set relative 
to this value. Two types of ROI were defined in the cerebral hemispheres: regions 
corresponding to the normal anatomy of the brain in one single-slice and in multi-slices; 
four rectangular ROI's consisted of 2x4 pixels in one single-slice, as described by Johnson 
et al.1 First, the ROI's corresponding to frontal, temporal, temporo-parietal, and occipital 
cortex, were drawn in each slice by hand with reference to an anatomical atlas15 (Figure 
3.1.1). The temporo-parietal region was defined in the transition area of the temporal 
and parietal cortex where no reliable differentiation between these two areas can be 
made. We placed the outer border of these anatomical ROI's at the first line of pixels 
with a fast decline in activity, assuming that this reflects the transition from brain tissue 
to cerebrospinal fluid. The inner border was set to a fixed distance of 2 em from the 
outer border to approximate the area of grey matter in the brain. With the exception of 
the outermost slices, all slices were included in the multi-slice analysis. Second, only 1 
slice with reference to the normal brain anatomy was used in the single-slice analysis. 
Third, the 4 rectangular ROI's were located in the frontal, temporal, temporo-parietal, 
and occipital cortices and were based on the ROI definition from Johnson et al.1 (Figure 
3.1.1). Semi-quantitative rCBF was defined as the average counts per pixel within a 
region of interest divided by that of the cerebellar reference slice and multiplied with 100 
(percentage). 
Statistical analysis 
Comparison of the mean semi-quantitative rCBF in 3 different ROI methods was 
performed with analysis of variance for repeated measures with the type of SPECT 
camera as a covariat~, and with the classification normal control or AD as grouping 
variable_ When there was a significant difference between methods, a post-hoc analysis 
was performed between all 3 methods separately with the same statistical method. To 
evaluate variability between methods in individual subjects, the difference scores were 
computed; the standard error of the difference score was used as a measure of variability 
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between methods. The discriminative ability of the combined left and right semi-
quantitative rCBF for the classification control person or AD patient was assessed with 
multivariate logistic regression, adjusted for age, sex, and type of SPECT camera and is 
expressed as adjusted odds ratio with 95% confidence interval. All regions significantly 
predicting the diagnostic classification were simultaneously entered into a second logistic 
model. Regions of interest that were no longer significant in this model were not used 
in further analyses. Receiver-operator-characteristic curves were plotted for the mean of 
right and left temporal semi-quantitative rCBF of the 3 ROI methods in patients with 
mild, moderate and severe AD separately on the basis of the results of the logistic 
regression analysis." The logistic model calculated the predicted probability of being a 
patient with AD for all subjects and subsequently generated the sensitivity and specificity 
for a series of probability cut-off points. In receiver-operator-curves, the true-positive rate 
(sensitivity) is plotted against the false-positive rate (1 minus specificity) and the 
discriminative ability of a test is shown by the position of the full curve: the farther 
upward and to the left the curve lies in the graph, the better is the test. 
Results 
Entry characteristics of control subjects and AD patients are presented in Table 3.1.1. 
Analysis of variance with repeated measures for patients and controls combined revealed 
a significant difference between the mean semi-quantitative rCBF values of the 3 
methods for all regions (p < 0.001 for all ROI's). For these differences, no significant 
group interactions were observed. Analysis for groups separately showed that semi-
quantitative rCBF values measured with the rectangular ROI method were significantly 
higher than from that of both methods with ROI's corresponding to the normal anatomy 
of the brain in both controls (Table 3.1.2) and AD patients (Table 3.1.3). No differences 
between the multi-slice and single-slice method with ROI's corresponding to the normal 
anatomy of the brain could be found in both controls (Table 3.1.2) and AD patients 
(Table 3.1.3). Analysis of individual variability between all3 methods revealed that the 
standard deviations of the differences of the mean rCBF values between the rectangular 
ROI and each of the two anatomical ROI's were consistently larger than the standard 
deviations of that between the two anatomically defined ROI's in both controls (Table 
3.1.2) and AD patients (Table 3.1.3). 
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Figure 3.1.1 An example of a SPECT scan (Siemens camera) of a normal controL Figures 
on the left hand panel: regions of interest drawn with reference to nonnal anatomy; the 
boundary of the cerebellar reference slice (C) is defined by activity higher than 70% of the 
maximum value in this slice. Figures on the right hand panel: 2x4 pixels rectangular ROJ's. 
C =cerebellum, F =frontal, T =temporal, P =parietal, TP =temporo-parietal, 0 =occipital 
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Table 3.1.2 Results of 3 different methods of semi-quantitative rCBF measurements in 60 control subjec/s 
rCBP values (% )' Difference in rCBF values between methods(%) 
Anatomical ROI Anatomical ROI Rectangular ROI A-B C-A C-B 
multi-slice single-slice single-slice 
(A) (B) (C) 
Frontal right 84.7 :!: 5.6 84.8 :!: 7.2 88.8 :!: 9.6t -0.1 ± 3.0 4.1 :!: 6.0 4.0 ± 4.8 
Frontal !eft 83.9 :!: 5.6 83.5 :!: 7.3 87.6 :!: 8.5t 0.4 :!: 3.3 3.8 ± 4.7 4.1 ± 3.7 
Temporal right 84.3 :!: 4.6 84.2 :!: 4.8 87.9 :!: 6.8t 0.1 ± 1.5 3.6 ± 5.2 3.7 ± 55 
Temporal left 81.7 :!: 5.7 81.9 :!: 5.7 85.9 :!: 7.ot -0.2 ± 1.8 4.1 :!: 5.3 4.0 :!: 5.3 
Temporo-parietal right 79.9 :!: 7.2 80.1 :!: 7.6 86.9 ± 8.9t -0.1 :!: 1.3 6.9 :!: 7.8 6.8 ± 7.9 
Temporo-parietal left 76.8 ± 6.4 77.1 ± 6.7 86.9 :!: 8.9t -0.3 :!: 1.9 10.1 ± 8.9 9.7 ± 8.9 
Occipital right 89.6 ± 6.1 89.9 ± 6.7 95.0 ± l0.5t -0.3 :!: 2.5 5.3 :!: 9.3 5.1 :!: 9.3 
Occipital left 88.8 :!: 6.1 89.1 :!: 6.5 96.5 ± to.Ot -0.3 ± 2.5 7.6 ± 7.2 7.3 ± 6.4 
"Values repr~..,nl mean pere<nlagc :t SD of rCBF r<lalivc 10 !hal of !he cerebellar relercoce <lice, adjus!ed for !ype of SPECI' camera 
tMean values are •igniflcanUy higher !han !hose ol {A) and (B) by analysis of variance Wllh repealed measures, adjusled for !ype of SPEer camera (p < 0.001) 
Table 3.13 Resu{(s of 3 different methods of semi-quantitative rCBF measurements in 48 Alzheimer patie/1/s 
rCBF values (%)• Difference in rCBF values between methods(%) 
Anatomical ROI Anatomical ROI Rectangular ROI A-B C-A C-B 
multi-slice single-slice single-slice 
(A) (B) (C) 
Frontal right 81.0 :!: 5.8 80.3 :!: 6.5 83.2 :!: 8.2:j: 0.6 :!: 2.9 2.3 ± 5.5 2.9 ± 5.1 
Frontal left 80.6 :!: 6.7 80.0 :!: 7.1 85.4 ± 9.6t 0.6 :!: 2.9 4.8 :!: 6.0 5.5 :!: 5.7 
Temporal right 77.3 ± 7.7 76.8 :!: 8.0 81.0 :!: 9.3t 0.5 :!: 1.5 3.7 ± 5.6 4.2 :!: 5.8 
Temporal left 74.8 :!: 6.4 74.3 :!: 6.9 78.0:!: 8.1t 0.5 ± L7 3.2 :!: 5.7 3.7 :!: 5.6 
Temporo-parietal right 72.0 :!: 9.5 72.5 :!: 9.9 78.0 :!: 11.9t -0.5 :!: 2.1 6.0 :!: 7.3 5.5 :!: 7.3 
Temporo-parietal left 68.9 :!: 10.0 69.3 :!: 10.5 78.0 :!: 11.9t -0.4 :!: 2.4 9.1 ± 8.9 8.8 :!: 9.2 
Occipital right 86.7 :!: 5.9 87.3 :!: 6.1 93.3 :!: 9.5t -0.6 :!: 2.1 6.5 :!: 9.0 5.9 :!: 8.8 
Occipital left 86.3 ± 6.9 86.7 ± 8.4 94.9 :!: 9.ot -0.5 :!: 3.2 8.7 :!: 8.8 8.2 :!: 9.6 
'Values reprc<<:nl mean percen!age "' SD of rCBF relati>e 10 !hat of the cerebellar reference •lice, odju.led for !ypo of SPEer cam ern 
t :!Mean value• are significao!ly higher !han !hose of (A) and (B) by analy>is of variance wilh repealed measures, adjusled for type of SPEer c:uncrn (p < 0.001 and p < 0.01, respeC!ively) 
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Figure 3.1.2 Receiver-operator-characteristic curves to analyze the discriminative ability of 
semi-quantitative rCBF values in 60 controls and 48 Alzheimer patients based on rCBF 
values of the temporal ROI's 
46 
Methods in SPECT studies 
Mter analysis with logistic regression, every combined left and right ROI was 
significantly associated with the diagnosis AD (Table 3.1.4 ). When all regions were 
simultaneously entered into a full multivariate model, only the temporal ROI remained 
significantly associated with the diagnosis AD for all 3 ROI methods investigated (Table 
3.1.4). Receiver-operator-characteristic curves plotted for all AD patients based on the 
analysis of the temporal ROI showed a lower discriminative ability for the rectangular 
ROI method, compared to both methods with ROI's corresponding to the normal 
anatomy (Figure 3.1.2). However, when dementia severity is taken into account, no major 
differences in sensitivity and specificity between the 3 ROI methods are found in mild 
and moderate AD. In contrast, worst diagnostic performance was observed for the 
rectangular ROI method in patients with severe AD (Figure 3.1.2). 
Table 3.1.4 The discriminative value of semi~quantitative rCBF measurements for controls and Alzheimer 
patients in 3 different regions of interest analyzed with logistic regression *t 
Regions separately entered 
in model 
Frontal 
Temporal 
Temporo-parietal 
Occipital 
Regions combined into full 
model 
Frontal 
Temporal 
Temporo-parietal 
Occipital 
Anatomical ROI 
multi~slice 
Odds ratio 95% CI 
1.12 1.04-1.22 
1.26 1.13-1.39 
1.13 1.06-1.20 
1.08 1.01-1.16 
0.96 0.82-1.08 
1.37 1.12-1.66 
0.99 0.84-1.14 
0.94 0.80-1.06 
Anatomical ROI 
single~slice 
Odds ratio 95% CI 
1.14 1.06-1.22 
1.23 1.12-1.36 
1.09 1.03-1.15 
1.08 1.01-1.15 
0.96 0.84-1.07 
1.44 1.17-1.75 
0.93 0.79-1.05 
0.98 0.87-1.08 
Rectangular ROI 
single-slice 
Odds ratio 95% CI 
1.09 1.03-1.14 
1.10 1.04-1.17 
1.08 1.03-1.13 
1.04 1.0-1.09 
1.05 0.98-1.11 
1.10 1.01-1.19 
1.05 0.99-1.11 
0.99 0.92-1.05 
"Odds ratios per percent change in rCBF (mean of right and left) are used to estimate the association of a regional perfusion value 
with the diagnostic outcome, normal control or Alzheimer patient, with logistic regression, adjusted for age, sex, and SPECf camera 
tSignificant prediction of the clinical diagnosis Alzheimer's disease when an odds ratio of 1.0 is not included in the confidence interval 
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Discussion 
We compared 3 methods of ROI definition in a semi-quantitative rCBF study with 
99mTc HM-PAO SPECT in controls and AD patients: multi-slice and single-slice ROI's 
with reference to normal anatomy of the brain; and single-slice rectangular ROI's (2x4 
pixels). No major differences in the mean semi-quantitative rCBF were found between 
the anatomically defined ROI in the single-slice method when compared to that of the 
multi-slice method. In contrast, the semi-quantitative rCBF values measured with the 
rectangular method resulted in significantly higher mean semi-quantitative rCBF values 
than that measured in the anatomically defined ROI's. These findings were similar in 
controls and in AD patients. Analysis with logistic regression followed by the construction 
of receiver-operator-characteristic curves showed superior discriminative ability between 
controls and severe AD patients of the temporal anatomically defined ROI's when 
compared to that of the rectangular ROI method. No major differences in discriminative 
ability between the 3 methods were found in mild and moderate AD. 
ROI's are designed to reduce the enormous amount of 3-dimensional data in SPECT 
scanning contained in thousands of pixels, but there is no agreement on the choice of the 
location, the size and shape of an ROI. In general, to be optimally sensitive for detection 
of rCBF decrease in a particular area of the brain, the ROI should be constructed 
conform the dimensions of this rCBF deficit. Abnormalities in rCBF may remain 
undetected when the analysis is limited to 1 slice as in the single-slice method with 
anatomically constructed ROI's, or when very small ROI's are employed, as in the 
geometric ROI method. However, an accurately placed small geometric ROI is 
potentially more sensitive for small areas of rCBF change than larger ROI's with 
reference to normal anatomy of the brain. On the other hand, these small ROI's may be 
imprecise because of their predetermined and fixed location. Thus, the validity and 
precision of a certain ROI method designed to detect changes in rCBF depends on both 
the nature of the rCBF deficit and on the shape, size and localization of the constructed 
ROI. The results of rCBF measurements with the 3 investigated ROI methods suggest 
that in studies of aging and AD analysis of the rCBF in the anatomically defined 
temporal ROI in one slice would suffice, as shown in the receiver-operator-characteristic 
curves. This may be explained by the diffusely distributed neuropathological 
abnormalities in AD. When rCBF reflects neuronal function, as has been suggested by 
a close coupling of rCBF and neuronal metabolism in PET studies/7•18 rCBF decrease 
is expected to be diffusely distributed in AD.19"21 In studies involving patients with 
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probable AD and control subjects without neurologic disease, the limitation of the 
analysis to one slice is a great benefit in terms of cost-effectiveness. It remains to be 
established if these results hold for patients where focal rCBF abnormalities can be 
expected, such as in those with vascular dementia,22'23 as problems of measurement 
validity and precision may then play a role. 
Analysis with receiver-operator-characteristic curves enables a comparison between 
methods with respect to discriminative ability between Alzheimer patients and controls. 
The superior discriminative ability of the method with reference to normal anatomy 
when compared to that of the geometric ROI's, is possibly a result of an additional rCBF 
decrease in severe AD in cortical areas beyond the boundaries of the rectangular ROI's 
and may have several consequences for research studies. The comparison of controls and 
AD patients representing a broad range of severity in studies with rectangular ROI's may 
tend to underestimate the differences between these groups. Therefore, it is suggested 
that the anatomically ROI method should be preferred in studies investigating rCBF 
characteristics of AD, for example in longitudinal studies of predictors of decline. On the 
other hand, when SPECT is used as a diagnostic adjunct for the diagnosis of mild AD, 
any of the 3 investigated methods may be used. The choice of the ROI method will 
therefore depend on the purpose for which SPECT is used. 
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Chapter 3.2 
The diagnostic valne of SPECT with 
99mTc HM-PAO in Alzheimer's disease: 
a population-based stndy 
Introduction 
The prevalence of Alzheimer's disease (AD) increases with advancing age1 and about 
two million patients in the European Community and a similar number of persons in the 
United States are affected by this disease2 Diagnostic accuracy is of primary importance 
with an increasing number of AD patients and several diagnostic criteria are currently 
available3 •4 However, considerable overlap exists between AD patients, especially those 
with mild AD, and non-demented elderly individuals in cognitive performance,' 
radiographic findings,' and neurochemical' and neuropathological changes8 •9 Recent 
interest has focused on regional cerebral blood flow (rCBF) measurements with single 
photon emission computed tomography (SPECT) with technetium-99M labeled 
hexamethyl-propylene amine oxime (99mTc HM-PAO) for the diagnosis of AD. SPECT 
studies have shown a reduction of rCBF in the temporo-parietal cortex in mild and 
moderately severe AD patients when compared to age-matched healthy control 
subjects."·" Encouraging results of SPECT in the diagnosis of AD have been 
reported10•11•14 and some authors suggest the routine administration of SPECT in the 
diagnostic evaluation of AD.l2·15•16 However, there are problems with the interpretation 
of these results since the selection procedures for controls in these studies are likely 
biased towards healthier individuals, resulting in reference groups that are not a reliable 
reflection of those in the general population that are at risk for the disease. Therefore, 
in the present study we compared patients with probable AD with controls originating 
from a population-based study to investigate the possible contribution of SPECT for the 
diagnosis of AD, especially for mildly affected patients. 
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Subjects and methods 
Patients 
Forty-eight patients referred from the metropolitan area of Rotterdam to the 
outpatient clinic of the Departments of Neurology and Geriatric Medicine, University 
Hospital Rotterdam Dijkzigt, for the evaluation of memory complaints in the period 1989 
to 1991, fulfilled NINCDS-ADRDA criteria for probable AD3 and were included in this 
study. Mean age was 72.2 years (range 50 to 89) and dementia severity was assessed with 
the Global Deterioration Scale (GDS).17 Patients with scores of 3 on the GDS were 
classified as having mild dementia (n= 12), patients with the score 4 as moderate 
dementia (n=20), and patients with scores 5 or higher as severe dementia (n=16). The 
mean Mini Mental State Examination (MMSEjl8 score was 19.9 and ranged from 9 to 
25 (Table 3.2.1). 
Table 3.2.1 Entry characteristics of 60 controls and 48 Alzheimer patients 
Controls All AD Mild AD Moderate AD Severe AD 
(n~60) patients (n~12) (n~20) (n~16) 
(n~48) 
Sex 
male 27 22 7 7 8 
female 33 26 5 13 8 
Age 
mean (in years) 74.1 ± 0.8 72.2 ± 1.2 70.8 ± 2.0 71.4 ± 2.1 74.3 ± 2.1 
range (in years) 62-86 50-89 56-78 50-81 56-89 
GDS 
3 12 12 0 0 
4 20 0 20 0 
5 or 6 16 0 0 16 
MMSE 
mean 28.3 ± 0.2 19.9 ± 0.7* 22.3 ± 0.8* 19.1 ± 1.2* 17.7 ± 1.3* 
range 25-30 9-25 19-25 9-25 11-24 
*Significantly different from controls by t-test (p < 0.01) 
Controls 
Controls for the SPECT study were recruited from a random sample of 111 persons 
from the Rotterdam Elderly Study that participated in an additional magnetic resonance 
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imaging (MRI) study (response rate for the MRI study: 87%) and were matched for age 
and sex to the AD patients (Table 3.2.1). The Rotterdam Elderly Study is an ongoing 
single center prospective follow-up study of the total population aged 55 years and over 
from the suburb Ommoord in Rotterdam. The total eligible population of this study 
comprises 11,854 persons and the refusal rate in those aged 65 to 84 years was 18 
percent. Rationale and design of the Rotterdam Elderly Study have been described 
elsewhere.19 A careful screening procedure for dementia was employed.Z0 Written 
informed consent was obtained from all subjects (controls and patients). Twenty-one of 
the 111 controls were excluded on the basis of a neurologic disease, such as a history of 
stroke or transient ischemic attacks, Parkinson's disease and AD. The remaining 90 
persons were eligible for the SPECT study. Twenty-four of these 90 refused participation 
and one died before the SPECT study could be performed. SPECT was performed in the 
remaining 65 persons, 5 of these scans were not available for analysis because of 
technical reasons. A total of 60 persons was therefore included in the control group. A 
comparison of these 60 persons with the 30 of the 90 eligible subjects that were not 
included in the study showed no significant differences in various cardiovascular 
parameters (history of myocardial infarction, hypertension, systolic and diastolic blood 
pressure, plasma fibrinogen, cholesterol, high density lipoprotein, and factor VII and 
factor VIII). 
SPECT 
Regional CBF studies were performed with 99mTc HM-PAO. Technetium-99M labeled 
HM-PAO was prepared by adding 1,110 megabecquerel (MBq) freshly eluted sodium 
pertechnate to a vial containing freeze-dried 0.5 mg d,/-HM-PAO, 7.6 microgram 
stannous chloride dihydrate, and 4.5 mg sodium chloride (Ceretec). From this mixture, 
740 MBq was intravenously administered within 30 minutes after preparation. SPECT 
was carried out 10 to 20 minutes later to avoid possible interference from cerebral 
uptake of free sodium pertechnate. Data acquisition was performed with either a single-
head rotating gamma-camera (model Siemens) with a low energy all purpose collimator 
or a 3-headed rotating gamma camera (model Picker). Total acquisition angle was 360', 
60 projections of 30 seconds each, with a 64x64 matrix and spatial resolution of 
approximately 12 mm for the Siemens camera, and 128x128 matrix and approximately 
7 mm spatial resolution for the Picker camera. Transversal (parallel to orbito-meatal 
line) slices were reconstructed with a ramp filter, after correction for attenuation, by 
calculation of the geometric means. 
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Regions of interest 
Analysis of the results of rCBF measurements was performed on a personal computer 
with GAMMAPC 1.41 software (Dr 0. Nickel, Department of Nuclear Medicine, 
University of Mainz, Germany). The matrix of images acquired with the Picker camera 
was reduced from 128x128 to 64x64. Regions of interest were drawn blinded to the 
clinical diagnosis by the following standardized procedure. The reference slice included 
one cerebellar hemisphere that contained a pixel with the highest counts of the entire 
cerebellum. After drawing a region by hand roughly around this hemisphere, the 
computer defined the reference region by activity higher than 70% of the maximum 
value in this slice (Fignre 3.2.1). The boundary of this reference region corresponds to 
the anatomical boundary of the cerebellum. The mean activity of this region of interest 
in counts per pixel was regarded as a reference value. All other slices were displayed in 
a color scale set relative to this value. The regions of interest corresponding to frontal, 
temporal, temporo-parietal, parietal and occipital cortex, were drawn by hand with 
reference to an anatomical atlas21 (Figure 32.1). The temporo-parietal region was 
defined in the transition area of the temporal and parietal cortex where no reliable 
differentiation between these two areas could be made. The outer border of these 
regions of interest was placed at the first line of pixels with a fast decline in activity, 
assuming that this reflects the transition from brain tissue to cerebrospinal fluid. The 
inner border was set to a fixed distance of 2 em from the outer border to approximate 
the area of grey matter in the brain. With this method our intra-observer variability in 
terms of mean counts per pixel in a specific region of interest was 0.8%. With the 
exception of the outermost slices, all slices were included in the analysis. Semi-
quantitative rCBF was defined as the average counts per pixel within a region of interest 
divided by that of the cerebellar reference slice and multiplied with 100 (percentage). 
Statistical analysis 
Semi-quantitative rCBF in corresponding regions of interest was compared between 
AD patients and controls. Unear regression analysis was performed to adjust for 
differences in age, sex and type of SPECT scanner. The predictive power of the semi-
quantitative rCBF in each individual region of interest for the classification normal 
control or AD patient was assessed in a multivariate logistic regression model, with 
adjustment for age, sex and type of SPECT camera and expressed as an adjusted odds 
ratio with a 95% confidence interval. All regions of interest significantly predicting the 
diagnostic classification in this model were simultaneously entered into a second logistic 
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Figure 3.21 Regions of interest (ROI"s) were drawn with reference to normal anatomy by 
a standardized procedure. Examples of SPECT (Siemens camera) with 99mTc HM-PAO from 
a control subject are shown for ROI"s from the cerebellum (C), from the frontal ROI (F), 
the temporal ROI (T), the parietal ROI (P), the temporo-parietal ROI (TP), and the 
occipital ROI (0) 
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model. Regions of interest that were no longer significant in the second logistic model 
were excluded. Thereafter, receiver-operator-characteristic curves were constructed for 
patients with ntild, moderate and severe AD separately on the basis of the results of the 
logistic regression analysis.22 The logistic model calculated the predicted probability of 
being a patient with AD for all subjects and subsequently generated the sensitivity and 
specificity for a series of probability cut-off points. In receiver-operator-characteristic 
curves, the true-positive rate (sensitivity) is plotted against the false-positive rate (1 
ntinus specificity) and the discrintinative ability of a test is shown by the position of the 
full curve: the farther upward and to the left the curve lies in the figure, the better is the 
test. After determining the sensitivity corresponding to a specificity of 90%, the 
incremental ruling-in and ruling-out gain was calculated and plotted against the prior 
probability in ntild AD, as estimated by the clinician.21 Post-test probability is calculated 
by adding the incremental gain to the prior probability that the disease is present in case 
of a positive test result or by adding the incremental gain to the prior probability that 
the disease is not present in case of a negative test. Specificity was defined at 90% 
because in this study emphasis is given to the value of SPECT to confirm AD. 
Results 
Entry characteristics of AD patients and controls are presented in Table 3.2.1. In 
Figure 3.2.2, regional differences of senti-quantitative rCBF between AD patients and 
controls are shown for combined right-left pairs of regions of interest. The lowest rCBF 
value was observed in the temporo-parietal cortex for patients and controls, while the 
greatest rCBF decrease in AD patients compared to controls was in the temporal region 
of interest. The relationship between dementia severity measured with the Global 
Deterioration Scale and senti-quantitative rCBF is shown in Table 3.2.2. In mild AD 
patients a significant decrease of rCBF was found only in temporal and temporo-parietal 
regions. No significant differences between right and left regions of interest were 
observed. In moderate and severe AD all investigated regions of interest were 
significantly decreased, with the exception of the occipital cortex in the group with severe 
AD. 
In Table 3.2.3, decreased rCBF was defined as a senti-quantitative rCBF value lower 
than 2 standard deviations from the mean of controls. Significantly more patients with 
AD had a decreased rCBF in the temporal, temporo-parietal, parietal and frontal regions 
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Figure 3.22 Semi-quantitative rCBF (percentage relative to mean rCBF of the cerebellar 
reference slice) in 60 controls and 48 Alzheimer patients, * p < 0.05, ** p < 0.01, *** p 
< 0.001. Values represent mean ± 1 standard deviation of both right and left regions of 
interest 
of interest. 
Mter analysis with logistic regression, every individual region of interest, with the 
exception of the left occipital lobe, was significantly associated with the diagnosis AD 
(Table 3.2.4). No consistent right-left differences were observed and in subsequent 
analyses the average of the combined left and right regions of interest was included. 
When all regions of interest were simultaneously entered into the full multivariate 
logistic model, only the temporal cortex remained significantly associated with the 
diagnosis of AD (OR = 1.37, 95% CI 1.24 to 1.51, per 1% change in rCBF) (Table 
3.2.4 ). As a result, only this region was included in the further analysis. 
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Table 3.22 Mean semi-quantitative regional cerebral blood flow in 60 controls and 48 Alzheimer patients* 
Region Controls MildADt Moderate ADt Severe ADt 
(n=60) (n=12) (n=20) (n=16) 
Frontal 
Mean 84.1 ± 5.5 81.7 ± 5.7 80.5 ± 6.9:1: 78.7 ± 6.1§ 
Right 84.5 ± 5.6 82.1 ± 5.9 80.6 ± 7.0t 78.9 ± 63§ 
Left 83.7 ± 5.6 81.5 ± 5.8 80.4 ± 7.2t 78.4 ± 6.4§ 
Temporal 
Mean 82.9 ± 4.7 78.1 ± 5.3 75.2 ± 6.8# 74.8 ± 5.4# 
Right 84.2 ± 4.6 80.2 ± 5.4:j: 76.4 ± 7.4# 75.8 ± 5.6# 
Left 83.7 ± 5.7 78.0 ± 6.2§ 76.1 ± 7.5# 75.9 ± 6.4# 
Parietal 
Mean 82.3 ± 5.5 79.8 ± 5.5 77.8 ± 7.2t 77.8 ± 7.1t 
Right 83.6 ± 5.4 81.6 ± 5.4 78.6 ± 7.1§ 78.6 ± 7.2t 
Left 81.0 ± 6.5 77.8 ± 6.2 no ± 8.zt 77.2 ± 7.6> 
Temporo-parietal 
Mean 78.5 ± 6.3 73.4 ± 6.9t 71.5 ± 8.3# 71.4 ± 7.3# 
Right 80.1 ± 7.2 75.5 ± 7.7'+ 73.7 ± 8.7# 72.9 ± 8.2# 
Left 76.9 ± 6.4 71.3 ± 7.2t 69.5 ± 9.2# 70.0 ± 7.7# 
Occipital 
Mean 89.0 ± 6.0 86.1 ± 6.6 85.0 ± 7.4:j: 86.9 ± 6.7 
Right 89.4 ± 6.1 86.7 ± 6.6 85.0 ± 7.6:j: 87.2 ± 6.7 
Left 88.6 ± 6.1 85.3 ± 6.7 84.9 ± 7.6:j: 86.5 ± 7.4 
*Values repr-esent mean percentage !: SO of rCBF relative to that of cerebellum, adjusted for age, sex, and SPECf camera 
tClassified according to the Global Deterioration Scale (GDS), mild Alzheimer's disease (AD), GDS=3; moderate AD, GDS=4; 
severe AD, GDS ~ 5 or 6 
:j: §#Significantly different from controls by linear regression (p < 0.05, p < 0.01, p < 0.001, respectively) 
Receiver-operator-characteristic curves showed that discriminative ability of SPECT 
was best for severe AD patients. The difference in discriminative ability of SPECT 
between mild and moderate AD was small (Figure 3.2.3). When the specificity was set 
at 90%, the corresponding sensitivity for the temporal region of interest was 42% in mild 
AD, 56% in moderate AD, 79% in severe AD and 60% for all AD patients. Based on 
these results, the incremental ruling-in and ruling-out gain for those with mild AD was 
plotted against the prior probability of having the disease (Figure 3.2.4). The contribution 
of SPECT to the diagnosis of AD proved to be poor when the test result was negative, 
varying from 3% to 11%. On the other hand, the gain from a positive test ranged from 
7% to 34% with the optimal gain at a prior probability of having the disease of 30% to 
40% (Figure 3.2.4). For example, at prior probability for AD of 50% the post-test 
probability was 39% after a negative test result and 81% after a positive test result. 
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Table 3.23 Proportion of patients with Alzheimer's disease and controls with decreased semi·quantitative 
rCBF 
Frontal 
Temporal 
Parietal 
Temporo·parietal 
Occipital 
Decreased rCBF* 
Control subjects Alzheimer patients 
(n=60) (n=4ll) 
10 (17%) 17 (35%)t 
8 (13%) 30 (63%)t 
7 (12%) 22 (46%)t 
7 (12%) 26 (54%)t 
9 (15%) 14 (29%) 
~Decreased rCBF is defined as lower than 2 SO from the mean of controls, for combined right and left regions of interest 
t :!:Significantly different from controls by Chi-square test (p < 0.05, p < 0.001, respectively) 
Table 3.24 The relation between rCBF and the clinical diagnosis of Alzheimer disease in 60 controls and 
48 Alzheimer patients, analyzed with logistic regression* 
Regions separately Right and left values combined into 
full model 
Region Odds Ratio 95% Cl Odds Ratio 95% Cl 
Frontal 
Right and left 1.12 1.04-1.22 0.97 0.91-1.03 
Right 1.13 1.07-1.23 
Left 1.10 1.02-1.19 
Temporal 
Right and left 1.26 1.13-1.39 1.37t 1.24-1.51 
Right 1.24 1.12-1.36 
Left 1.22 1.12-1.34 
Parietal 
Right and left 1.09 1.02-1.17 0.97 0.91-1.03 
Right 1.10 1.03-1.18 
Left 1.07 1.01-1.14 
Temporo-parietal 
Right and left 1.13 1.06-1.20 1.0 0.93-l.o? 
Right 1.11 1.04-1.17 
Left 1.12 1.05-1.19 
Occipital 
Right and left 1.08 1.01-1.16 0.95 0.89-1.01 
Right 1.09 1.02-1.17 
Left 1.08 1.01-1.15 
~odds ratios per percent change in rCBF are used to estimate the association of a regional perfusion value with the diagnostic 
outcome, normal control or Alzheimer patient, with logistic regression, adjusted for age, sex, and SPEer camera 
tSignificant prediction of the clinical diagnosis Alzheimer's disease when an odds ratio of 1.0 is not included in the confidence interval 
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Figure 3.24 Expected incremental ruling-in and ruling-out gain in percentage plotted against 
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Curves are computed at sensitivity level of 42% and specificity level of 90% 
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Discussion 
Several methodological issues need consideration before discussing the results of this 
study. Strenuous efforts were made to compose a control group that is representative for 
those in the general population at risk for the disease. Since 30 of the 90 eligible 
individuals were not included in the study, selection in the recruitment of controls 
resulting in a group biased towards healthier individuals can theoretically still he 
possible. If this bias played a role, it might have resulted in an overestimation of the 
difference in rCBF measurements between Alzheimer patients and controls. However, 
no evidence could be found that the non-participation was selective. Another potential 
problem is the inaccuracy of the clinical diagnosis of AD.Z3•24 The inclusion of non-
Alzheimer individuals in the patient group could have resulted in an underestimation of 
the true difference in rCBF between AD patients and controls. Therefore, we carefully 
defined our group of AD by means of the NINCDS-ADRDA criteria, and the results 
apply to these criteria as they are currently employed in clinical routine. 
We compared AD patients with population controls to estimate the diagnostic 
characteristics of SPECT with 99mTc HM-PAO. The control individuals were recruited 
from a population-based study; we excluded only those with a neurologic disease 
including AD and no restrictions were made with cognitive screening tests. In patients 
with AD, rCBF was decreased in all regions of interest when compared to that of 
controls, and temporal rCBF proved to be the best discriminating region. If analysis is 
restricted to the temporal cortex, sensitivity and specificity of the SPECT scan as a 
diagnostic test for AD were strongly dependent on dementia severity. Although sensitivity 
of SPECT is best in severe AD, the need for a diagnostic adjunct is strongest in those 
with mild AD. Analysis of the practical usefulness of SPECT by means of the 
incremental ruling-in and ruling-out gain provides quantification of how much SPECT 
scanning will change the prior view of the clinician that the disease is present. We 
limited this analysis to patients with mild AD. Since SPECT as a diagnostic tool is aimed 
to confirm a clinical suspicion of AD rather than to exclude this disease, stringent criteria 
for a positive test were applied and specificity was set at 90%. Consequently, little is 
gained when the test result is negative. On the other hand, there is a more substantial 
gain from a positive test result, reaching a maximum of 34% increase in the probability 
of having AD. This gain may be clinically relevant with a 40% to 60% prior probability, 
resulting in an increase in the pr~bability from 40% to 74% and from 60% to 86%, 
respectively. Thus, a benefit from a positive SPECT result in mild AD is expected only 
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when considerable doubt about the diagnosis exists. However, the problem of low 
sensitivity remains, since SPECT as a diagnostic test will only be positive in 42% of the 
mild AD patients which is a severe limitation in terms of cost-effectiveness. 
Earlier SPECT studies of rCBF in AD patients have paid little attention to the control 
group. No attempts have been made to recruit controls from a random sample of the 
general population. Various selection criteria have been applied, and the number of 
persons in the control groups have been small.10·11·14·15•25-28 As a result, selection of 
controls is likely biased towards healthier individuals which may explain the following 
discrepancies between our study and previous reports. First, in our study temporal rCBF 
was the variable with the largest difference between controls and AD patients. By 
contrast, most other investigators have found the largest rCBF decrease in parietal and 
temporo-parietal cortex of AD patients when compared to controls.10•14•15•29-31 Although 
our controls were non-demented, they had a wide range of cognitive function and a 
history of various illnesses such as cardiovascular disease as would be expected in the 
general population. Individuals with these characteristics were excluded in several other 
studies.14·15·25•26 Persons with various cerebrovascular risk factors reportedly have a 
decreased bilateral parietal rCBF compared to age-matched controls without these risk 
factors." Moreover, it is known that the temporo-parietal cortex (watershed area) proves 
to be particularly sensitive to hypoxia, hypotension, or both.33·34 Nevertheless, the 
possibility that low temporo-parietal rCBF in some of our controls is an early sign of 
developing AD can not be excluded and should be investigated in follow-up studies. 
Second, sensitivity and specificity figures from previous SPECT and PET studies were 
better than those of our study.10•11•14•35•36 In addition to differences in selection of controls, 
this may be explained by the inclusion of more severely diseased patients in some stndies 
when compared to those of our study.31•32 
An apparent discrepancy in results may arise when the decision of clinical 
administration of SPECT in the diagnosis of AD is based on the predictive value of the 
test alone. In a recent report,37 the authors concluded that 99rnTc HM-PAO SPECT is 
useful in the diagnostic evaluation of patients with memory and cognitive abnormalities, 
based on the finding that a bilateral temporo-parietal rCBF defect in patients referred 
for cognitive impairment had a predictive value of 82% for AD. Their high predictive 
value corresponds with the probability of having mild AD after a positive test in patients 
with a prior probability of 50-60% in our study (Figure 32.4 ). After our recalculation 
based on the results published in their study, sensitivity for all patients with this temporo-
parietal defect is about 65%, which is in the range of that in our study (overall sensitivity 
64 
SPECT in Alzheimer's disease 
of 60% ). The authors would probably have arrived at a different conclusion, had they 
taken dementia severity and all diagnostic characteristics into account, including 
sensitivity, specificity and predictive value. 
We conclude that the inclusion of controls recruited from a randomly sampled 
population-based study lowered the diagnostic accuracy of SPECTwith 99mTc HM-PAO 
in AD as compared to previous studies. In particular, our findings suggest that the use 
of SPECT as a diagnostic adjunct in patients with mild AD should be limited to those 
in whom considerable doubt about the diagnosis exists. 
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Chapter 3.3 
Vascular risk factors and regional cerebral blood flow in 
a population-based study: the Rotterdam Elderly Study 
Introduction 
Determinants of regional cerebral blood flow (rCBF) in elderly individuals have been 
investigated with positron emission tomography (PET) and single photon emission 
computed tomography (SPECT). A decrease of rCBF with age has been reported in the 
limbic and cortical association areas with PET.'·' and a rCBF decline in frontal cortex 
and subcortical structures was observed with SPECT.4 Few subjects over eighty years 
were included in these studies and it is unknown whether the observed relation of rCBF 
and age extends into the eighth decade of life. In addition to age, risk factors for 
cerebrovascular disease have been associated with changes of overall CBF. Studies 
comparing persons with vascular risk factors to age-matched controls without these risk 
factors showed that overall CBF was decreased in the former group.5•6 However, few 
studies investigated the individual contribution of various risk factors and their 
interdependence with rCBF, although hypertension,5 blood viscosity,' and smoking8 have 
been suggested to play a role. Furthermore, few attempts have been made to study rCBF 
in relation to age and vascular risk factors in the general population. To further elucidate 
the association of age and vascular risk factors with rCBF, we sampled subjects from a 
population-based study, and studied rCBF with SPECT using technetium99M-labeled 
hexamethyl-propylene amine oxime (''mTc HM-PAO). 
Subjects and methods 
Subjects 
Subjects were selected from participants of the Rotterdam Elderly Study, a single 
center prospective follow-up study conducted among the total population aged 55 years 
and over of the suburb Ommoord in Rotterdam, The Netherlands. Written informed 
consent was obtained for participation in this study as well as for the SPECT 
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investigation. Rationale and design of the Rotterdam Elderly Study have been described 
elsewhere.' In brief, the objective of the study is to investigate determinants of chronic 
and disabling cardiovascular, neurogeriatric, locomotor and ophthalmologic diseases. The 
total eligible population comprises 11,854 persons, with 6,494 persons between the ages 
of 65 and 85 years. Persons residing in homes for the elderly are included. The refusal 
rate in the persons aged 65 to 84 years was 18 percent at the time of the present study. 
Participants are extensively interviewed at home and receive further investigations during 
two visits at a special research center. Subjects for the present study were recruited from 
a group of 111 persons from ihe Rotterdam Elderly Study that participated in a magnetic 
resonance imaging study, of which the response rate was 87%. A total number of 66 
subjects were included in the present study, aged 63 to 89 years. 
Measurements 
At a home interview subjects received a computerized questionnaire to obtain 
information on current health status, medical history, drug prescriptions and actual use, 
smoking behavior and level of education. A history of cerebrovascular event was 
considered positive when the diagnosis had been made by a physician and the diagnosis 
of myocardial infarction was based on ECG. Subjects were divided in 3 groups of 
smoking behavior: current smokers, former smokers, and those who had never smoked. 
At the research center several measurements were performed. The average of two 
blood pressure measurements, separated by a count of the pulse rate, taken in sitting 
position at the right upper arm with a random-zero sphygmomanometer was used for the 
analysis.10 Hypertension was defined as a systolic blood pressure of 160 mmHg or over 
and/ or diastolic blood pressure of 95 mmHg or over, and/ or as the use of 
antihypertensive drugs. A venipuncture was performed, with minimal stasis, through a 21 
gauge butterfly needle (surflo winged infusion set, Terumo, Belgium). Blood samples 
were collected into siliconized Vacutainer tubes (Becton & Dickinson, France) containing 
clotting activator and separator for serum, or 0.129 M sodium citrate for plasma. Serum 
was separated by a one-stage centrifugation for 10 min at 1,600 g. From the citrate tubes 
platelet poor plasma was prepared by a two-stage centrifugation; first for 10 minutes at 
1,600 g at 4 'C and subsequently for 10 minutes at 10,000 g at 4 'C. All samples were 
quickly frozen in liquid nitrogen and then stored at -80 'C before assay. Serum total 
cholesterol was determined with an automated enzymatic procedure." High density 
lipoprotein cholesterol level was measured similarly, after precipitation of the non HDL 
fraction with phosphotungstate-magnesium. Plasma fibrinogen level was assessed 
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according to the Clauss method (Diamed AG, Switzerland)." Factor VIle and factor 
VIlle activity were assayed by means of Automated Coagulation Laboratory (ACL) 
(Instrumentation Laboratory, IJsselstein, The Netherlands), with the aid offactor VII and 
factor VIII deficient plasma (Ortho Diagnostic Systems, Beerse, Belgium), with 
Thromborel S (Behringwerke, Germany) and Thrombosil I (Ortho Diagnostic Systems, 
Beerse, Belgium) as reagents, respectively. Plasma obtained from 40 healthy men was 
pooled and served as reference for the measurements of factor VIle and factor VIlle. 
Factor VIle and factor VIIIc levels of the donors were all within normal range and no 
differences between reference pools could be detected. 
Ultrasonography of both carotid arteries was performed with a 7.5 MHz linear array 
transducer using a Duplex scanner (ATL Ultramark IV, Advanced Technology 
Laboratories, Bethel, Washington, USA). According to the Rotterdam Elderly Study 
scanning protocol, a careful search was performed for the intima-lumen interface on the 
near wall, the lumen-intima interface and the media-adventitia interface on the far wall 
of the distal common carotid artery.13 The distances between the interfaces represent the 
lumen diameter and the intima-media thickness, respectively.14'15 When optimal 
longitudinal image was obtained, it was frozen on the R wave of the electrocardiogram 
and stored on video tape. This procedure was repeated three times for both sides. 
Subsequently, the carotid artery was evaluated for the presence of atherosclerotic 
plaques, defined as focal widening relative to adjacent segments, with protrusion into the 
lumen. The actual measurements were performed off-line. The frozen images on video 
tape were digitized and displayed on a screen using additional dedicated software. This 
procedure has been described in detail previously.15 In short, the interfaces of the distal 
common carotid artery were marked with a cursor over a length of 10 mm. The 
beginning of the dilatation of the distal common carotid artery served as a reference 
point for the start of the measurement. This method permits the determination of mean 
values as well as maximal values for intima-media wall thickness and lumen diameter. 
The average of the intima-media wall thickness and lumen diameter of each of the 3 
frozen images was taken as a measure for current wall thickness of the distal common 
carotid artery and lumen diameter, respectively. In addition, for each subject total intima-
media wall thickness was calculated: (left side + right side)/2. 
SPECT 
Regional CBF studies were performed with 99mTc HM-PAO. Technetium-99M labeled 
HM-PAO was prepared by adding 1,110 megabecquerel (MBq) freshly eluted sodium 
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pertechnate to a vial contammg freeze dried 0.5 mg d,l-HM-PAO, 7.6 microgram 
stanoous chloride dihydrate, and 4.5 mg sodium chloride (Ceretec). From this mixture, 
740 MBq was intravenously administered within 30 minutes after preparation. SPECf 
was carried out 10 to 20 minutes later to avoid possible interference from cerebral 
uptake of free sodium pertechnate. Data acquisition was performed with either a single-
head rotating gamma-camera (model Siemens) with a low energy all purpose collimator, 
or a 3-headed rotating gamma camera (model Picker). Total acquisition angle was 360°, 
60 projections of 30 seconds each, with a 64x64 matrix and spatial resolution of 
approximately 12 mm for the Siemens camera, and 128x128 matrix and approximately 
7 mm spatial resolution for the Picker camera. Transversal (parallel to orbito-meatal 
line) slices were reconstructed with a ramp filter, after correction for attenuation, by 
calculation of the geometric means. 
Regions of interest 
Analysis of the results of rCBF measurements was performed on a personal computer 
with GAMMAPC 1.41 software (Dr 0. Nickel, Department of Nuclear Medicine, 
University of Mainz, Germany). The matrix of images acquired with the Picker camera 
was reduced from 128x128 to 64x64. Regions of interest were drawn blinded by the 
following standardized procedure. The reference slice included one cerebellar 
hemisphere that contained a pixel with the highest counts of the entire cerebellum. After 
drawing a region by hand roughly around this hemisphere, the computer defined the 
reference region by activity higher than 70% of the maximum value in this slice (Figure 
3.3.1). The boundary of this reference region corresponds to the anatomical boundary 
of the cerebellum. The mean activity of this region of interest in counts per pixel was 
regarded as a reference value. All other slices were displayed in a color scale set relative 
to this value. The regions of interest corresponding to frontal, temporal, temporo-
parietal, parietal and occipital cortex, were drawn by hand with reference to an 
anatomical atlas16 (Figure 3.3.1). The temporo-parietal region was defined in the 
transition area of the temporal and parietal cortex where no reliable differentiation 
between these two areas could be made. The outer border of these regions of interest 
was placed at the first line of pixels with a fast decline in activity, assuming that this 
reflects the transition from brain tissue to cerebrospinal fluid. The inner border was set 
to a fixed distance of 2 em from the outer border to approximate the area of grey matter 
in the brain. With this method our intra-observer variability in terms of mean counts per 
pixel in a specific region of interest was 0.8%. 
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Figure 3.3.1 Regions of interest (ROI's) were drawn with reference to normal anatomy by 
a standardized procedure. Examples of SPECT (Siemens camera) with 99mTc HM·PAO from 
a control subject are shown for ROI's from the cerebellum (C), from the frontal ROI (F), 
the temporal ROI (T), the parietal ROI (P), the temporo-parietal ROI (TP), and the 
occipital ROI (0) 
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With the exception of the outermost slices, all slices were included in the analysis. Semi-
quantitative rCBF was defined as the average counts per pixel within a region of interest 
divided by that of the cerebellar reference slice and multiplied with 100 (percentage). 
Statistical analysis 
The association of vascular risk factors and rCBF was investigated with multiple linear 
regression aoalysis, with adjustment for age, sex and type of SPECT camera. The relation 
of age and rCBF was separately evaluated with linear regression, adjusted for sex aod 
type of camera, with the cumulative addition of vascular risk indicators, and then 
indicators for atherosclerosis to the same regression model. Analysis of the differences 
between quartiles of the distribution of a determinant and rCBF was performed with 
indicator variables. Regression coefficients (with 95% confidence interval, 95% Cl) are 
reported as a measure of the strength of the association of determinants and rCBF. 
Results 
The distribution of various demographic and vascular characteristics under study was 
very similar in the 66 subjects studied with SPECT to that in all subjects examined in the 
Rotterdam Elderly Study in the same age range. A decrease in values of rCBF with 
advaocing age was observed in all cortical regions studied (Figure 3.3.2). The regression 
coefficients were significant for temporal (-0.29% rCBF per year, 95% CI [-0.47,-0.11]), 
parietal (-0.27, [-0.47,-0.07]), and temporo-parietal (-0.25, [-0.47,-0.03]) regions of interest, 
but not for the frontal cortex (-0.20, [-0.42,0.02]). 
A positive diagnosis of myocardial infarction was not significantly related to rCBF 
(Table 3.3.1). Higher diastolic blood pressure was associated with higher values of rCBF 
in all cortical regions and reached a level of statistical significance in the temporo-
parietal region (Table 3.3.2). The same trend was observed for systolic blood pressure 
aod rCBF but the relations were not significant (Table 3.3.2). A threshold effect was 
observed for the relation of diastolic blood pressure and temporo-parietal rCBF. Subjects 
in the lowest quartile of the distribution of diastolic blood pressure (:5 60 mmHg) had 
significantly less temporo-parietal rCBF than subjects above the 25th percentile 
(difference -5.1% rCBF, 95% CI [-9.2%,-1.1%]) (Figure 3.3.3). 
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Table 3.3.1 The association between positive history of myocardial infarction and 
rCBF' 
Variable Frontal Parietal Temporo- Temporal 
parietal 
Myocardial infarction 86.3 ± 1.8 82.9 ± 2.1 78.9 ± 1.9 83.6 ± 1.6 
(n:9) 
No myocardial infarction 83.6 ± 0.8 81.2 ± 0.7 77.2 ± 0.8 82.3 ± 0.7 
(n:57) 
Difference (% rCBF) 2.7 1.7 1.7 1.3 
[95% CI] [-1.3,6.7] [ -1.9,5.3] [-2.3,5.7] [-1.9,4.5] 
*Values represent mean ± SEM of right and left rCBF in percentage relative to that of cerebellum, 
adjusted for age, sex, and type of SPECT camera 
Table 3.3.2 The association between blood pressure and rCBF* 
Variable Frontal Parietal Temporo- Temporal 
parietal 
Systolic blood 0.04 0.03 0.06 0.05 
pressure (per mmHg) [ -0.04,0.12] [ -0.03,0.09] [-0.02,0.14] [-0.01,0.11] 
Diastolic blood 0.01 0.08 0.16 0.05 
pressure (per mmHg) [-0.13,0.14] [ -0.04,0.20] [0.04,0.28] [-0.05,0.15] 
*Multiple linear regression coefficients in % rCBF per mmHg, adjusted for age, sex, and type of 
SPECT camera, with 95% confidence intervals ( n = 66) 
Similar results were observed when subjects using antihypertensive drugs were excluded. 
The pattern of increasing rCBF with higher blood pressures was confirmed with the 
dichotomized definition of hypertension, but these values were not significant (Table 
3.3.3). 
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Table 3.3.3 The association between hypertension and rCBF* 
Variable 
Hypertensiont (n=19) 
No hypertension (n=47) 
Difference (% rCBF) 
[95% CI] 
Frontal 
84.0 ± 1.0 
823 ± 1.0 
1.7 
[-1.3,4.8] 
Parietal 
83.3 ± 1.2 
82.0 ± 0.9 
1.3 
[-1.4,4.1] 
Temporo-
parietal 
79.7 ± 1.3 
78.0 ± 0.9 
1.7 
[-1.3,4.8] 
Temporal 
83.7 ± 1.0 
82.0 ± 0.7 
1.7 
[-1.3,4.8] 
*Values represent mean ± SEM of right and left rCBF in percentage relative to that of cerebellum, 
adjusted for age, sex, and type of SPECf camera 
tDefmed as systolic blood pressure ~ 160 mmHg and/or diastolic blood pressure ~ 95 mmHg, 
and/or use of antihypertensive medication (n==19 with hypertension) 
Frontal Parietal 
60-69 70-79 60-89 (years) 
Temporo-parietal Temporal 
60-69 70-79 80-89 (years) 60-69 70-79 80-89 
(years) 
(years) 
Figure 3.3.2 Mean values of rCBF in percentage relative to cerebellum of frontal, parietal, 
temporo-parietal, and temporal rCBF, per age category ( 60-69, 70-79, and 80-89 years, 
respectively) 
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Figure 3.3.3 Mean temporo-parietal rCBF values in percentage relative to cerebellum are 
shown for quartiles of diastolic blood pressure distribution. The 1st quartile is significantly 
different from the other quartiles with linear regression, adjusted for age, sex, type of SPECT 
camera (p < 0.01) 
Analysis of hemostatic factors revealed an inverse association of fibrinogen with rCBF 
in all regions, that was significant in the parietal cortex (Table 3.3.4). This relation 
persisted after adjustment for previous stroke or myocardial infarction. Detailed analysis 
suggested a threshold effect for fibrinogen in the highest quartile of the fibrinogen 
distribution. Persons above the 75th percentile of this distribution (;, 3.2 g/1) had 
significantly lower parietal rCBF than those below the 75th percentile (difference -3.0% 
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rCBF, 95% CI [-5.7,-0.2]) (Figure 3.3.4). Since current smoking is associated with 
increased levels of fibrinogen, these analyses were adjusted for current smoking. Smoking 
itself, defined in 3 groups of smoking behavior, was not related to rCBF. No significant 
associations were found between factor VUe, factor VIlle, and rCBF (Table 3.3.4 ). 
Table 3.3.4 The association between plasma fibrinogen, factor VIle, factor VIlle and 
rCBF* 
Variable Frontal Parietal Tempore- Temporal 
parietal 
Fibrinogen -0.1 -2.0 -1.8 -0.5 
(per gj!)t [-2.4,2.1) [-4.0,-0.04) [-4.0,0.4) [-2.4,1.3) 
Factor V!Ic 0.06 0.06 0.05 0.05 
activity (per [ -0.01,0.13) [-0.02,0.14) [-0.03,0.13) [ -0.01,0.11) 
10'1IU /ml):j: 
Factor VIlle O.Dl 0.00 0.01 0.01 
activity (per [-0.01,0.03) [ -0.00,0.00] [-0.01,0.03] [-0.01,0.03) 
10'1IU /ml):j: 
*Multiple linear regression adjusted for smoking, age, sex, and type of SPECT camera, with 95% 
confidence intervals 
tAdjusted for current smoking; regression coefficients in% rCBF per gjl (n=63) 
.:t:Subjects taking currently anticoagulant drugs excluded; regression coefficients in % rCBF per 10·1 
lU/ml (n=53) 
Neither cholesterol nor high density lipoprotein cholesterol levels were significantly 
related to rCBF (Table 3.3.5). Measurements of the carotid artery revealed a significant 
inverse association of intima-media wall thickness of the carotid artery and parietal rCBF 
(Table 3.3.6). However, this relation was no longer significant when patients with stroke 
(n=3) were excluded (regression coefficient -0.04% rCBF per mm, 95% CI [-0.10,0.01]). 
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Figure 3.3.4 Mean parietal rCBF values in percentage relative to cerebellum are shown for 
quartiles of fibrinogen distribution. The 4th quartile is significantly different from the other 
quartiles with linear regression, adjusted for age, sex, and type of SPECT camera, and 
smoking (p < 0. 05) 
Table 3.3.5 The association between plasma lipid levels and rCBF* 
Variable Frontal Parietal Temporo- Temporal 
parietal 
Cholesterol (per mmol/1) 0.3 0.2 0.1 -0.4 
[-0.8,1.4] [-0.9,1.2] [ -1.0, 1.2] [-2. 7, 1.9] 
HDL (per W 1 mmol/1) 0.4 -0.5 -3.0 -2.0 
[-3.9,4.6] [-4.4,3.3] [-7.1,1.2] [-5.5, 1.4] 
*Multiple linear regression coefficients in % rCBF per mmol/1, adjusted for age, sex, and type of 
SPECT camera, with 95% confidence intervals (n=64) 
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Table 3.3.6 The association between carotid artery characteristics and rCBF* 
Variable Frontal Parietal Temporo- Temporal 
parietal 
Intima-media vessel wall -0.03 -0.06 -0.07 -0.04 
thickness [-0.10,0.04] [ -0.12,-0.00] [ -0.13,0.00] [-0.09,0.02] 
(per mm) (n=61)t 
Lumen diameter -0.00 -0.01 -0.01 -0.00 
(per mm) (n=53) [-0.02,0.02] [ -0.02,0.01] [ -0.03,0.01] [-0.02,0.01] 
*Multiple linear regression coefficients in % rCBF per mm, adjusted for age, sex, and type of SPEer 
camera, with 95% confidence intervals 
tintirna-media vessel wall thickness refers to (left side+right side)/2 
No significant relations between the lumen of the carotid artery and rCBF were found 
(Table 3.3.6), or between plaques in the carotid artery or bifurcation and rCBF (Table 
3.3.7). 
Table 3.3. 7 The association between plaques in the carotid artery and rCBF* 
Variable Frontal Parietal Temporo- Temporal 
parietal 
Plaques carotid 1.0 -0.50 -0.40 1.32 
artery (n=62)t [-2.91,4.81] [-3.97,2.97] [-4.18,1.53] [-1.91,2.97] 
Plaques -2.82 -2.10 -2.05 -1.57 
bifurcation (n=53):1: [-6.11,0.47] [-5.12,0.92] [-5.34,1.24] [ -4.31, 1.17] 
*Multiple linear regression coefficients are differences in % rCBF between persons without plaques 
and persons with plaques, respectively, adjusted for age, sex, and type of SPECT camera, with 95% 
confidence intervals 
tPlaques present in either left or right common carotid artery 
;i:Plaques present in either left or right carotid bifurcation 
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The effect of various vascular risk factors and indicators of atherosclerosis on the 
relation between age and rCBF was evaluated in a separate regression analysis. The 
regression coefficients for the relations of age and rCBF were essentially similar when 
various vascular risk factors (major cardiovascular event such as myocardial infarction 
or stroke, hypertension, fibrinogen and smoking, factor VUe, factor VIlle) were added 
cumulatively into the regression model (Table 3.3.8). However, major changes of 
regression coefficients were observed when indicators of atherosclerosis (intima-media 
wall thickness of the carotid artery and plaques in the bifurcation of the carotid artery) 
were added into the regression model (Table 3.3.8). 
Table 3.3.8 The association between age, vascular risk indicators, indicators for atherosclerosis and rCBF* 
Variable Frontal Parietal Temporo-parietal Temporal 
Age (years )t -0.20 [-0.42,0.02] -0.27 [-0.47,-0.07] -0.25 [-0.47,-0.03] -0.29 [-0.47,-0.11] 
Vascular risk indicators::t: 
+ Major CV event§ -0.20 [-0.42,0.02] -0.27 [-0.47,-0.07] -0.25 [-0.47,-0.03] -0.29 [-0.47,-0.11] 
+ Hypertension# -0.20 [ -0.42,0.02] -0.27 [-0.47,-0.07] -0.25 [-0.47,-0.03] -0.30 [·0.48,-0.12] 
+ Fibrinogen'll' -0.20 (·0.44,-0.04] -0.19 [-0.41,0.03] -0.18 [-0.42,0.06] -0.27 [-0.47,-0.07] 
+ Factor VUe~ -0.16 [-0.42,0.10] -0.14 [-0.40,0.12] -0.23 [-0.51,0.05] -0.28 [-0.50,-0.06] 
+ Factor VIIIc ~ -0.15 [-0.41,0.11] -0.17 [-0.43,0.09] -0.24 [-0.54,0.06] -0.29 [-0.51,0.07] 
Atherosclerosis indicators:l: 
+ Wall thickness of -0.11 [-0.39,0.17] -0.07 [-0.33,0.19] -0.08 [-0.38,0.22] -0.21 [-0.45,0.03] 
carotid artery 
(mm)b 
+ Plaques in either -0.09[-0.39,0.21] -0.00 [-0.32,0.32] 0.03 [-0.37,0.43] -0.15 [-0.45,0.15] 
carotid bifurcation 
*All regression coefficients reported are for age, in percentage rCBF relative to cerebellum per year, with 95% confidence intervals 
tMultiple linear regression of age and rCBF adjusted for sex, and type of SPECT camera (n"'66) 
tMultiple linear regression of age and rCBF adjusted for the presence of vascular risk indicators or indicators for atherosclerosis 
(data for some patients were missing); The plus indicates that the variable is added to the regression model while the- previous 
variables are kept in the model as well 
§History of major cardiovascular event, myocardial infarction or stroke 
#Defined as systolic blood pressure~ 160 mmHg and/or diastolic blood pressure~ 95 mmHg, and/or use of antihypertensive 
medication 
'!!Adjusted for current smoking 
~Subjects taking currently anticoagulant drugs excluded 
~Intima-media vessel wall thickness refers to (left side+right side)/2 
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Discussion 
Age and vascular risk factors were studied in relation to rCBF in a sample from the 
general population of 60 years and over. An age related decrease in rCBF was observed 
in tbe parietal, temporo-parietal and temporal cortex. Analysis of various vascular risk 
factors revealed that high levels of fibrinogen were independently associated with 
decreased rCBF in the parietal cortex. Intima-media wall thickness of the carotid artery 
was inversely related to parietal rCBF only when stroke patients were included. In 
addition, low diastolic blood pressure was found to be related to decreased rCBF in the 
temporo-parietal region. 
Most studies report a decline of rCBF with advancing age.l-3.17 An early study by Kety 
et a!, employing the nitrous oxide method, suggested that there is a rapid fall of global 
CBF from childhood through adolescence followed by a more gradual but progressive 
reduction throughout the remaining age span.18 The observation in our study that rCBF 
shows an age related decline from the 6th to 8th decade therefore extends earlier 
findings of rCBF and age from PET studies1-3•6 and a HM-PAO SPECT study,< although 
younger persons were included in these studies and no attempts have been made to 
sample subjects from the general population. However, the possibility exists that the 
presence of age-related vascular disease and vascular risk factors19 in our population-
based study, where these age-related changes are likely to be encountered, explains the 
relation of rCBF and age. Dastur et al reported that there was no decline of CBF with 
age unless asymptomatic vascular disease was present, and it was suggested that 
decreases in overall CBF are not the consequence of chronological aging per se but 
rather of arteriosclerosis." This hypothesis was not supported by later findings with PET 
that CBF showed a decline with age in persons not compromised by subclinical vascular 
disease? Furthermore, changes in rCBF were observed in aged individuals without 
vascular risk factors, while those with vascular risk factors showed an accelerated decline 
in CBF,5 and independent contributions of aging and vascular risk factors for rCBF were 
suggested.21 
In the present study we found that the contribution of age to rCBF decline was 
relatively independent of the presence of vascular risk indicators. However, when 
additionally was controlled for indicators of atherosclerosis, a large decrease or even a 
reversal of the relationship of age and rCBF was observed. These findings raise serious 
doubts about age as an independent determinant of rCBF decrease from the 6th to 8th 
decade of life, and they suggest that this relationship is explained for the major part by 
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the presence of both vascular risk factors and atherosclerotic manifestations, evidenced 
by the presence of plaques in the carotid artery and intima-media vessel wall thickness. 
These findings are in agreement with previous reports of Dastur et al20 and Shenkin et 
al." 
Fibrinogen has been identified as a major risk factor for cardiovascular disease and 
stroke.Z3'24 Moreover, an association was found between overall CBF and fibrinogen in 
a heterogeneous sample of patients with vascular disease and controls25 and an inverse 
relation of fibrinogen and blood velocity of the middle cerebral artery was reported.26 ln 
our study, the observed inverse and independent relation of fibrinogen with parietal 
rCBF in a population sample is in agreement with these findings. The relationship 
appeared to be attributable to a threshold effect of the highest quartile of the fibrinogen 
distribution, suggesting that high fibrinogen may be a risk factor for parietal rCBF 
deficits. The mechanisms of fibrinogen as a risk factor for ischemic vascular events and 
as determinant of rCBF are not fully understood. Conversion to fibrin, platelet 
aggregation and adhesion, altered blood viscosity, and fibrinogen vessel wall interactions 
have all been implicated,27 and each or combinations of these mechanisms may be 
responsible for decreased parietal rCBF. On the other hand, no support was found for 
the hypothesis that elevated coagulation factors are related to rCBF, although 
coagulation factors are risk factors for cardiovascular disease28 and factor VIle is 
associated with atherosclerotic disease." We had no readily explanation for the fact that 
only in the parietal cortex the effect of fibrinogen was significant. The negative 
association of fibrinogen with rCBF in all cortical areas examined could indicate that too 
few subjects were included in this study to fully examine this relationship. The possibility 
may exist, however, that it reflects the vulnerability to ischemia of the watershed areas 
in the parieto-occipital region, which is the furthest from the origins of the anterior, 
middle and posterior cerebral arteries.3° Some support for this contention comes from 
a study that shows compromised rCBF in bilateral parietal regions in persons with 
vascular risk factors as compared to those without these risk factors6 
With respect to increased intima-media wall thickness of the carotid artery, it may be 
argued that this does not truly reflect the atherosclerotic process. Atherosclerosis is 
viewed as a disorder which is restricted to the intimal layer of the arterial vessel wall.31 
Ultrasound technique can not discriminate between the intima layer and the media layer 
of vessel wall. However, evidence that increased intima-media wall thickness may be 
regarded as indicator for atherosclerosis may come from several studies, in which 
ultrasonographically assessed increased intima-media wall thickness of the common 
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carotid artery has been associated with elevated levels of cardiovascular risk factors.32•33 
Moreover, increased carotid intima-media wall thickness and carotid plaques have been 
associated with presence of atherosclerotic vessel abnormalities in coronary arteries,34 
abdominal aorta35 and peripheral arteries.36 In this study, the inverse association of 
intima-media wall thickness of the carotid artery and parietal rCBF approached 
significance when stroke patients were excluded. These results suggest that atherogenic 
mechanisms may be related to parietal rCBF, and that this relation is enhanced by the 
presence of clinical symptoms. Support for this hypothesis comes from several studies. 
Similar observations were reported for the relation of hyperlipidemia and rCBF. Patients 
with transient ischemic attacks with elevated levels of cholesterol or triglycerides had 
decreased rCBF when compared to patients with normal serum lipid levels, while a non 
significant trend was observed when neurologically normal volunteers were investigated.37 
It was also demonstrated that decline in rCBF accompanies development and progression 
of aorta-cerebral atherosclerosis prior to the appearance of signs and symptoms of 
cerebrovascular disease.38 Furthermore, carotid artery stenosis in asymptomatic 
individuals is a well defined risk factor for transient ischemic attacks and stroke.3941 
Independent factors associated with carotid atherosclerosis include coronary artery 
disease, hypertension, smoking and low HDL cholesterol,'2•43 whereas elevated LDL and 
fibrinogen levels are associated with atherosclerosis progression.44'45 The relation of 
parietal rCBF with both fibrinogen and carotid artery intima-media wall thickness could 
point to a common underlying mechanism, which is supported by the physiological role 
of fibrinogen in carotid atherosclerosis.44 In turn, these may be, at least in part, 
independent relations. Statistical analysis in this study would favour the latter view since 
the association of intima-media wall thickness of the carotid artery and parietal rCBF 
was independent of fibrinogen levels and vice versa. 
Autoregulation of the vascular supply to the brain is a mechanism to keep rCBF 
essentially constant over a broad range of cerebral perfusion pressure, ranging from 
approximately 60 to 140 mmHg46 When the cerebral perfusion pressure falls below 40 
mmHg, rCBF is invariably reduced and the parieto-occipital watershed borders are the 
sites of lowest supratentorial perfusion.47•48 The threshold effect of a diastolic blood 
pressure below 60 mmHg and low temporo-parietal rCBF in our study is in agreement 
with these findings and supports the concept that this region is particularly vulnerable 
to changes in cerebral perfusion pressure. Indeed, a recent study suggested that the 
temporo-parietal cortex may be particularly sensitive to hypoxia, hypotension, or both.49 
In conclusion, this study suggests that the observed general decline in rCBF from the 
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6th to 8th decade of life is in large part dependent on the presence of both vascular risk 
factors and indicators of atherosclerosis. In addition, both thrombogenic and atherogenic 
mechanisms may be related to parietal rCBF. There is some evidence that low temporo-
parietal rCBF may be associated with low diastolic blood pressure. 
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Introduction 
The increasing number of patients with dementia is an important problem 
confronting both society and medical science. Alzheimer's disease accounts for more 
than 60% of the total number of patients suffering from dementia and is 
characterized by a slowly progressive decline in language, orientation, and visuo-
spatial abilities.1•2 There are at least 50,000 patients with this disease in the 
Netherlands' and approximately two million in the United States,1 and estimations 
indicate that in the year 2040 these numbers will have doubled4 Currently, no 
treatment is available for the cognitive symptoms of Alzheimer's disease. The 
development of effective therapeutic strategies in addition to etiologic and 
pathogenetic studies is therefore one of the important goals of dementia research. A 
variety of therapeutic approaches are currently under investigation. First, these 
strategies include the development of pharmaceuticals that confer only symptomatic 
benefit, such as with neurotransmitter substitution therapy or with metabolic 
stimulation. Second, new areas of research seek to understand and ultimately modify 
putative causal mechanisms that could result in retarding the progression of the 
disease, although at present definitive treatment remains elusive. We will briefly 
describe methodological issues in the conduct of clinical trials and then proceed to 
review symptomatic and causal therapeutic strategies with special reference to the 
improvement of cognitive symptoms of Alzheimer's disease. 
Methodological issues in clinical trials 
The randomized parallel study design is generally regarded as the "gold standard" 
for research of the efficacy of treatment. The validity of therapeutic results in the 
widely used cross-over study may be affected by period-effects or carry-over effects5 •6 
Period-effects are for example progression of the disease or learning after repeated 
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neuropsychological testing that may occur in early Alzheimer's disease.' Although it is 
statistically possible to test for carry-over effects, most studies include too few subjects 
to generate sufficient power to test for the assumption.' One of the main advantages 
of the cross-over trial is the increased precision of estimation of the outcome 
parameters and thereby the need of fewer subjects.' 
Various pharmaceuticals show an inverted U-shaped dose-response curve with 
ineffective high and low doses. In addition, the optimal individual dose shows 
considerable variability which led to the development of a study design that consists 
of two phases. In the first phase a dose titration is performed to find the optimal 
dose, while in the second phase the drug efficacy is evaluated through comparison of 
the presumptive "best-dose" with placebo. After the dose-finding phase, patients that 
do not show a predetermined response can be excluded to participate in the second 
phase, which is called an "enrichment-population" design. Although the possibility to 
find an antidementia effect is increased with this procedure, the generalization of the 
results is diminished. 
Diagnostic misclassification is an important problem in clinical Alzheimer trials 
because no biological marker is available for the disease. The careful application of 
current diagnostic criteria is therefore necessary to avoid the inclusion of patients 
with another disease that potentially leads to dilution of the clinical drug effect. 
Although the development of the DSM-l!I10 and NlNCDS-ADRDA criteria11 has 
improved diagnostic accuracy for Alzheimer's disease, a recent study showed that 
considerable disagreement may occur between medical specialists.12 The introduction 
of standard measurement instruments has facilitated the comparison of clinical trials 
but the variation in results can, at least in part, be attributed to differences in 
dementia severity. 
Outcome measures for therapeutic efficacy are generally focused on the principal 
domains of cognitive decline. It is important, however, to evaluate non-cognitive 
variables including attention and mood since they possibly interact with cognitive 
functions and have a prominent impact on the quality of life. A well defined 
hypothesis about the pharmacologic mechanism of action with a presumptive clinical 
effect can lead to the evaluation of selective neuropsychological functions in certain 
instances. A potential drug effect in the development of new pharmaceuticals may be 
indicated by improvement in specific neuropsychological functions; for the patient and 
caregiver, on the other hand, improvement in functions of activities of daily living are 
of decisive importance. The same holds true for disturbances in behavior and the 
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occurrence of psychiatric problems such as depression and psychosis that have 
receiVed less therapeutic investigative attention. In most current therapeutic 
evaluations, measurements of activities of daily living, behavior assessment scales, and 
ratings of global function are included. 
Symptomatic therapy 
Acetylcholine 
In the last decade improvement of cholinergic function has received most attention 
in the attempt to improve cognitive function in Alzheimer's disease. In the 1970's, it 
was discovered that Alzheimer patients had decreased levels of choline 
acetyltransferase (a cholinergic marker) in the hippocampus and cerebral cortex13 that 
correlated with cognitive decline.14 A few years later neuronal cell loss was shown in 
the nucleus basalis of Meynert, an important source for cortical cholinergic 
projections15 Furthermore, blockade of cholinergic receptors with scopolamine caused 
cognitive impairment in healthy volunteers that could partially be reversed by 
physostigmine." Based on these findings the "cholinergic hypothesis" was proposed 
suggesting that the cognitive abnormalities including memory impairment in 
Alzheimer's disease could largely be attributed to cholinergic dysfunction."·" In 
analogy with dopamine substitution in Parkinson's disease, compounds that enhanced 
central cholinergic function would improve symptoms of Alzheimer's disease. 
Three approaches have been used for cholinomimetic therapy: the administration 
of metabolic precursors, inhibition of the enzyme acetylcholinesterase that degrades 
acetylcholine, and stimulation with agonists of the receptors situated post-synaptically 
to the degenerating cortical projections (Table 4.1). Each of these therapeutic 
approaches will be discussed. 
(1) Precursor mono-therapy with choline or lecithin (phosphatidylcholine) has not 
been successful, either in short-term,19'20 or in relatively long-term treatment.21'22 A 
possible explanation for these findings is that precursors do not enhance central 
cholinergic activity. 
(2) Cholinesterase inhibitors such as physostigmine and tetrahydro-aminoacridine 
(tacrine) may increase the synaptically available acetylcholine. A multitude of trials 
have been performed with physostigmine, a compound that is limited by its short 
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Table 4.1 Therapeutic strategies for Alzheimer's disease 
Therapeutic strategy 
I. Symptomatic therapy 
1. Acetylcholine 
A. Precursors 
B. Cholinesterase inhibitors 
C. Receptor agonists 
2. Noradrenaline 
3. Serotonin 
4. Dopamine 
5. Neuropeptides 
6. GABA 
7. Metabolic enhancers 
II. Causal therapy 
1. Amyloid metabolism 
2. Excitoxin hypothesis 
3. Oxy-radical scavengers 
4. Growth stimulants 
Experimental compounds 
lecithin, choline 
physostigmine, tacrine, HP029 
RS-86, bethanechol, AF102B nicotine 
clonidine 
zimeldine, mCPP 
L-dopa, selegiline 
somatostatin, vasopressin, naltrexon 
TH!P, )l-carbolines 
hydergine, piracetam, pramiracetam, 
intervention in amyloid formation 
NMDA-antagonists, calcium blockers 
selegiline, acetyl-1-carnitine, lazaroids 
nerve growth factor, ganglioside GM-1 
half-life, narrow therapeutic window and cholinergic side-effects. Double-blind studies 
have reported that physostigmine improves verbal memory and visuo-spatial abilities 
and a decrease of intrusions (spontaneous false answers),23-27 while others studies have 
not substantiated these findings.28•29 In negative studies, it is possible that the level of 
attained central cholinergic activity plays a role since an association was found 
between cognitive improvement and cholinesterase inhibition in the spinal fluid.24 
Trials with tacrine have shown controversial results thus far,30-37 and several studies 
have received criticism with regard to methodological issues (Table 4.2). 
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Table 4.2 Clinical trials with tacrine 
Study Study-design Dose-titration* "Enrichment" ADL Result 
(first author) 
Summers30,31 cross-over best-dose no no +t 
1986 (maximal 200 mg) 
Chatellier32 cross-over to maximal dose no no 
1990 (125 mg) 
Gauthier33 cross-over to maximal dose no yes 
1990 (100 mg) 
Eagger34 cross-over to maximal dose no yes + /·:t: 
1991 (150 mg) 
Weinstein35 parallel to maximal dose no yes 
1991 (100 mg) 
Davis36 parallel best-dose yes yes + 
1992 (40 or 80 mg) 
Farlow"7 parallel fixed-dose no yes + 
1992 (20, 40 or 80 mg) 
*Dose in mg tacrine per day 
tResults questioned after FDA inspection31 
:t:Significant improvement in Mini~Mental State Examination, not in neuropsychological tests 
and ADL-measurements 
Recently, it was concluded that there is no scientific evidence to treat patients with 
tacrine.3841 Criticism has focused on trial design, dose-titration, and choice of 
outcome measures. Few studies use the parallel design and are not subject to the 
disadvantages of the cross-over trial. Although at least some degree of response 
variability is to be expected with tacrine, most studies titrate to the maximally 
tolerated dose, that is not necessarily the best-dose. At best, it seems that tacrino 
could afford limited improvement in an early stage of the disease, because the effect 
of cholinesterase inhibitors is based on a functional reserve of cholinergic neurrns 
that declines with progression of the disease. Moreover, the response variability and 
liver toxicity of tacrine limit the number of patients for potential treatment. In the 
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meantime, other cholinesterase inhibitors are under investigation including HP-029, 
and less toxic compounds are in development. 
(3) The therapeutic rationale for receptor agonists is supported by the finding that 
post-synaptic receptors are relatively intact.42 Cholinergic receptor agonists such as 
RS-8643 and intravenously administered betanechol44 have not shown convincing 
symptomatic benefit. A possible explanation for these findings is that agonists have an 
aspecific effect on subgroups of muscarinic receptors." Selective agonists, for example 
the Ml agonist AF102B, could theoretically lead to better therapeutic results.46 
Attempts have been made to stimulate nicotinic receptors because the density of 
these receptors in cortical structures is decreased in Alzheimer's disease. In addition, 
through presynaptic receptors nicotine can stimulate the release of acetylcholine. Two 
trials show an increase in attention47 and decrease of intrusions, but also a dose-
related appearance of anxiety and depression.48 
Monoamines 
A decreased activity in central noradrenergic49 and serotonergid5° systems has been 
found in Alzheimer patients, and dopamine activity is possibly decreased as well45•51 
Although noradrenaline and serotonin are the focus of many preclinical studies of 
memory functions and learning, the effect of monoamines in Alzheimer's disease is 
not consistent. In clinical studies, treatment with clonidine and the second generation 
a2-adrenergic receptor agonist guanfacine, was not effective.
52
'
53 Blockade of 
presynaptic serotonin uptake with zimeldine had no effect on cognitive or affective 
functions." Furthermore, m-chlorophenyl-piperazine (mCPP), a serotonergic receptor 
agonist, negatively influenced memory and mood in Alzheimer patients and control 
subjects.55 Although dopaminomimetic therapy yielded small improvement in aspects 
of cognitive function in non-demented parkinsonians,56'57 no successful results were 
reported for patients with Alzheimer's disease.58 However, short-term treatment with 
selegiline, a selective monoamine-oxidase-B inhibitor in relatively low dosages that 
blocks dopamine catabolism, suggested improvement in verbal memory and 
attention.59 
Neuropeptides 
The rationale for treatment of Alzheimer's disease with most neuropeptides is 
based on evidence from preclinical studies, including the improvement of learning and 
memory in animal models.60 In Alzheimer dementia, changes in central neuropeptide 
96 
Therapy for Alzheimer's disease 
concentrations have been reported." Most clinical trials, however, have reported 
negative results and a relationship with the advancement of neuronal cell loss was 
suggested.62•63 A trial with a synthetic vasopressin analogon did not show clinical 
improvement." ACfH-related compounds have an effect on attention and motivation 
in animal experiments," but a study with ORG 2766, a synthetic analogon of ACfH 
4-9, did not show clinical benefit.66 Central somatostatin concentration are diminished 
in Alzheimer's disease and the reduction of serotonin and metabolites in spinal fluid 
reportedly correlate with the severity of dementia.67 No significant improvement was 
found after treatment with the somatostatin analogon L363,586.68 Opiate antagonists 
have been investigated in Alzheimer's disease because endorphines and enkephalines 
can impair memory functions.69 A trial with naltrexon was without clinical effect?' 
GABA 
Gamma-amino-butyric acid (GABA) has an inhibitory effect on neuronal function 
and decreased activity in the temporal cortex,71 and decreased levels in cerebrospinal 
fluid72 are shown in Alzheimer patients. An attempt to improve cognitive function 
with tetrahydro-isoxazolpyridine (lli!P) was not successful.73 The benzodiazepine 
agonist diazepam, on the other hand, impairs cognitive function in healthy individuals, 
possibly through GABA activation.74 A relative overactivation of GABA in the 
presence of reductions in other neurotransmitters could contribute to the symptoms of 
Alzheimer's disease.75 The j3-carbolines, inverse benzodiazepine agonists that 
antagonate GABA-ergic transmission, will therefore be tested in clinical trials. 
Metabolic enhancers 
Numerous clinical trials have been conducted to evaluate the putative effect of 
metabolic enhancers with unknown pharmacologic mechanisms of action. It is 
suggested for some compounds that they stimulate neuronal metabolism and increase 
cerebral perfusion, such as for codergocrine (hydergine )76 Hydergine is the only 
compound marketed in the U.S.A. for symptomatic treatment of Alzheimer dementia, 
but its clinical effect is controversial. A recent study with 80 patients concluded that 
hydergine is ineffective in Alzheimer's disease77 This confirms the findings of other 
studies that hydergine and related compounds have no clinical effect in memory 
impairment and dementing disorders.78 
Nootropics are a group of psychotropic drugs of which piracetam was first 
discovered as GABA derivative. The precise mechanism of action is unknown but 
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may be related to facilitation of cholinergic function." In animal models of dementia 
these compounds are effective in the reversal of scopolamine or hypoxia induced 
amnesia, but the validity of these animal models has been questioned.80 Piracetam at 
high dosages increases cerebral metabolism in Alzheimer patients,81 but its clinical 
effect is minimal82 or absent.83 The same results were found with oxiracetam.84 To 
accommodate the inverted U-shaped dose-response curve in most nootropics, a recent 
clinical trial employed a two-phase "enrichment-population" design. No improvement 
was found in cognition, mood, or ADL functions.85 Sabeluzole, a pharmaceutical with 
no interaction with memory related neurotransmitters,86 is currently under evaluation 
in a multi-center trial. The therapeutic potential of nootropics will receive further 
attention in ntildly affected Alzheimer patients and in age-associated memory 
impairment. A large number of compounds is in development and will be evaluated 
in clinical studies. 
New areas of research: causal therapy 
Amyloid metabolism 
The neuropathologic hallmarks of Alzheimer's disease, neuritic plaques and 
neurofibrillary tangles, have characteristic locations in neocortex, hippocampus, 
amygdala and subcortical nuclei projecting to the cortex.87•88 It has been suggested 
that the deposition of the 42 amino acids containing 13-amyloid protein (!lAP) in 
discrete plaques is an early event in the pathogenesis of Alzheimer's disease." 
However, it remains unknown whether the formation of amyloid depositions arises as 
a primary consequence of the degenerative process or whether these structures may 
appear secondarily as a part of the complex pathogenetic cascade. The !lAP is 
released through proteolytic activity from the transmembrane part of the 695 antino 
acids containing amyloid precursor protein, the precursor of ,BAP.90 Several variants of 
amyloid precursor protein have been found, including one with a 56 amino acids 
containi11g insertion with protease inhibiting activity of the Kunitz type.91 The neuritic 
plaques contain several proteases, including elastase and ubiquitine, and protease 
inhibitors such as a 1-antichymotrypsine. As yet, there is little understanding of the 
significance of these proteases and protease inhibitors in the pathogenesis of amyloid 
formation, but abnormal genetic expression and abnormal degradation of the amyloid 
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precursor protein could play a role. The neurofibrillary tangles contain intracellular 
accumulated structures that can be visualized with electronmicroscopy as "paired 
helical filaments". One of the proteins found in these structures is tau.92 Abnormal 
phosphorylation of tau may contribute to the formation of neurofibrillary tangles, but 
this process remains largely unknown. 
Intervention in the complex cascade of amyloid formation could possibly prevent 
amyloid depositions, for example with the development of selective protease 
inhibitors. Furthermore, modifications of the genetic expression of the amyloid 
precursor protein with DNA- or RNA-binding proteins or with promotor specific 
proteins are considered as possible interventions. The development of transgenic 
mouse models expressing an extra amyloid gene is important to test potential 
therapeutic drugs. Encouraging results were recently reported, but two of these papers 
were retracted,93•94 while the other transgenic mouse does not provide a model for 
testing drugs at this stage.9s New insights in amyloid formation are necessary before 
rational intervention is possible. 
Excitotoxin hypothesis 
Excitatory amino acids including glutamate and aspartate are neurotransmitters of 
pyramidal neurons in cerebral cortex and hippocampus that play a role in memory 
and learning.96 In Alzheimer's disease, these neurons are involved in the 
neuropathology and contain neurofibrillary tangles.97 The glutamatergic dysfunction 
could contribute to the symptoms of Alzheimer's disease and a relation of glutamate 
neurotoxicity with biochemical and structural changes has been suggested." Excitatory 
amino acids are potentially neurotoxic in instances of overactivation, and the N-
methyl-D-aspartate (NMDA) receptor has been suggested to play a crucial role.99 
Hyperstimulation of these receptors, for example through overproduction or 
decreased uptake of glutamate, can lead to intracellular influx of chloride and calcium 
and may result in neuronal death.W0 Inhibition of excitatory amino acid activity has 
the potential of neuroprotection as was shown in animal models of ischemia and 
hypoglycaemia.101 If excitotoxicity plays a role in the neuronal degeneration of 
Alzheimer's disease, excitatory amino acid antagonists could retard the progression of 
the disease. Other potential avenues for therapeutic intervention are modulation of 
receptor function through the glycine recognition site of the NMDA receptor 
complex, and calcium antagonists can block the calcium entry into the cell that occurs 
with activation of the NMDA receptor. Clinical trials with NMDA antagonists could 
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contribute to the understanding of the role of excitotoxicity in the pathogenesis of 
Alzheimer's disease. At present, these compounds have substantial side-effects which 
is a limitation for their clinical application. 
Anti~oxidants 
Under normal circumstances the cell produces free oxy-radicals, superoxides, and 
peroxides, that are scavenged by superoxide dismutase to prevent potential toxicity. A 
defect in this protection mechanism or overproduction of incompletely reduced 
oxygen molecules can lead to cell injury, for example through peroxidation of 
membrane lipids. A recent study suggests that selegiline retards the progression of 
Parkinson's disease, possibly through inhibition of the presumptive oxidative effects 
associated with MAO-B activity.102 MAO-B activity in the cerebral cortex is increased 
in normal aging and in Alzheimer patients/03·104 and MAO-B activity is decreased in 
the nucleus basalis in Alzheimer's disease.103 The hypothesis that oxidative stress plays 
a role in the neuronal degeneration of Alzheimer's disease is under investigation with 
long-term administration of selegiline. Other compounds that could produce 
neuroprotection through this mechanism are acetyl-l-carnitine105 and the lazaroid 
pharmaceuticals that inhibit lipid peroxidase.106 
Growth factors 
New therapeutic possibilities are sought with the development of nerve growth 
factors that have a function in neuronal growth and survival. Several studies show that 
nerve growth factor has a trophic function for cholinergic neurons.107·108 In aged rats, 
nerve growth factor improves visual memory and decreases atrophy of cholinergic 
neurons.109 Administration of nerve growth factor in an early phase of Alzheimer's 
disease could decrease cell loss, but the possibility that the pathologic process is 
enhanced can not be excluded."' Recently, guidelines were provided by a workgroup 
of the National Institute on Aging for the clinical application of nerve growth factor 
including the conduct of future studies on toxicity, dosage, and best way of 
administration.111 Other growth stimulating factors such as ganglioside GM-1 are 
under investigation without definitive results. A study of GM-1 treatment of mild to 
moderately severe patients with Alzheimer's disease showed no overall symptomatic 
benefit.112 
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Conclusion 
Symptomatic treatment of Alzheimer's disease with neurotransmitter substitution or 
metabolic stimulation has yielded disappointing results so far. Several new compounds 
are in development or are tested for clinical efficacy which may lead to a palliative 
therapy in the future. This therapeutic strategy does not interfere in the underlying 
pathogenetic process which stresses the need for the development of interventions in 
causal mechanisms. Methodological aspects are important for the interpretation of 
trial results. Several studies have been criticized for issues related to trial design, 
dose-titration, and choice of adequate outcome measures. The increasing knowledge 
in recent years of the neurobiology and molecular genetics of Alzheimer's disease has 
stimulated several hypotheses on the etiology. Various mechanisms are now suggested 
to play a role in the neuronal degeneration of Alzheimer's disease, including amyloid 
metabolism, excitatory amino acids, growth factors, and oxidative stress. The 
development of treatment strategies based on these insights may lead to intervention 
that retards or halts the progression of the disease and will contribute to the 
understanding of the etiology. 
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Chapter 5 
Studies of therapy 

Chapter 5.1 
Clinical trials in dementia: 
learning effects with repeated testing 
Introduction 
Clinical trials of putative anti dementia drugs, have increased dramatically during the 
past decade. Study designs, evaluating the effect of experimental agents on cognition, 
often employ various treatment conditions, such as dose-finding or multiple drug levels 
versus placebo.1•2 Repeat testing involved in these designs is~ as much as possible, 
performed with alternate forms in an attempt to create equivalent conditions. It is 
unknown, however, whether multiple testing is immune to practise effects. 
Residual learning abilities have been reported in patients with Alzheimer's disease, 
even in advanced stages of this disorder' For example, studies of procedural learning 
yielded comparable acquisition curves in Alzheimer patients and matched controls4 •s 
These data suggest that Alzheimer patients may show learning in certain instances, when 
tested repeatedly. 
Current concerns about repeat testing and learning effects have been addressed by 
randomization of placebo and drug treatment. Nevertheless, the possible confounding 
role of learning on outcome measures remains uncertain. Learning effects may affect 
measurement accuracy by increasing overall variance.6 To further evaluate this problem, 
we selected a broad sample of both verbally and visuospatially mediated tests as well as 
of attention, both manually administered and computerized, for repeat administration to 
mimic a baseline, placebo, and drug condition. 
Methods 
Seventeen patients (7 men, 10 women), with the diagnosis of Alzheimer's disease,7 and 
National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's 
Disease and Related Disorders Association criteria of probable Alzheimer's disease,' 
were randomly selected from participants of drug trials at the National Institute of 
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Neurologic Disorders and Stroke, and consented to participate in this study. Patients had 
a mean(± SEM, range) age of 64 ± 1.7 years (55 to 77), education 16 ± 0.7 years (12 
to 20); duration of dementia symptoms was 4 ± 0.7 years (1 to 11). Dementia severity 
was assessed with the Mattis Dementia Rating Scale' and ranged from mild (129) to 
severe (73), with a mean score of 104 ± 3.5. Sixteen healthy subjects (10 men, 6 women), 
matched for age (mean 64 ± 1.7; 49 to 73) and education (mean 17 ± 0.9; 12 to 20), 
served as controls. Intellectual and memory status was evaluated at study onset with the 
Wechsler Adult Intelligence Scale-Revised10 and the Wechsler Memory Scale (Table 
5.1.1)." 
Table 5.1.1 Demographic variables* 
Age 
Education 
Symptom duration 
WAIS-R verbal IQ 
WAIS-R performance IQ 
WAIS-R full scale IQ 
Wechsler Memory Scale 
Mattis Dementia Rating Scale 
*Values are the means ± SEM (range) 
Alzheimer patients 
64 ± 1.7 (55- 77) 
16 ± 0.7 (12- 20) 
4 ± 0.7 ( 1- 11) 
82 ± 2.9 (62-106) 
75 ± 3.1 (62-105) 
79 ± 2.6 (62-106) 
70 ± 3.1 (52-100) 
104 ± 3.5 (73-129) 
Control subjects 
64 ± 1.7 ( 49- 68) 
17 ± 0.9 ( 12- 20) 
120 ± 3.3 ( 92-144) 
121 ± 2.8 (101-135) 
123 ± 3.2 ( 97-141) 
128 ± 2.9 (103-143) 
142 ± 0.4 (140-144) 
Neuropsychological function was assessed with tests of verbal and visual memory, as 
well as attention. The battery consisted of both manually administered tests and 
computerized evaluations. Computerized testing was performed with a touch-sensitive 
television screenY Subjects were tested at baseline with alternate forms of the same 
tests in random order at weekly intervals for a total of 3 sessions. Duration of testing was 
approximately 90 minutes and occurred at the same time for all assessment sessions. 
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Verbal memory was assessed with the following neuropsychological tests: Verbal 
Learning,13 Logical Memory,11 Paired Associate Learning,11 Selective Reminding 
( computerized).U Visual memory was evaluated with the following items: Benton Visual 
Retention Test,14 Misplaced Objects (computerized), 12 Delayed Non-Matching to Sample 
( computerized).U In addition, a novel experimental Visual Learning Test was 
administered: 5 trials with immediate and 1 with delayed recall. Five targets (indicated 
by a crossed out dot) on a 5 by 5 dotted matrix, had to be located after a 10 second 
exposure to the target design on a blank matrix. Attention was measured with Telephone 
Dialing (computerized)." Data were analyzed with repeated measures analysis of 
variance (BMDP P2V)15 with the following design: first, both patients and controls 
combined over trial 1, 2, and 3, to determine order of test trial and group interaction 
effects. If the order of test trial effect was significant, a post-hoc analysis (BMDP P2V) 
was performed to determine learning curves for groups separately. In case of significant 
group interactions, a post-hoc analysis for groups was performed separately to determine 
differential learning effects. Effects on performance across trials were evaluated by 
calculating a symmetric change score.16 Results are reported as means ± SEM. 
Correlations between demographic variables and change scores were evaluated by 
Pearson's correlational analysis (BMDP P7D). 
Results 
Alzheimer patients were significantly impaired compared to controls on virtually all 
functions assessed (Table 5.1.2). Evaluation of learning effects with repeated measures 
analysis of variance showed that patients were unable to significantly enhance 
performance from the initial trial (trial 1) to subsequent trials (trial2 and 3). In contrast, 
normal age-matched controls evidenced consistent learning effects in 3 of 9 
neuropsychological tests: improvement took place in two tasks of visual memory, 
Misplaced Objects 1st try (p < .05) and the Benton Visual Retention Test (BVRT) 
immediate recall (p < .05), as well as in one test of verbal memory, Logical Memory 
delayed recall (p < .05). 
More subtle learning effects, sought through correlational analysis between 
demographic variables and change scores (triall to 3), suggested a significant association 
in Alzheimer patients between dementia severity (Mattis Dementia Rating Scale) and 
percentage change in Verbal Learning (immediate recall; r = .51, p < .05), and Visual 
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Table 5.1.2 Mean test scores 
Alzheimer patients Control subjects 
Triall Trial2 Trial3 Trial! Trial2 Tria13 
Verbal Memory 
Verbal Learning total§ 15.5 :!: 1.3* 16.2 :!: 1.8 15.8 :!: 1.7 34.2 :!: 1.0 33.7 :!: 1.0 33.8 :!: 0.9 
Verbal Learning delay 0.5 :!: 0.3• 0.4 :!: 0.3 0.4 :!: 0.3 4.8 :!: 0.6 4.1 :!: 0.7 5.0 :!: 0.6 
Logical Memory total 1.4 ± 0.3* 1.6 ± 0.4 2.0 :!: 0.3 9.4 :!: 0.8 95 :!: 0.8 10.3 :!: 0.7 
Logical Memory delay o.s ± o.z- 0.4 :!: 0.2 0.3 :!: 0.1 7.3 :!: 1.0 7.8 :!: 0.7 9.0 :!: 0.6:t: 
Paired Associates total 3.5 ± o.8• 3.4 :!: 0.5 3.7 :!: 0.7 16.5 :!: 0.9 15.9 :!: 0.8 15.5 :!: 0.9 
Paired Associates delay 1.4 :!: 0.3• 1.1 :!: 0.2 1.2 :!: 0.2 5.5 :!: 0.5 5.8 :!: 0.4 5.5 :!: 0.4 
Selective Reminding total 11.4 :!: 1.9* 12.4 :!: 1.8 12.4 :!: 1.9 49.1 :!: 3.4 48.9 :!: 3.4 49.9 :!: 3.5 
Selective Reminding delay 1.3 :!: 0.4* 1.4 :!: 0.4 1.4 :!: 0.5 11.3 :!: 0.7 10.9 :!: 1.0 10.7 ± 0.9 
Visual Memory 
Misplaced Objects 1st try 3.4 :!: 0.6~ 3.0 :!: 0.4 3.5 :!: 0.6 11.9 :!: 0.9 13.6 :!: 0.8 14.4 ± 0.8::1: 
Misplaced Objects 2nd try 5.3 :!: 0.8* 5.0 :!: 0.6 5.5 :!: 0.9 15.6 :!: 0.7 16.4 :!: 0.7 16.6 :!: 0.7 
Visual Retention total 2.9 ± 0.4* 3.8 :!: 0.5 3.4 ± 0.5 6.0 :!: 0.4 6.8 :!: 0.3 7.1 :!: 0.2:j: 
Visual Retention delay 2.6 ± 0.4* 2.6 :!: 0.5 2.9 :!: 0.5 6.4 :!: 0.4 6.6 :!: 0.4 6.6 :!: 0.4 
Visual Learning total 11.9 :!: 1.2* 12.8 :!: 1.6 13.6 :!: 1.7 20.5 :!: 1.7 21.7 :!: 1.5 21.6 ± 1.9 
Visual Learning delay 2.2 :!: 0.3' 2.4 :!: 0.3 2.2 :!: 0.4 4.8 ± 0.5 4.3 ± 0.5 4.3 ± 0.6 
Delayed Non Match Sample 7.6 :!: 1.3* 7.9 :!: 1.2 8.3 ± 1.2 19.7 :!: 0.8 18.8 ± 0.8 18.9 ± 1.7 
Attention 
Telephone Dialing 3 numbers 2.3 :!: 0.2t 2.2 ± 0.2 2.3 ± 0.2 3.0 :!: 0.2 3.0 :!: 0.0 3.0 :!: 0.0 
Telephone Dialing 7 numbers 2.9 ± 0.6• 3.4 ± 0.5 3.2 :!: 0.5 6.7 :!: 0.1 6.6 ± 0.1 6.8 :!: 0.1 
Telephone Dialing 10 numbers 2.3 :!: 0.5* 2.3 ± 0.4 2.2 :!: 0.5 6.9 ± 0.4 7.4 ± 0.4 7.0 ± 0.4 
'Alzheimer patients baseline (trial 1) significantly different from bose line a:mtrols at p < 0.001 
tAizheimer patients baseline (trial!) signilicamly different from baseline controls at p < 0.05 
tsignificant perfonnance increase in controls scross trial!, 2 and 3 a( p < 0.05 
§Total scores represent total immediate recaU 
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Learning (immediate recall; r = .59, p < .01). Thus, the lower the cognitive impairment, 
the higher the capacity to increase performance across trials. No consistent relation was 
found for any of the other demographic variables and change scores in patients or in the 
control group. 
Discussion 
No alterations were found in performance in Alzheimer patients across test trials; in 
contrast, control subjects demonstrated learning in one third of all neuropsychological 
tasks administered. Although alternate randomized test forms were used in each of the 
3 trials, controls increased scores in tests of verbal and visual memory, in manual as well 
as computerized tests. Thus learning seemed not confined to a certain cognitive domain 
or to a specific testmodality. On the other hand, the possibility exists that ceiling effects 
in neuropsychological testing in controls (e.g. Visual Learning, Telephone Dialing) and 
floor effects in testing in Alzheimer patients (e.g. delayed recall scores of most tests) play 
a role in the absence of learning in these tests. 
Learning potential in Alzheimer patients is suggested on the basis of reported abilities 
in procedural learning and implicit memory,4.S,l7 and normal rates of forgetting as 
compared to controls18•19 Accordingly, it could be expected that these residual capacities 
of memory and learning confound outcome measures in clinical trials. However, in the 
design employed in this study, chosen to model the widely used cross-over design with 
a comparison of baseline, drug and placebo, no learning could be ascertained in the 
patient group. Although some learning capacity may in fact be retained, the time interval 
of one week and the use of alternate forms could be sufficient to prevent Alzheimer 
patients from learning on these tests. On the other hand, learning could be a 
confounding factor when the number of test trials exceeds the number of available forms, 
which makes repetition of the same form necessary. Indeed, Alzheimer patients show 
better performance when tested repeatedly with same test items than with alternate items 
over a relatively long period of time,20 and improve in a variety of cognitive domains 
when the same form is repeated' 
Subtle learning effects were suggested in the patient group by the association of 
symptom severity with change in verbal as well as visual learning. Encoding and learning 
may thus be preserved to a certain extent in patients with mild Alzheimer's disease. 
However, the patient number performing in the range of mild dementia is too small in 
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the present study to address this issue in terms of seeking a subset showing consistent 
learning. 
The present results indicate that alternate forms of neuropsychological tests are not 
subject to learning in patients with Alzheimer's disease, in particular in those with 
moderately severe impairment. However, the suggestion of relative preservation of some 
learning capacity In patients with mild Alzheimer's disease and consistent learning in 
controls suggest that mental status could play an important role in the acquisition of 
material and the ability to increase performance. Thus, subjects with no or minimal 
cognitive impairment may show learning effects, which can decrease measurement 
precision in clinical trials.' Accordingly, researchers using repeat testing in controls or 
mild Alzheimer's disease, should be cautious for the possible confounding role of 
learning effects, even when alternate test forms are used. 
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Chapter 5.2 
Noot.ropic drugs in Alzheimer's disease: 
symptomatic treatment with pramiracetam 
Introduction 
Nootropics are a class of psychotropic drugs that enhance learning acquisition and 
reverse learning impairment in the experimental animal.' As yet, there has been no 
established mechanism of action for these drugs, but their toxic potential appears to be 
low.1·2 The initial compound discovered was piracetam, but several more potent nootropic 
drugs have since been developed,3•4 including pramiracetam.5 
Behavioral pharmacologic studies with pramiracetam have yielded positive results in 
several animal models of learning and memory.Z These models include reversal of 
electroconvulsive shock induced amnesia, improved performance in a delayed spatial 
alternation task, and reversal of learning deficits produced by hippocampal stimulation 
in rodents as well as facilitation of visual discrimination learning in primates. The 
mechanism of action of nootropic drugs remains poorly understood, although for some, 
cholinomimetic effects may contribute to the cognitive enhancing effects.' Pramiracetam, 
for example, increases high affinity choline uptake in rat hippocampus 7•8 and may 
stimulate hippocampal cholinergic neuronal impulse flow? Pramiracetam shows no effect 
on other central neurotransmitter levels and does not bind to their receptors.7 
To date, although it has been difficult to document the ability of any nootropic to 
alleviate symptoms of Alzheimer's disease (AD),9•10 previous clinical trials failed to 
employ adequate dose-finding in the individual patient, despite the characteristic 
presence of an inverted U-shaped dose-response curve for these drugs in the 
experimental animal.4·11·12 Moreover, preclinical studies often reveal considerable: 
intersubject variability with respect to the optimally effective dose. Clinical trials using 
a broad range of doses in an initial dose-finding phase, followed by a replication phase 
for those patients evidencing a best-dose, might help compensate for both these 
problems. As a test of this possibility, we evaluated the antidementia efficacy of 
pramiracetam, based on its activity in animal models and its reported effects on 
cholinergic function. 
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Patients and methods 
Ten patients (3 men, ?women) who satisfied NINCDS-ADRDA criteria13 for probable 
AD consented to participate in this study after full disclosure of its potential risks and 
benefits. Mean(± SEM and range) age was 66 ± 2.3 years (55 to 77), education 14 ± 
1.4 years (8 to 20), and symptom duration 4 ± 0.7 years (1 to 7). Dementia severity, 
assessed with the Mattis Dementia Rating Scale, 14 ranged from moderately severe to 
mild (68 to 125), with a mean score of 101 ± 5.2. Wechsler Adult Intelligence 
Scale-Revised15 yielded a mean full scale IQ of 74 ± 3.6 (62 to 83), and Wechsler 
Memory Scale16 an MQ of 70 ± 3.9 (59 to 96). All patients were free of centrally active 
medications for at least 4 weeks prior to study. 
Pramiracetam was evaluated in 2 phases under double-blind placebo-controlled 
conditions. In an initial dose-finding phase, baseline assessments were obtained after 1 
week treatment with placebo. Pramiracetam was then introduced at an initial dose of 300 
mg per day, and increased by weekly increments of up to 50% until a daily dose of 4000 
mg per day was attained. The duration of this phase was 5 weeks, but for safety purposes 
the initial 3 patients were treated for 8, 7 and 6 weeks respectively. Neuropsychological 
testing was performed weekly by means of the cognitive portion of the Alzheimer's 
Disease Assessment Scale (ADAS)P The non-cognitive portion of the ADAS was not 
included in the assessment of drug efficacy because the rating is relatively subjective. 
Patients found to have a "best-dose" (the largest ADAS scale reduction of at least 4 
points) then entered a 2nd, replication phase, during which they received 2 weeks 
placebo and of pramiracetam treatment in random order. Placebo was given for at least 
1 week immediately preceding and following active drug administration. 
Drug efficacy was evaluated by a blinded rater during baseline, placebo and best-dose 
treatment periods with alternate forms of the following neuropsychological tests: 
cognitive ADAS,17 Verbal Selective Reminding Test18 (15 word version), Digit Span,15 
Word Fluency,19 and Logical Memory.16 Visual memory was assessed with a novel Visual 
Learning Test using 5 trials with immediate and 1 with delayed recall. Five targets 
(indicated by a crossed out dot) on a 5 by 5 dotted matrix, have to be located after a 10 
second exposure to the target design on a blank matrix. In addition, the Dementia Mood 
Assessment Scale,20 a modified version of the Instrumental Activities of Daily Living 
Scale,21 and a novel Visual Selective Reminding Test (developed as an analog to the 
Verbal Selective Reminding Test; 15 pictures) were administered. In comparison to 8 
healthy subjects (2 men, 6 women: mean age 66 ± 1.8, 57 to 71; mean education 15 ± 
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1.2, 12 to 20), matched for age, sex and education to those patients that completed the 
replication phase, AD patients were significantly impaired in most outcome measures 
(Table 5.2.1). 
Pramiracetam levels were measured22 in plasma during the dose-finding and 
replication pbases as well as simultaneously in plasma and CSF after 2 additional weeks 
of best-dose treatment in 7 patients to assess blood-brain-barrier penetration. Lumbar 
punctures were performed 3.5 hours after the 1st morning drug dose. Pramiracetam side 
effects were monitored every 2 weeks with ECG and blood samples. 
Drug effects on brain energy metabolism were studied in 2 patients using 
18F-Fluorodeoxyglucose and Scanditronix-15B Positron Emission Tomography (PET) 
camera. Patients were scanned (using deoxyglucose autoradiographic method applied to 
PET)23 without drug and after 2 weeks of best-dose treatment. During tbe 2nd scan the 
head was precisely repositioned in the same position by using the mask employed in the 
1st scan. 18F-Fluorodeoxyglucose (5mc) was injected 180 min after drug ingestion and 
scanning began 30 min later. Irregular regions of interest were defined with the help of 
an anatomical atlas24 for cortical and subcortical structures in 9 contiguous slices of the 
1st scan and copied on to the corresponding slices of the 2nd scan. In patient 1 absolute 
quantification was not obtained (arterial blood samples not available) and differences 
between scans were calculated in regions of interest/whole brain ratios. 
Neuropsychological data are reported as means ± SEM and analyzed with AN OVA 
techniques (BMDP P7D)25 and repeated measures analysis of variance (BMDP P2V).25 
Correlations of spinal fluid pramiracetam levels and pretreatment psychometric values 
with drug therapy change scores26 in the replication phase were evaluated by Pearson's 
correlational analysis (BMDP P7D).25 
Results 
During the 1st phase of this study, 8 of the 10 patients were found to have a best-dose 
of pramiracetam (Table 5.2.2). In these individuals, improvement in ADAS scores, where 
lower values reflect better performance, ranged from -8.3 to -4.3 (Table 5.2.3). ADAS 
score changes in the 2 remaining patients ranged from -0.6 to 7. The degree of change 
did not correlate with untreated dementia severity, as measured by the Mattis Dementia 
Rating Scale. 
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Table 5.21 Effect of pramiracetam on cognitive function* 
General cognitive function 
ADAS cognitive 
ADAS non-cognitive 
Activities of Daily Living 
Mood Assessment 
Verbal Memory 
Verbal Selective Reminding total 
Verbal Selective Reminding delay 
Digit Span forward 
Digit Span backward 
Logical Memory immediate recall 
Logical Memory delayed recall 
Verbal Fluency total 
Verbal Fluency perseverations 
Visual Memory 
Visual Selective Reminding total 
Visual Selective Reminding delay 
Visual Learning total 
Visual Learning delay 
"Values are the means :!: SEM 
Controls 
Baseline 
2.9 ± 0.6 
0.5 ± 0.2 
43.6 ± 4.4 
5.5 ± 1.2 
10.4 ± 0.7 
7.9 ± 0.9 
8.7 ± 1.5 
7.1 ± 1.5 
43,0 ± 4.0 
1.5 ± 0.9 
52.4 ± 3.1 
11.6 ± 0.6 
17.4 ± 2.5 
4.4 ± 0.7 
tBaseline AD patients significantly different from baseline controls at p < 0.001 
:!:Baseline AD patients significantly different from baseline controls at p < 0.05 
§Drug significantly different from baseline and placebo at p < 0.05 
Patients 
Baseline Placebo Drug 
30.8 ± 4.2t 29.9 ± 4.3 29.1 ± 4.0 
4.5 ± 1.7j: 4.9 ± 1.3 4.9 ± 1.5 
35.7 ± 9.3t 35.9 ± 9.3 35.6 ± 9.3 
26.6 ± 4.9t 24.0 ± 5.8 25.0 ± 5.7 
15.4 ± 2.3t 12.9 ± 2.5 12.5 ± 2.1 
o.o ± o.ot 0.4 ± 0.4 0.0 ± 0.0 
8.1 ± 1.0 8.3 ± 0.8 7.6 ± 0.8 
3.3 ± 0.5t 3.1 ± 0.9 3.8 ± 0.5 
1.1 ± o.2t 1.5 ± 0.4 1.4 ± 0.4 
0.4 ± 0.3t 0.3 ± 0.2 0.3 ± 0.2 
10.4 ± 3.4t 10.1 ± 3.6 9.3 ± 4.1 
1.9 ± 1.0 1.8 ± 0.9 1.0 ± 0.9 
14.8 ± 3.5t 14.0 ± 2.5 16.5 ± 3.2 
1.1 ± o.8t 0.5 ± 0.5 1.4 ± 0.9 
10.9 ± 2.5 14.1 ± 2.3 14.4 ± 3.1 
1.4 ± 0.3t 1.9 ± 0.6 2.9 ± 0.6§ 
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Table 5.22 Pramiracetam levels in plasma and CSF* 
Best dose Plasma CSF CSF/plasma 
(mg/day) (l'm/ml) (l'm/ml) ratio 
Patient 
1 2,000 7.5 1.0 0.13 
2 3,200 12.7 4.1 0.32 
3 1,600 9.1 2.0 0.22 
4 2,400 11.4 1.4 0.12 
5 3,200 14.5 3.8 0.26 
6 2,000 6.8 1.1 0.16 
7 1,200 1.3 0.5 0.38 
Mean± SEM 2,229 ± 288 9.0 ± 3.4 2.0 ± 0.5 0.23 ± 0.04 
* Values are from simultaneously obtained venous blood and lumbar CSF samples from all but one 
patient evidencing a best dose of pramiracetam. The missing patient had a best dose of 4,000 mg/ d 
and completed the study but was unsuitable for lumbar punction 
During the 2nd, replication phase, all 8 patients evidenced a significant improvement 
in the Visual Learning delay task (p < .05). There was, however, no improvement on any 
other neuropsychological test (Table 5.2.1). Indeed, the ADAS score change from 
placebo to drug treatment averaged only -0.8 ± 1.1 (Table 5.2.3). Moreover, there was 
no correlation between the change in ADAS scores from baseline to best-dose in the 
dose-finding phase and alteration from placebo to drug in the replication phase. 
Evaluation of individual patient data indicated that in the replication phase only 2 
individuals (patient 1 and 2) had a more than 4 point reduction in their ADAS score 
with drug treatment (Table 5.2.3). Patient 1 also showed improvement in 3 other 
neuropsychological tests (Visual Selective Reminding total and delay, Visual Learning 
total and delay, and Logical Memory immediate recall). Analysis of individual dose-
response curves in the dose-finding phase revealed no consistent inverted U-shaped 
pattern. 
PET scans using 18F-Fiuorodeoxyglucose were completed in the 2 patients evidencing 
more than a 4 point improvement in the ADAS scale. Relative metabolic values (ratio 
of cerebral metabolic rates for glucose for regions of interest to the whole brain) showed 
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Table 5.23 Effect of pramiracetam on cognitive ADAS scores 
Dose-finding phase' Replication phase 
Patient Baseline Best-dose Change Placebo Best-dose Change 
1 40.3 32.0 -8.3 36.3 32.0 -4.3 
2 21.0 15.6 -5.4 21.6 16.3 -5.3 
3 35.6 30.4 -5.2 35.7 35.0 -0.7 
4 20.7 16.3 -4.4 18.7 21.7 +3.0 
5 38.0 32.4 -5.6 34.0 35.0 + 1.0 
6 21.0 16.7 -4.3 21.3 21.0 -0.3 
7 23.4 18.3 -5.1 18.7 21.0 +2.3 
8 52.3 45.3 -7.0 53.0 50.7 -2.3 
Means± SEM 31.5 ± 4.2 25.9 ± 3.8 -5.7 ± 0.5 29.9 ± 4.3 29.1 ± 4.0 -0.8 ± 1.1 
* Two patients did not evidence an improvement of 4 points or more. Baseline scores and best scores in dose fmding were 34.0 and 35.7 for patient 9 and 7.3 
and 6.7 for patient 10 
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no consistent differences between the untreated and pramiracetam treated states: these 
differences from frontal, temporal, and parietal cortex, and from striata and thalamus 
ranged from -7.0 to 4.3 in patient 1, and from -8.4 to 4.6 in patient 2. Absolute metabolic 
values obtained in patient 1 showed an increase in glucose consumption (ranging from 
9% to 20%) while on drug as compared to placebo. 
Measurement of pramiracetam levels revealed a consistent oral dose-plasma level 
relationship (Figure 5.2). CSF /plasma partition coefficients for the group ranged from 
0.12 to 0.38 (Table 5.2.2). No consistent relation between cognitive change scores and 
spinal fluid pramiracetam levels or pretreatment neuropsychological tests could be 
established. 
Side effects occurring during pramiracetam administration were few and mild. Two 
patients described headache at 400 to 1200 mg/day, and one experienced sleepiness, 
decreased appetite and dizziness for 2 days when placebo was begun after treatment with 
the highest drug dose (4000 mg). Pramiracetam had no effect on vital signs, standard 
hematologic and blood chemistry values or on the ECG. 
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Discussion 
We could not demonstrate any clinically significant improvement in cognition, mood 
or activities of daily living in the pramiracetam treated AD patients admitted to this 
study. Indeed, among the numerous outcome measures employed, statistically significant 
benefit occurred only in the delay scores from a visual learning task. Since similar tests 
showed no such change, these seemingly positive results presumably reflect the chance 
variations that are frequently observed when using multiple measures. Our findings thus 
failed to confirm the encouraging inferences drawn from an earlier open-label trial using 
much lower pramiracetam doses,27 and extended those of previous controlled studies of 
other nootropics indicating that agents of this type confer no consistent symptomatic 
benefit in AD28•29 and in Parkinson's disease.30 
Strenuous efforts were made to improve the design in this clinical trial so the 
possibility of demonstrating antidementia efficacy would be maximally increased. In 
particular, we attempted to deal with the potential problems of narrow range of efficacy 
and wide intersubject variability by means of a 2 phase study, initially involving the 
ascertainment of a putative best-dose for each patient over a wide range of drug dosages. 
At 1st glance it would seem surprising that our "enrichment" strategy of admitting only 
patients showing an "effect" of pramiracetam in the initial dose-finding phase to the 
subsequent replication phase actually seemed to function counterproductively: while 80% 
of those entering the study were found to have a best-dose and thus to evidence a 
presumptive antidementia effect, only 25% of this subgroup achieved a similar response 
during the replication phase. Presumably, a 4 point change in the cognitive portion of the 
ADAS simply reflects the variability normally attending the repeated administration of 
this test under similar conditions over a relatively long period. Future applications of this 
enrichment strategy using the ADAS may thus require more rigorous criteria for 
admission into the replication phase. 
The failure of this study to demonstrate antidementia activity also does not appear 
attributable to pharmacokinetic issues. Pramiracetam doses administered here, calculated 
on a mg/kg basis, were in the range found to benefit behavioral function in the 
experimental animal (2). Moreover, pramiracetam's access to the central nervous system 
of our patients, as estimated by a mean CSF /plasma partition coefficient of 0.23, 
approximates the coefficient of 0.15 found in rodent studies (unpublished data). 
The PET scan results supported the possibility that pramiracetam may have no 
intrinsic activity in Alzheimer dementia. In neither of two cases was there any consistent 
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regional variation in relative metabolic values. Moreover, pramiracetam induced no 
marked increase in absolute metabolic values in one of these individuals. The present 
results contrast with earlier observations suggesting that relatively high doses of a closely 
related nootropic, piracetam, enhance regional glucose metabolism in AD patients." In 
view of our PET findings, however, it is hardly surprising that pramiracetam, at doses up 
to 4000 mg, afforded no clinically evident symptomatic benefit. 
It is tempting to speculate that animal models32•33 currently in use to screen potential 
antidementia compounds may not be valid predictors of therapeutic efficacy in AD. To 
the extent now possible, it will be important to validate these models as well as to 
develop alternatives of greater predictive value. In the meantime, clinical trials of 
pharmaceuticals selected solely on the basis of activity in current preclinical models of 
learning and memory may no longer be tenable. 
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Serotonergic mechanisms in Alzheimer's disease: 
preliminary results of a controlled clinical trial with 
lisuride 
Introduction 
Lisuride is a semisynthetic ergot derivative and a potent ligand for both serotonergic 
and doparninergic receptors in the central nervous system. Pharmacologic preclinical 
studies of lisuride have shown a serotonergic antagonistic effect in low doses.1 A decrease 
in serotonin (5-HT) synthesis and turnover was reportedly caused by lisuride, probably 
mediated through cessation of spontaneous firing of 5-HT neurons by 5-HT receptor 
stimulation.2•3 Intravenous infusions of lisuride in the rat produce a suppression of 
neurons in the raphe dorsalis, the major ascending serotonergic pathway of the brain.4 
Receptor binding studies show that lisuride has high affinity for the 5-HT,. receptor.'·' 
Studies in animal models of learning and memory suggest that serotonergic 
mechanisms may play an important role in information processing. Although results have 
been inconsistent, the general observation is that interventions designed to elevate levels 
of 5-HT throughout the brain impair cognitive function.' In turn, experiments with 5-HT 
antagonists in aged rats demonstrated improvement of memory acquisition and retrieval.7 
It is further suggested that 5-HT activity exhibits an inhibitory influence on other 
neurotransmitters, including the noradrenergic8 and cholinergic systems.9•10 
Clinical trials in Alzheimer's disease have attempted to restore serotonergic 
neurotransmission, based on evidence that serotonergic activity is impaired in this 
disease.11·15 A recent study with m-chlorophenyl-piperazine (mCPP), a 5-HT receptor 
agonist, reported worsening of memory and behavioral functions in patients with 
Alzheimer's disease16 These results, together with preclinical findings, suggest that 
inhibition of serotonergic neurotransmission might confer benefit to the symptoms of 
Alzheimer's disease. To obtain some preliminary data on this hypothesis, a controlled 
clinical trial with lisuride was carried out in 16 Dutch patients with mild to moderately 
severe Alzheimer's disease. 
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Subjects and methods 
Sixteen patients (10 men, 6 women) who satisfied N!NCDS-ADRDA criteria for 
probable Alzheimer's disease17 consented to participate in this study after full disclosure 
of its potential risks and benefits. Approval was obtained from the Medical Ethics 
Committee of the University Hospital Rotterdam Dijkzigt and of the Erasmus University 
Rotterdam. Subjects were selected from participants of the Rotterdam Elderly Study, a 
single center prospective follow-up study conducted among the total population aged 55 
years and over of the suburb Ommoord in Rotterdam, The Netherlands. Rationale and 
design of the Rotterdam Elderly Study have been described elsewhere.18 In addition, 
patients were referred from the metropolitan area of Rotterdam to the outpatient clinic 
of the Departments of Neurology and Geriatric Medicine, University Hospital Rotterdam 
Dijkzigt. Inclusion criteria for the study were: Mini-Mental State Examination score19 
higher or equal to 15 and lower or equal to 24, Hachinski ischemic score20 maximum 4, 
and blood pressure between 100 and 170 mmHg systolic and 60 to 100 mmHg diastolic. 
Dementia severity, assessed with the Global Deterioration Scale21 ranged from mild to 
moderately severe (3 to 6). On admission to the study, all patients had been free of 
centrally active drugs for at least 1 month. 
Lisuride was administered in a randomized double-blind, placebo-controlled, parallel 
group design. Baseline assessments were obtained after an initial 2-week single-blind 
treatment with placebo. Patients were then randomized to either lisuride or placebo, and 
started the first study phase, a dose-finding phase of 4 weeks, with an initial dose of 0.075 
mg per day increased by weekly increments of 0.075 mg, divided in 3 daily doses, until 
a dose of 0.3 mg per day was attained. The "best-dose", defined as an optimal ratio 
between efficacy and tolerance, was determined with the Clinical Global Impression 
Scale.22 When no clinical change was observed, the highest dose of 0.3 mg per day was 
administered as the best-dose. All patients then entered the second study phase, an 
efficacy phase of 8 weeks with treatment of the best-dose. 
Outcome measures were evaluated at baseline, at the end of the dose-finding phase 
at the maximal dose, and after 8 weeks treatment of the best-dose. Assessment of global 
cognitive and non-cognitive function, included the Clinical Global Impression Scale, the 
Dementia Mood Assessment Scale23 and the Standardized Investigation of Dementia 
(SIDAM).24 The Mini-Mental State Examination is part of the SIDAM and is reported 
additionally. Neuropsychological evaluations were performed with the following tests: 
modified version of the California Verbal Learning Test,25 Word Fluency,26 and Visual 
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Vigilance Task. In the Visual Vigilance task the patient must perceive a darker forming 
square from white noise in one of 4 squares of a computer monitor as quickly as 
possible. In addition, 3 computerized tests of visual memory from the Cambridge 
Neuropsychological Test Automated Battery (CANTAB) were included: Delayed 
matching-to-sample, Conditional visuospatial associative learning, and Working memory 
test.27'29 Psychomotor function was assessed with 2 tests of the psychoexperimental test 
battery, including Tapping and Peg switching.30 Side effects and blood pressure were 
monitored at weekly intervals during the dose-finding phase, and at 4 weekly intervals 
during the efficacy phase, and ECG at baseline was repeated at termination of the study. 
Outcome measures of cognitive and non-cognitive function are reported as means ± 
SEM. Percentage change scores31 from baseline to best-dose treatment were compared 
between groups with !-tests. The association between change scores of psychometric 
performance and the SIDAM baseline score in the lisuride treated group was evaluated 
with linear regression analysis. 
Results 
Entry characteristics of the lisuride and placebo treated patients are presented in 
Table 5.3.1. No significant differences between groups in pretreatment baseline scores 
were found in neuropsychological outcome measures, but significantly higher scores on 
the SID AM (p < 0.01) and the MMSE (p < 0.05) were observed at baseline in the 
lisuride treated group (Table 5.3.2). 
During the dose-finding phase of this study, 6 patients had 0.3 mg per day and 1 
patient 0.225 mg of lisuride as their best-dose. The single patient with a best-dose of 
0.225 mg had improved attention and increased initiative at this dose and evidenced 
tiredness at the maximal dose of 0.3 mg per day. Assessment with the Clinical Global 
Impression Scale for individual patients at the highest dose showed no differences 
between groups. No change was observed in 4 Jisuride patients and in 4 placebo patients, 
worse impression in 1 lisuride patient and in 3 placebo patients, and better impression 
in 1 lisuride patient and in 2 placebo patients. 
During the efficacy phase, patients treated with lisuride showed significantly better 
performance (p < 0.05) compared to placebo treated patients in the modified version 
of the California Verbal Learning Test (Table 5.3.3). In contrast, patients with lisuride 
showed a decrease in scores of two tests of attention (Tapping and Visual Vigilance 
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Table 5.3.1 Entry characteristics of Alzheimer patients for the lisuride and placebo group at screening* 
Lisuride (n=7) Placebo (n=9) 
Sex 
Male 4 6 
Female 3 3 
Age (years) 74.4 ± 5.0 (65-79) 74.6 ± 1.7 (65-82) 
Education (years) 9.9 ± 4.1 (6-18) 8.3 ± 1.8 (6-10) 
Symptom duration (years) 4.7 ± 2.8 (2-10) 5.0 ± 2.0 (2-9) 
Mini-Mental State Examination 22.1 ± 2.7 (17-24) 17.9 ± 3.9 (15-24) 
GDS 4.6 ± 1.0 (3-6) 5.4 ± 0.7 (4-6) 
~values are presented as means ;!: SO (range) 
Task), while the placebo group increased performance (table 5.3.3). However, these 
changes were not statistically significant. Similar results were obtained when 3 patients 
with the highest Mini-Mental scores were excluded. No consistent alterations in any of 
the other tests of verbal and visual memory, attention, psychomotor function, and 
measures of global cognitive function or mood were observed (Table 5.3.2 and Table 
5.3.3). A similar slight decrease in global cognitive function as measured with the SID AM 
was present in both groups over time. Moreover, no differences were observed between 
lisuride and placebo treated patients for clinical impression. No change was observed in 
3 lisuride patients and in 3 placebo patients, worse impression in 4 Iisuride patients and 
in 5 placebo patients, and better impression in none of the lisuride patients and in 1 
placebo patient. In addition, anecdotal reports by some patients and their families were 
in agreement with the generally negative results. No significant relations were found 
between percentage change scores and baseline SID AM scores. Side effects were few and 
mild. Possible drug related side effects were tiredness in 1 patient at 0.3 mg lisuride per 
day and headache and dizziness in 1 other patient at 0.225 mg, for both patients only in 
the dose finding phase. 
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Table 5.3.2 Effect of lisuride on measures of general cognitive function and mood* 
General Cognitive function 
SID AM 
Mini-Mental State Examination 
Mood 
Dementia Mood Assessment Scale 
Clinical Impression 
Clinical Global Impression Scale§ 
•Values are the means ± SEM 
Baseline 
38.0 ± 3.0t 
23.2 ± 1.3t 
20.9 ± 4.0 
Lisuride (n=7) 
Highest 
dose 
37.7 ± 3.3 
22.9 ± 2.0 
20.4 ± 3.3 
29% 
Best-dose 
36.3 ± 4.2 
22.0 ± 1.8 
24.3 ± 4.2 
57% 
Baseline 
23.0 ± 2.9 
16.9 ± 1.7 
26.8 ± 3.8 
t :t:Baseline of Jisuride treated patients significantly different from baseline of placebo treated patients at p < 0.01, and p < 0.05, respectively 
§In percentage patients that appeared worse in clinical impression 
Placebo (n=9) 
Highest 
dose 
22.3 ± 2.4 
16.1 ± 1.4 
25.8 ± 3.6 
33% 
Best-dose 
21.8 ± 2.5 
14,8 ± 1.3 
29.1 ± 4.3 
56% 
Table 5.3.3 Effect of lisuride on cognitive function* 
Lisuride (n=7) 
Baseline Highest dose Best-dose 
Verbal Memory 
California Verbal Learning Test:t: 23.9 ± 4.2 23.2 ± 4.3 27.0 ± 4.0t 
Verbal Fluency 14.9 ± 2.9 12.6 ± 3.0 15.9 ± 3.4 
Visual Memory 
Visuospatial Associative Learning:t: 20.1 ± 3.8 12.1 ± 0.9 14.7 ± 2.4 
Delayed Matching to Sample:t: 15.9 ± 2.5 16.4 ± 1.9 16.3 ± 2.1 
Working Memory Test 
between errors 49.9 ± 9.4 39.4 ± 8.8 28.6 ± 6.6 
within errors 3.1 ± 1.2 1.7 ± 1.1 1.6 ± 0.4 
Attention 
Visual Vigilance Task 18.7 ± 2.9 22.3 ± 4.1 11.7 ± 3.1 
Psychomotor 
Tapping 318.1 ± 11.1 295.6 ± 31.5 283.0 ± 48.8 
Pegboard 139.7 ± 8.1 134.7 ± 13.0 136.1 ± 14.4 
•values are the means ± SEM 
tPercentage change from baseline to best-dose significantly different from patients with placebo by t-test at p < 0.05 
:tScores are presented for total recall 
Placebo (n=9) 
Baseline Highest dose Best-dose 
17.0 ± 2.8 12.1 ± 3.2 14.1 ± 2.5 
11.4 ± 2.3 10.7 ± 2.7 10.8 ± 1.9 
18.4 ± 4.4 15.3 ± 3.8 11.1 ± 3.6 
12.4 ± 2.2 11.4 ± 2.0 10.8 ± 2.0 
27.1 ± 9.8 29.4 ± 10.2 28.9 ± 9.8 
2.1 ± 0.8 1.2 ± 0.5 1.8 ± 0.8 
18.7 ± 5.1 21.1 ± 4.2 22.5 ± 5.5 
240.4 ± 48.6 256.8 ± 36.1 300.0 ± 19.7 
104.3 ± 24.4 125.0 ± 15.1 118.3 ± 14.9 
Lisuride in Alzheimer's disease 
Discussion 
Short-term treatment with lisuride in low doses in patients with mild to moderately 
severe Alzheimer's disease significantly improved performance on a verbal learning task, 
whereas no effects could be demonstrated in non-verbal cognitive tests. Clinical global 
impression was in agreement with an apparent lack of clinically significant therapeutic 
benefit, and indicated that more than half of both lisuride and placebo treated patients 
showed progressive worsening of their symptoms. The number of subjects in this study 
is small and statistical power to demonstrate a clinical effect is limited. Differences at 
baseline in test scores of screening tests were found but appear to be due to chance in 
our parallel study design and result from the small study number. This did not appear 
to influence the outcome of the study since similar results were obtained when subjects 
with the highest scores on these tests were excluded to allow comparison of groups more 
equal in baseline scores. Our preliminary findings thus suggest that a partial serotonergic 
agonist with predominant binding to the 5-HT,. receptor is unlikely to prove clinically 
useful in Alzheimer's disease, but may have effects on verbal memory. 
The pharmacologic action of lisuride suggests an inhibitory effect on serotonergic 
neurotransmission in Alzheimer's disease, mediated through its binding at the 5-HT,. 
site. To attain this central pharmacologic effect, we administered lisuride in dosages up 
to 4 times the dose that was effective in the prevention of seizures.32 Receptor 
modulation as a potential therapeutic strategy is dependent on the functional integrity 
of residual neurons. In Alzheimer's disease, receptor loss has been reported in 5-HT2 
sites, and to a lesser extent in 5-HT1 sites.33•34 We included patients in an early stage of 
the disease to maximize this potential therapeutic effect. However, it is possible that 
lisuride is active at both presynaptic (in dorsal raphe) and postsynaptic (in hippocampus 
and cerebral cortex) 5-HT,. receptors. While the presynaptic effect may well result in 
decreased serotonergic function, postsynaptic stimulation in hippocampal and cortical 
neurons may have the opposite effect (i.e. maintaining inhibitory serotonergic tone), 
attenuating its beneficial action. In addition to its high affinity for the 5-HT,. receptor, 
lisuride also binds with equal affinity to D2 receptors and to 5-HT2 and D1 receptors with 
10-100 times lower affinity.35 Interactions between these receptors have been suggested. 
For example, it has been shown that the 5-HT2 site may have an inhibitory effect on the 
5-HT1 receptor sites.36 These findings may provide an explanation for the finding in this 
study that lisuride affords no clinically evident symptomatic benefit. 
The functional significance of serotonergic mechanisms in Alzheimer's disease is not 
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fully understood. Impaired serotonergic function is shown in Alzheimer"s disease, but no 
correlations of this impairment with neuropathologic findings and cognitive dysfunction 
could be established37 On the mher hand, the serotonergic deficiency in this disease has 
been linked to behavioral disturbances, including depression, agressive behavior, and 
anxiety.3840 Neither clinical trials in Alzheimer's disease41-43 nor evidence from the 
preclinical level have yet elucidated a well defined role of 5-HT in behavioral and 
mnemonic functions. Indeed, several issues complicate the interpretation of cognitive 
concomitants of serotonergic receptor modulation. At present, drugs may not be selective 
enough in their pharmacologic action. The clinical evaluation of new compounds, such 
as selective 5-HT1, receptor antagonists,44 may provide more insight in the relevance of 
serotonergic mechanisms in Alzheimer's disease. The high concentration of 5-HT1a 
receptors in the hippocampus and entorhinal cortex,45 structures intimately involved in 
memory and learning are in favour of further exploration of the significance of this 
receptor. Nevertheless, the clinical correlates of interactions with other neurotransmitter 
systems are still elusive, e.g. for cholinergic and noradrenergic neurons.8•10 Furthermore, 
serotonergic impairment is regional in Alzheimer's disease and functional effects of 
serotonergic modulation may be accordingly different. 
In conclusion, treatment of Alzheimer patients with lisuride had no consistent effect 
on cognitive functions or on global clinical change. It appears therefore unlikely that 
modulation of central serotonergic activity by this agent will alleviate symptoms of 
Alzheimer's disease. However, the study number was small in this preliminary study and 
the pharmacological profile with respect to receptor binding of lisuride may not be 
specific enough. The possibility can not be excluded that further treatment strategies 
designed to alter serotonergic neurotransmission are more successful. 
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Introduction 
Epidemiologic studies may address several types of research questions, related to 
the etiology, diagnosis and prognosis of the disease. In this thesis aspects of these 3 
domaios of research receive attention with respect to aging and Alzheimer's disease. 
In this chapter we will first focus on studies of cerebral blood flow (CBF) in aging 
and Alzheimer's disease measured with single photon emission computed tomography 
(SPEer) using technetium-99M labeled hexamethyl propylene amine oxime (99mTc 
HM-PAO) as tracer. In addition to methodological issues with respect to the internal 
and external validity of these studies, the diagnostic role of SPEer for Alzheimer's 
disease and vascular risk factors as possible etiologic determinants of regional 
cerebral blood flow (rCBF) will be discussed. We will then deal with the prognosis of 
Alzheimer's disease, in this thesis with reference to current and future therapeutic 
strategies, as well as with some methodological aspects related to the conduct of 
clinical trials. 
Regional cerebral blood flow measured with , ... Tc HM-PAO SPECT in 
aging and dementia 
Methodological considerations 
Several concerns of validity may arise for SPECT studies of Alzheimer's disease. 
Some of the problems that could have played a role in the SPECT studies presented 
in this thesis include diagnostic misclassification, selection bias, and the effects of 
non-participation. In addition, selection bias may be a problem in the definition of 
regions of interest in the analysis of SPEer studies. Each of these issues will be 
discussed. 
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Diagnostic misclassification 
For Alzheimer's disease, one of the primary obstacles for researchers is the 
inaccuracy of the clinical diagnosis, since at present no biological marker for 
aotemortem diagnosis is available. The introduction of the DSM-TII criteria for 
primary degenerative dementia' aod the NINCDS-ADRDA criteria for probable and 
possible Alzheimer's disease' has considerably improved diagnostic accuracy and 
staodardization of clinical criteria, but diagnostic errors are still estimated to vary 
from 8-32%.3 Despite huge current research efforts to find a biological marker in 
cerebrospinal fluid, cerebral cortex, or blood, no definitive results have been reported. 
Recent studies suggest a possible role for abnormally phosphorylated tau, elevated 
levels of ubiquitin,4 neuronal thread protein,5 or the amyloid precursor protein.6 
Studies investigating the contribution of SPECT to the diagnosis of Alzheimer's 
disease will be confronted with the problem of uncertain diagnosis, however to a 
certain extent. In the study evaluating the diagnostic characteristics of SPECT in this 
thesis (chapter 3.2), the clinical diagnosis of probable Alzheimer's disease' is taken as 
the gold standard. Notwithstanding the diagnostic error also present in our study, 
possibly resulting in an underestimation of the true difference in rCBF between 
Alzheimer patients and controls, the results apply to the criteria as they are currently 
used in clinical practise. 
Diagnostic misclassification could also have occurred in the control group. We 
sampled controls from the population and excluded only those with a neurologic 
disease including subjects with a dementia syndrome and no restrictions were imposed 
with cognitive screening tests. Indeed, some overlap was present in the Mini Mental 
State Examination test for patients and controls, and a striking observation was made 
that the meao rCBF of the temporo-parietal cortex in controls was lower than the 
mean parietal rCBF of Alzheimer patients. The possibility that some patients with 
low temporo-parietal rCBF had preclinically developing Alzheimer's disease can not 
be excluded. This would have resulted in an underestimation of the difference in 
rCBF between Alzheimer subjects and controls. 
Selection bias for subjects 
Selection bias refers to any error that may occur in the process of identifying a 
study population. It could have played a role in the SPECT studies presented in this 
thesis: selection bias for control subjects (chapter 3.2) aod for a sample from the 
general population (chapter 3.3). 
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In chapter 3.2, it was reasoned that an adequate comparison of Alzheimer patients 
for estimation of the diagnostic characteristics of SPECT should be performed with 
those at risk for the disease; therefore we sampled controls from the general 
population. It was hypothesized that previous studies included control subjects that 
were likely biased towards healthier individuals and that this could have resulted in 
an overestimation of the diagnostic potential of SPECT. Several results reported in 
this thesis supported this hypothesis, including the finding that temporal rCBF was the 
best discriminating variable while most other studies report largest differences 
between Alzheimer patients and controls in parietal and temporo-parietal cortex. It 
was speculated that this finding could be explained by the presence of various 
cerebrovascular risk factors in our control group from the population. Individuals with 
a history of various illnesses including cardiovascular disease were excluded in several 
other SPECT studies. Support for the contention that vascular risk factors may be 
related to parietal and temporo-parietal rCBF comes from the study presented in 
chapter 3.3. These findings may therefore explain the consistently higher figures of 
sensitivity and specificity of SPECT as a potential diagnostic tool in the diagnosis of 
Alzheimer's disease reported in the literature, as compared to our results. Three 
issues require further comment. The 1st issue refers to selection criteria for control 
subjects determined hy the investigator, the 2nd and 3rd refer to the effect of non-
response for controls and Alzheimer patients, respectively. 
First, there is considerable debate about how to define normal aging of the nervous 
system and how to define a control group7 •8 Differences in selection criteria for 
control populations may, at least in part, explain differences in study results, as for 
example in studies of cerebral glucose metabolism and normal aging.8•9 A distinction 
was proposed of "usual aging" and "successful aging", the latter category representing 
an elite group without the apparent age-related changes, and recently a plea was 
made to investigate these groups separately.10 We took as a point of departure that 
controls should represent those who, had they developed the disease, would have 
been selected as casesY Subjects with a history of a neurologic disease were excluded 
from the control group, because interference may occur with the predicting variable, 
the rCBF. On the other hand, some nondemented subjects with a history of a 
neurologic disease that may compromise rCBF, are also at risk for Alzheimer's 
disease. In fact, these subjects may therefore be eligible for inclusion in the control 
group in certain instances, such as subjects with previous transient ischemic attacks. 
Exclusion of these subjects would result in an overestimation of the contrast between 
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groups. This would refer to only very few persons in our study but illustrates 
theoretical problems of selecting subjects for Alzheimer studies. 
Second, selection bias for the control group could have resulted from non-response. 
Several subjects refused participation, but detailed analysis revealed that this was 
unlikely to be selective (chapter 3.2). Furthermore, the distribution of various vascular 
risk factors was similar to a sample considered representative for the general 
population in Ommoord. Thus, although the possibility of selection bias could not be 
fully excluded for the controls, these findings suggested that it is unlikely that 
selection bias played an essential role in this study. 
Third, selection bias from non-response could have played a role for the Alzheimer 
subjects, recruited from the outpatient memory clinic from the University Hospital 
Rotterdam Dijkzigt. However, all patients in the period 1989 to 1991 referred for 
evaluation of memory complaints received a SPECT investigation. Thus, selection 
ntight have occurred in the referral pattern to the outpatient clinic, but it remains 
hard to predict how this would have affected the estimation of the difference in rCBF 
between Alzheimer patients and controls. 
In chapter 3.3, the study of risk factors for atherosclerotic vessel disease as 
deterntinants of rCBF, we sought to sample a group of individuals representing a 
large spectrum of these possible determinants. This was performed by taking a sample 
from the general population in Ommoord. The non-response for all participants in 
the Rotterdam Elderly Study might have been selective, with less participation of 
more diseased subjects. In addition, selective refusal of subjects from the population 
of 111 subjects that participated in a magnetic resonance imaging study could be a 
source of selection bias. The potential problem refers to external validity, implying 
possibly comprontised generalization of the results. However, this is not a primary 
concern in this study, since we sought to establish a relationship between age, vascular 
risk factors and rCBF. Thus no threat to the internal validity of the results was 
suggested on these grounds. Nevertheless, one may speculate that selective non-
response may lead to an underestimation of the association of the determinants 
(vascular risk factors) with the outcome (rCBF). 
Sampling bias in regions of interest 
Regions of interest are constructed to have an anatomical reference for 
measurements of rCBF and to reduce the enormous amount of information generated 
by a cerebral SPEer study. The sampling of these regions could introduce bias since 
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areas of hypoperfusion outside the sampled area are not detected. Qualitative analysis 
would circumvent the problem of sampling bias only partially because no criteria for 
subjective judgement are generally accepted. We investigated 3 different methods for 
the definition of regions of interest as determining factors for the outcome of rCBF 
measurements (chapter 3.1). The regions of interest were constructed with reference 
to normal anatomy, including 1 method with multi-slices and 1 method using a single-
slice, and a 3rd, rectangular region. It was suggested in this thesis that rectangular 
regions of interest are associated with decreased measurement precision and less 
discriminative ability for patients with Alzheimer's disease and control subjects, as 
shown with receiver-operator-characteristic curves, when compared to regions with 
reference to normal anatomy. However, these differences appeared to be dependent 
on dementia severity: with increasing dementia severity, there is an increasing risk of 
underestimating the difference between Alzheimer patients and control subjects with 
rectangular regions, while no differences between the 3 methods were observed for 
mild Alzheimer patients. With respect to discriminative ability, future SPECT studies 
using these rectangular regions of interest should be aware of the potential problems 
of this method, and may base the choice of method for analysis on the purpose for 
which SPECT is used. 
The absence of a gold standard for rCBF assessment in humans, however, 
precludes a definitive interpretation of what may constitute a "best" method of 
analysis. Indeed, one of the concerns for regions of interest with reference to normal 
anatomy is the limited resolution of SPECT imaging. With the current spatial 
resolution, no reliable distinction can be made between cerebrospinal fluid and 
contiguous brain tissue. Thus, the partial volume effect described for PET studies, 12•13 
can not be excluded as a confounding factor artificially reducing rCBF values for the 
method employed in our studies, in spite of the rigorously defined criteria for the 
outer borders of the regions of interest. Future technological advances and high 
resolution SPECT cameras may help to resolve this issue. In addition, quantification 
of rCBF measurements with SPECT may provide opportunities for more accurate 
assessment of rCBF. 
SPECT in the diagnosis of Alzheimer's disease 
Several encouraging reports were published in recent years that rCBF might be 
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used as a diagnostic marker for Alzheimer's disease.14·16 In particular, hypoperfusion 
in the parietal or temporo-parietal cortex has been suggested as a reliable 
discriminator between Alzheimer patients and normal aging. Four issues complicate 
the interpretation of results from previous SPECT studies: the composition of the 
control group, the severity of dementia, the interpretation of diagnostic characteristics, 
and finally, the methods used for the construction of regions of interest. Each of these 
issues may have a different and sometimes opposite effects on the discriminative 
ability of rCBF between patients and controls. First, our results suggest that use of 
controls from the general population may lower the etiologic contrast between 
Alzheimer patients and control subjects compared to previous reports, resulting in 
lower sensitivity and specificity (chapter 3.2). Previous studies thus tend to 
overestimate the contrast between groups. Second, we found a strong relationship of 
dementia severity and diagnostic performance, shown in receiver-operator-
characteristic curves (chapter 32). The higher figures of sensitivity and specificity 
reported in previous studies compared to our findings may be explained by the use of 
more severe patients in some of these studies. Third, some principles of test 
interpretation were neglected in previous studies. The essence was summarized in an 
article from 1980 on this subject by Griner et al.17 "Knowledge of test characteristics 
does not, per se, permit accurate interpretation of the test result. Such knowledge 
tells us only what proportion of patients with and without the disease in question will 
have a positive and negative result, respectively. Since the task of the clinician is to 
determine the presence or absence of the disease, the questions he or she must 
address are as follows: 1) Given a positive test, what is the probability that the 
disease is present? 2) Given a negative test, what is the probability that the disease is 
not present? ... The estimation of these post-test probabilities requires the integration 
of knowledge concerning test characteristics with the clinician's estimate of the 
likelihood of disease before the ordering of the test (prior probability or pretest 
probability)". Thus, integration of pre-test probability, dependent on the clinician, and 
post-test probability, dependent on the sensitivity and specificity of the test, is an 
essential step. Indeed, post-test probability is intimately dependent on and varies with 
the pre-test probability. Based on these guidelines, the results from our study 
suggested that the diagnostic value of SPECT in Alzheimer's disease is limited for 
patients with mild Alzheimer's disease: only in patients where considerable doubt 
exists about the diagnosis, with specificity set at 90%, clinically relevant diagnostic 
ruling-in gain can be expected (chapter 3.2). Fourth, the method of rectangular 
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regions of interest used in various studies may not be optimal for the discrimination 
of Alzheimer patients and control subjects, at least for patients with severe 
Alzheimer's disease. Especially longitudinal SPECT studies of Alzheimer's disease in 
search of predictors for decline in rCBF using rectangular regions of interest may 
tend to underestimate the difference between patients and controls. 
Determinants of cerebral blood flow 
Cerebral blood flow is subject to changes in local neuronal metabolic requirements 
and adequate blood supply can be maintained under circumstances of hypotension 
and hypoxemia. Autoregulation is one of the mechanisms that enable the adequate 
maintenance of cerebral perfusion through rapid adjustments of cerebrovascular 
resistance in response to alterations in arterial perfusion pressure. Factors 
determining blood viscosity are also important for rCBF, including hematocrit and 
platelet aggregation. In addition, increasing age has been related to decreased rCBF 
in most studies. The relation of vascular risk factors and the occurrence of 
cerebrovascular disease such as stroke has fuelled interest in the study of these risk 
factors as determinants of rCBF. One approach to study this relation is the 
comparison of individuals with and without vascular risk factors for differences -in 
rCBF, and several reports indicate compromised rCBF in the former group. Another 
possibility is the investigation of individual determinants of rCBF and the examination 
of their interdependence with multivariate regression analysis. Hypertension, blood 
viscosity, and smoking have been suggested as independent contributors to rCBF in 
most studies employing with the 133Xenon inhalation technique. Not all studies have 
examined the regional distribution of these putative relationships for individual risk 
factors. The Rotterdam Elderly Study provided an opportunity to study various 
vascular risk factors in relation to rCBF with 99mTc HM-PAO SPECT in a sample 
from the population. The study of individuals from the population has the advantage 
that a broad range of these risk factors is represented. We extended previous 
concepts of the contribution of age to rCBF. However, the relation of age and rCBF 
was explained for the major part by the presence of both vascular risk factors and 
indicators of atherosclerosis. It is tempting to speculate that age by itself from the 6th 
to 8th decade of life is associated with only minor changes in rCBF and that extrinsic 
factors related to the aging process, but not aging as a factor per se,18 are responsible 
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for the observed decline in rCBF. In addition, we identified high fibrinogen levels and 
intima-media wall thickness of the carotid artery as determinants for low parietal 
rCBF. Furthermore, low diastolic blood pressure seems to be associated with low 
temporo-parietal rCBF. Although these results would suggest that both thrombogenic 
and atherogenic mechanisms contribute to rCBF, not all relationships examined were 
in the same direction or were consistent with these concepts. The relatively low 
number of subjects could have played a role. In addition, it remains difficult to 
explain why the parietal rCBF would be most susceptible for alterations in 
thrombogenic and atherogenic status. Especially watershed areas in the parieto-
occipital region, which is the furthest from the origins of the anterior, middle, and 
posterior cerebral arteries, may be most susceptible to decreases in rCBF, 19 providing 
a possible explanation. A technical limitation is that regions of interest with reference 
to anatomical borders of the cerebral cortex, may not be optimal for detection of 
changes in the watershed areas. 
Treatment strategies for Alzheimer's disease 
Methodological considerations 
In the conduct of clinical trials in Alzheimer's disease a host of methodological 
issues need careful attention. One of the important factors is the diagnostic screening 
of potential patients. Alzheimer's disease is most commonly diagnosed through the 
application of either the DSM-ill criteria or the NINCDS-ADRDA criteria. As 
already mentioned, diagnostic accuracy of these criteria is imperfect, since no 
biological marker of disease exists at present. This poses a validity problem to trials 
because the inclusion of patients with another diagnosis dilutes the clinical effect and 
may lead to underestimation of the drug effect. Further, the selection of appropriate 
outcome measures is a controversial issue (chapter ·4). There is a need for 
standardization of tests since little agreement exists on what tests should be included 
in a drug efficacy evaluation. An important stride in this direction was taken with the 
introduction of the Alzheimer's Disease Assessment Scale (ADAS).20 Other aspects 
that need to be considered in the choice of outcome measures include length and 
complexity of the testbattery, floor and ceiling effects, and response variability in 
demented patients.21 Recently, it was suggested that neuropsychological outcome 
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measures should concentrate on domains known to be affected by a particular 
compound, called the "testing toward the deficit" concept by the authors.22 In addition, 
multiple test forms should be available to permit repeated administration of the tests. 
Even with multiple test forms there is the potential problem of learning effects that 
may act as period effects and affect the measurement precision of study results. In 
this thesis, significant learning effects with repeated test administration in several 
cognitive domains were found in control subjects but not in the Alzheimer patients as 
a group (chapter 5.1). More careful statistical analysis showed that improvement with 
repetition also may play a role in patients with mild Alzheimer's disease and it is 
suggested that mental status plays an important role in the acquisition of material and 
the ability to increase performance (chapter 5.1). Efficacy evaluations in controls and 
patients with mild Alzheimer's disease, should be aware of the possible confounding 
role of learning effects. The issue of learning effects is most important in the cross-
over trial, whereas in the parallel trial desigo the period effect will be similar in both 
treatment arms and is not a statistical threat to the analysis. This is one of the 
reasons why generally the parallel desigo is preferred over the cross-over desigo. 
Especially for Alzheimer's disease this may be important since this disease is 
characterized by a gradual progression of symptoms. Although the cross-over study is 
attractive for its need of fewer subjects, carry-over effects and period-effects may 
confound the outcome measurements. It is possible to test for these confounding 
effects but most cross-over studies include too few subjects to generate enough power 
to perform these tests. Too few studies pay attention to these problems, which is 
demonstrated for example by the criticism on several of the recent tacrine trials 
(chapter 4). One of the issues raised is that some studies do not employ dose-finding 
for the individual patient, in spite of evidence of response variability in preclinical 
and clinical studies. 
Preclinical models 
The development of appropriate animal models for Alzheimer's disease and related 
disorders is important for the preclinical evaluation of potential therapeutic drugs. 
Current models include normal animals such as rodents, experimentally induced 
deficits in normal and aged animals, and aged nonhuman primates, but no animal 
model is yet universally accepted. There is a striking discrepancy between the clinical 
predictive ability of these models and results of clinical trials in humans, as shown in 
chapter 4. Sarter reviewed several of the invalidities associated with the current 
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models.23 The first problem refers to the limited construct validity of these models: 
they do not reflect etiological or theoretical assumptions about the disease. Second, 
the face validity of current animal models is limited. The underlying cognitive 
functions of various behavioral changes remain unknown. For example, response 
latency in the passive avoidance task has been widely used as an outcome measure in 
the search for cognition enhancing agents, while the cognitive correlates, and thus the 
face validity of this task, has been questioned. The neuropsychological processes that 
are related to pharmacological modulation of neuronal mechanisms require further 
study. The predictive ability of an animal model will be dependent on both construct 
and face validity. With regard to construct validity, recently several studies reported 
transgenic mice models expressing an extra amyloid gene."'"26 The development of 
these models is based on the hypothesis that in Alzheimer's disease accumulation of 
)3-amyloid is responsible for the degenerative neuropathology, but it remains to be 
established whether deposition of )3-amyloid is the cause or the consequence of 
neuronal death. In the meantime, 2 of these papers have been retracted while the 3rd 
model is not appropriate for testing drugs at this stage. 
Enhancement of metabolic function 
Nootropics are psychotropic drugs with unknown mechanism of action and have a 
characteristic inverted U-shaped dose-response curve. In this thesis we tested the 
hypothesis that employment of dose-finding over a broad range of doses and exclusion 
of patients for the replication phase not demonstrating a best-dose, could maximize 
the possibility of demonstrating an antidementia effect of pramiracetam (chapter 5.2). 
Despite these efforts, no improvement in cognitive function, mood, or functions of 
activities of daily living was observed in this study. These findings confirmed results 
from previous studies with piracetam and other nootropics. One of the explanations 
for the general failure of nootropics to alleviate symptoms of Alzheimer's disease is 
that current animal models are not valid predictors for therapeutic efficacy. Indeed, 
the rationale for pramiracetam administration in our study as well as the 
improvements in study design were entirely based on these preclinical models. 
Nevertheless, a PET study demonstrated an increase in regional glucose metabolism 
after piracetam treatment of Alzheimer patients in high doses.27 The effect of 
nootropics is probably aspecific and may not result in improvement of cognitive 
functions. Based on the results of our study and similar studies with related 
nootropics, it may no longer be tenable to select pharmaceuticals solely on the basis 
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of preclinical models. 
Neurotransmitter modulation 
In analogy with the successful treatment of Parkinson's disease with 
dopaminomimetic agents, several hypotheses were generated about the treatment of 
Alzheimer's disease with neurotransmitter replacement. The cholinergic hypothesis 
has perhaps attracted most attention, since it was based on the presence of a well 
documented cholinergic deficit in Alzheimer's disease that showed an association with 
dementia severity and neuropathologic findings. Various other neurotransmitters and 
several neuropeptides have been shown deficient in Alzheimer's disease and 
numerous trials were conducted based on the replacement strategy. However, no 
consistent clinical benefit for Alzheimer patients was observed. For this reason, the 
cholinergic hypothesis, although still attractive, has been questioned. Two recent 
multi-center clinical trials with tacrine show positive effects on cognitive function,28,29 
while one of these studies also showed improvement in clinician-rated and caregiver-
rated observations." At present, it may be concluded that "from a scientific point of 
view, the very modest effects of short-term tacrine administration indicate that 
enhancement of acetylcholine transmission is inadequate to reverse the signs and 
symptoms of Alzheimer's disease".30 
In this thesis, lisuride treatment in low doses of Alzheimer's disease is based on the 
hypothesis that inhibition of serotonergic neurotransmission in preclinical models 
helps improve memory function (chapter 5.3). Lisuride binds to various subtypes of 
serotonergic receptors, with highest affinity for the 5HT-la receptor. The cognitive 
corollaries of serotonergic mechanisms in Alzheimer's remain poorly understood, and 
conflicting results have been reported in clinical trials. The design employed in this 
study was with parallel groups receiving either lisuride or placebo, with dose-finding 
over four doses to a maximum dose of 0.3 mg/day. The best-dose was defined as the 
optimal score on a clinical rating scale. Outcome measures included cognitive as well 
as non-cognitive functions, and global clinical impression. Although a statistically 
significant benefit was observed in a verbal learning task for lisuride treated patients 
as compared to the placebo group, the study showed no consistent improvement in 
cognitive or affective functions as well as in global clinical impression, confirming 
similar results in previous studies. 
Several explanations may be considered for the limited success of lisuride 
treatment and of neurotransmitter specific therapy in general. The neurotransmitter 
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abnormalities and receptor alterations in Alzheimer's disease remain poorly 
understood. Moreover, their relation to specific neuropsychological functions is not 
clear. In addition, Alzheimer's disease is a multisystem disorder suggesting that 
treatment based on replacement of a single neurotransmitter will not be of major 
benefit. Therapeutic Alzheimer trials are further complicated by the inaccuracy of the 
clinical diagnosis and the heterogeneity of the disease. Variability and the existence of 
various subtypes has been suggested on clinical grounds, in neuropathological studies, 
and for neurochemical findings. Furthermore, linkage studies show that several 
different mutations may be responsible for the development of Alzheimer's disease,31 
and a genetic linkage study recently showed evidence for a familial Alzheimer's 
disease locus on chromosome 14.32 Therefore, it becomes more likely that the 
possibility of demonstrating a drug effect may be impossible when all patients 
fulfilling the clinical diagnosis of Alzheimer's disease are included in a therapeutic 
trial. Another problem is that some drugs tested to date are aspecific in their 
pharmacologic mechanism. For example, cholinergic stimulation of subtypes of 
cholinergic receptors, including the postsynaptic excitatory Ml receptors and the 
inhibitory presynaptic M2 receptors, may yield a diminished net drug effect." Lisuride 
may also stimulate several subtypes of serotonergic receptors while the functional 
importance of these receptors remains to be solved (chapter 5.3). Finally, several 
other factors contribute to the therapeutic failure of neurotransmitter replacement. 
These include the current insufficient animal models to predict clinical efficacy, the 
use of inadequate experimental designs in some studies, and the assurance to attain 
central pharmacologic drug activity. In future studies, it will be important to find 
factors that characterize potential responders for drug treatment in an early phase of 
the disease. The visualization of neurotransmitter receptors with neuroimaging might 
contribute to identifying these patients. 
Future research 
Several of the designs employed in studies reported in this thesis are. descriptive 
cross-sectional. Notwithstanding the advantages of these study designs, one of the 
major disadvantages of these studies is that only prevalent cases are studied and that 
the interpretations of etiologic mechanisms remain speculative. This is most evident 
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in the SPECT study of the relation of vascular risk factors, indicators of 
atherosclerosis and rCBF. To gain further insight in the development of vascular risk 
factors and determinants of atherosclerotic vessel disease and rCBF, epidemiologic 
longitudinal population-based studies are needed. In addition, dementia severity, 
identified as an important variable for the interpretation of the results of both SPECT 
studies of the diagnostic value of SPECT in Alzheimer's disease and the study of 
regions of interest, was investigated in a cross-sectional sample of subjects recruited 
from a population based study. Longitudinal studies of the follow-up type could add 
to our current knowledge by attenuating the effect of selective survival that may 
confound cross-sectional studies. Furthermore, future follow-up studies are needed to 
determine the predictive value of low temporo-parietal rCBF for Alzheimer's disease 
in cognitively normal elderly individuals from the population. It became evident from 
the studies in this thesis that careful attention should be payed to the selection 
procedures employed for both Alzheimer patients and control subjects, and that the 
methods used to analyze tomographic SPECT scans may have important 
consequences for the results and thus for the subsequent interpretation of the study 
findings. 
Another important issue is the search for a biological marker, which is one of the 
primary goals of current Alzheimer's disease research. Although recent evidence has 
shown that mutations in the amyloid precursor gene may be responsible for some 
cases of familial Alzheimer's disease, the biological characterization of the disease 
would greatly facilitate the conduct of clinical studies of Alzheimer's disease. 
The development of therapeutic strategies for the intercession in pathogenetic 
mechanisms is needed in addition to the search for a palliative treatment. Knowledge 
about the etiologic mechanisms that are responsible for the degenerative neuronal 
degeneration in Alzheimer's disease may yield clues for selective intervention that 
may retard the progression of the disease or even restore neuronal function. Several 
hypotheses about the cause of neuronal death have emerged in recent years, largely 
based on research at the preclinical level. The formation of amyloid depositions as a 
central event in the pathogenesis of Alzheimer's disease is gaining increased attention 
and may provide a site for therapeutic intervention. Recent advances include the 
discovery of a mutation in the )3-amyloid precursor locus in several families, and the 
demonstration of a modified tau protein that exclusively correlates with a fraction 
containing only paired helical filaments. Other mechanisms suggested to play a role in 
the neuronal degeneration of Alzheimer's disease are excitotoxic effects of excitatory 
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amino acids, oxidative stress possibly mediated by the enzyme monoamine oxidase-B, 
and the lack of neuronal growth factors. 
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The diagnosis of Alzheimer's disease1 the most common dementing disorder, is 
uncertain and no satisfactory treatment is available (chapter 1). This thesis deals with 
single photon emission computed tomography (SPECT) with technetium-99M labeled 
hexamethyl-propylene amine oxime (99mTc HM-PAO), an imaging technique to assess 
regional cerebral blood flow (rCBF) that has been suggested as a diagnostic aid for 
the clinical diagnosis of Alzheimer's disease (chapter 2). This suggestion was based on 
studies that showed distinctive rCBF decrements in cerebral cortex of patients who 
were diagnosed as having Alzheimer's disease compared to age-matched healthy 
control subjects. 
Studies of methods used for the definition of regions of interest (ROI's) with 
SPECT are presented in chapter 3.1. In 60 control subjects and 48 patients with 
probable Alzheimer's disease, the difference was evaluated between ROI's with 
reference to normal anatomy using a single-slice and multi-slice method, and a 
geometrically shaped ROI. No differences were observed for the rCBF means 
between the single-slice and multi-slice method. The discriminative ability for controls 
and Alzheimer patients, evaluated with multivariate logistic regression and receiver-
operator-characteristic curves, was similar across methods for mild Alzheimer 
patients. However, with increasing dementia severity the geometric ROT method 
showed lower performance compared to both anatomically defined methods. These 
results suggest that analysis of one slice would suffice in these study populations and 
that the choice of an ROI method is dependent on the purpose for which SPECT is 
used. 
In chapter 3.2, the diagnostic accuracy of SPECT was studied in 48 patients with 
probable Alzheimer's disease and 60 controls recruited from a population-based 
study. Receiver-operator-characteristic curves showed that the discriminative ability of 
SPECT improved with increasing dementia severity. With specificity set at 90%, 
sensitivity figures were 42% in mild, 56% in moderate and 79% in severe Alzheimer's 
disease. Diagnostic gain for mild Alzheimer patients was substantial (maximum 34%) 
for a positive test result, when the prior probability varied around 50%, but poor for 
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a negative test result. The findings suggest that the practical usefulness of SPECT as a 
diagnostic adjunct in patients suspected of mild Alzheimer's disease is confined to the 
situation when, on clinical grounds, considerable doubt exists about the diagnosis. 
Chapter 3.3 addresses the association of various risk factors for atherosclerotic 
vessel disease and rCBF in a cross-sectional study. Sixty-six persons, aged 63 to 89 
years, were recruited from the general population and studied with SPECT. 
Increasing age was significantly associated with a decrease in parietal, temporo-
parietal and temporal rCBF, and the association approached significance for frontal 
rCBF. However, these relations appeared to be dependent on the presence of both 
vascular risk factors and indicators of atherosclerosis. Levels of plasma fibrinogen 
were independently and inversely associated with parietal rCBF, which appeared 
attributable to a threshold effect of high fibrinogen levels. Intima-media wall 
thickness of the carotid artery was also significantly and inversely related to parietal 
rCBF, but this association was no longer significant when subjects with a previous 
history of stroke were excluded. A threshold effect was observed for the relation of 
low diastolic blood pressure and low temporo-parietal rCBF. These findings suggest 
that the observed age-related decline in rCBF from the sixth to eighth decade of life 
is dependent on the presence of both vascular risk factors and atherosclerosis. In 
addition, low parietal rCBF may be related to both thrombogenic and atherogenic 
mechanisms, and low temporo-parietal rCBF may be associated with low diastolic 
blood pressure. 
The development of effective treatment strategies for Alzheimer's disease is one of 
the major goals of dementia research. Attempts for symptomatic treatment with 
neurotransmitter substitution or metabolic stimulation have yielded disappointing 
results so far (chapter 4). Methodological issues related to trial design, dose-titration 
and choice of adequate outcome measures are important for the interpretation of 
trial results. Future interventions that retard or halt the progression of the disease 
may be based on new insights from various mechanisms that are now suggested to 
play a role in the neuronal degeneration in Alzheimer's disease, including amyloid 
metabolism, excitatory amino acids, growth factors, and oxidative stress (chapter 4). 
The possible confounding role of learning effects during multiple test 
administration in clinical trials was evaluated in 17 mildly to severely affected patients 
with Alzheimer's disease and 16 controls (chapter 5.1). Mean scores of Alzheimer 
patients showed no stable improvement, but more subtle learning effects were 
suggested by an association of dementia severity and change scores in verbal and 
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visual learning. Controls evidenced learning in 3 of 9 tests. It is suggested that the 
degree of cognitive impairment may be related to learning capacity, which implies 
caution for learning effects in controls and possibly in patients with mild Alzheimer's 
disease. 
The antidementia efficacy of the nootropic compound pramiracetam was evaluated 
in 10 patients with probable Alzheimer's disease (chapter 5.2). A 2-phase placebo-
controlled enrichment-type design was employed, based on the characteristic inverted 
U-shaped dose-response curve of pramiracetam in preclinical models of learning and 
memory. Eight patients evidenced a best dose (defined as the largest ADAS scale 
reduction of at least 4 points) in the dose-finding, but in the subsequent replication 
phase only two again improved to a similar degree. Studies with positron emission 
tomography in two patients showed no definite change. It is therefore unlikely that 
pramiracetam in doses up to 4,000 mg confers symptomatic benefit to Alzheimer 
patients. 
The hypothesis that inhibition of serotonergic neurotransmission with lisuride in 
low doses may have a positive effect on symptoms of Alzheimer's disease, based on 
its high affinity for the 5-HT, receptor, was tested in chapter 5.3. Sixteen patients 
with probable Alzheimer's disease were included in a trial with a double-blind 
parallel group trial design with dose-finding of lisuride in doses up to 0.3 mgjday. 
Outcome measures included global clinical impression, as well as several measures of 
cognitive and non-cognitive function. Statistically significant improvement occurred in 
a task of verbal memory in patients treated with lisuride compared to those with 
placebo, but no consistent differences between groups emerged from this preliminary 
study. Indeed, the global clinical impression was in agreement with a general lack of 
clinical effect of lisuride. Therefore, modulation of serotonergic activity with lisuride 
in Alzheimer's disease is not likely to confer clinically demonstrable benefit to these 
patients. 
In chapter 6 methodological aspects of the studies presented in this thesis, as well 
as the interpretation of results and their implications are discussed from an 
epidemiologic point of view. In addition, the findings of these studies are discussed 
withio the broad framework of current research of SPECT in degenerative dementia 
and therapeutic strategies of Alzheimer's disease, and directions for future research 
studies are suggested. 
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De klinische diagnose van de ziekte van Alzheimer, de me est voorkomende vorm 
van dementie, kan op dit moment niet met zekerheid worden gesteld. Ook is er geen 
afdoende therapie beschikbaar (hoofdstuk 1). Single photon emission computed 
tomography (SPECf) met technetium-99M gemerkt hexamethyl-propylene amine 
oxime (99mTc HM-PAO) is een beeldvormende techniek voor het meten van regionale 
cerebrale perfusie (rCBF) en SPECT is gesuggereerd als diagnostisch hulpmiddel 
voor het stellen van de klinische diagnose van de ziekte van Alzheimer (hoofdstuk 2). 
Dit is gebaseerd op vermindering van rCBF bij patienten met "probable Alzheimer's 
disease" volgens de NINCDS-ADRDA criteria, in vergelijking met gezonde controle 
personen van dezelfde leeftijd. 
Methoden die gebruikt worden voor het definieren van "regions of interest" (ROI's) 
werden bestudeerd in hoofdstuk 3.1. Het verschil werd nagegaan tussen ROI's 
gebaseerd op de normale anatomie met een of meerdere tomografische coupes, en 
een geometrische ROI, bij 60 controle personen en 48 patienten met de ziekte van 
Alzheimer (hoofdstuk 3.1 ). Er werden geen verschillen gevonden tussen de methode 
waarin meerdere coupes werden geanalyseerd en de methode met een coupe. Het 
onderscheidend vermogen tussen controle personen en patienten met de ziekte van 
Alzheimer, onderzocht met multivariate logistische regressie en receiver-operator-
characteristic curves, toonde geen verschillen tussen de 3 methoden voor vroege 
Alzheimer patienten. Met toenemende ernst van de dementie was bet onderscheidend 
vermogen van de geometrische ROI methode echter lager in vergelijking met beide 
anatomisch gedefinieerde methoden. De resultaten geven aan dat analyse van een 
coupe voldoende is bij deze onderzoeksgroepen en dat de keuze van ROI methode 
afhangt van bet doe! waarvoor SPECT word! gebruikt. 
In hoofdstuk 3.2 is een onderzoek beschreven naar de diagnostische 
nauwkeurigheid van SPECT bij 48 patienten met de ziekte van Alzheimer en 60 
controle personen die werden gerecruteerd uit een bevolkingsonderzoek. Receiver-
operator-characteristic curves toonden dat het onderscheidend vermogen van SPECT 
verbeterde met toenemende ernst van de dementie. Bij een specificiteit van 90% was 
de sensitiviteit 42% voor vroege Alzheimer patienten, 56o/o voor matig ernstige en 
79% voor ernstige patienten. De diagnostische winst was aanzienlijk voor vroege 
Alzheimer patienten (maximaal 34%) bij een positieve testuitslag, indien de 
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voorafkans op ziekte varieerde rond de 50%; de diagnostische wins! was gering voor 
een negatieve testuitslag. Deze bevindingen maken aannemelijk dat het praktisch nut 
van SPECT als een diagnostisch hulpmiddel bij patienten verdacht voor de vroege 
ziekte van Alzheimer beperkt is tot de situatie waarin, gebaseerd op klinische 
gegevens, aanzienlijke twijfel bestaat omtrent de diagnose. 
In hoofdstuk 3.3 word! bet verband nagegaan tussen verscheidene risicofactoren 
voor atherosclerotische vaata:fwijkingen en rCBF in een cross-sectioneel onderzoek. 
Zes-en-zestig personen van 63 tot 89 jaar werden gerecruteerd voor SPECT 
onderzoek uit de algemene bevolking. Toenemende leeftijd was geassocieerd met een 
afname in parietale, temporo-parietale en temporale rCBF, terwijl het verband het 
niveau van significantie benaderde voor frontale rCBF. Deze relaties, echter, bleken 
grotendeels afhankelijk van het voorkomen van zowel vasculaire risicofactoren als 
indicatoren voor atherosclerose. Het niveau van plasma fibrinogeen was onafhankelijk 
en omgekeerd gerelateerd aan parietale rCBF. Dit kan mogelijk worden 
toegeschreven aan een drempeleffect van hoge fibrinogeen waarden. De intima-media 
wanddikte van de arteria carotis communis was eveneens omgekeerd gerelateerd aan 
parietale rCBF, maar deze associatie was niet statistisch significant wanneer personen 
met een cerebrovasculair accident werden uitgesloten. Een drempeleffect werd 
gevonden voor de relatie van !age diastolische bloeddruk en parietale rCBF. Deze 
bevindingen suggereren dat de geobserveerde rCBF daling van het zestigste tot 
negentigste levensjaar afhankelijk is van zowel het v66rkomen van vasculaire 
risicofactoren als van atherosclerose. Tevens is het mogelijk dat parietale rCBF wordt 
beinvloedt door zowel thrombogene als atherogene mechanismen, en dat !age 
temporo-parietale rCBF geassocieerd is met !age diastolische bloeddruk. 
De ontwikkeling van effectieve behandelingsstrategieen is een van de belangrijke 
doelstellingen van dementie onderzoek. Symptomatische behandeling via 
neurotransmitter substitutie of metabole stimulatie heeft tot op heden teleurstellende 
resultaten opgeleverd (hoofdstuk 4 ). Methodologische as pecten betreffende 
onderzoeksopzet, dosis-titratie, en keuze van adequate uitkomstmaten zijn belangrijk 
voor de interpretatie van trial resultaten. Toekomstige interventies die de progressie 
van de ziekte vertragen of tegengaan kunnen worden gebaseerd op nieuwe inzichten 
uit diverse mechanismen die mogelijk een rol spelen in de neuronale degeneratie van 
de ziekte van Alzheimer, zoals bet amyloid metabolisme, excitatoire aminozuren, 
groeifactoren en oxidatieve stress (hoofdstuk 4). 
De mogelijk verstorende rol die leereffecten bij herhaalde testafname kunnen 
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spelen in klinische trials werd onderzocht bij 17 vroege tot ernstige patienten met de 
ziekte van Alzheimer en 16 controle personen (hoofdstuk 5.1). De gemiddelde 
testscores van Alzheimer patienten vertoonden geen duidelijke verbetering, echter 
subtiele leereffecten werden gesuggereerd door de omgekeerde associatie van de 
ernst van de dementie en veranderingsscores van visueel en verbaal leren. Controle 
personen toonden leereffecten in 3 van de 9 testen. De resultaten suggereren dat de 
mate van cognitieve achteruitgang samenhangt met de leercapaciteit, hetgeen 
voorzichtigheid gebiedt voor leereffecten bij controle personen en mogelijk voor 
vroege Alzheimer patienten. 
Het effect van bet nootropicum pramiracetam werd onderzocht bij 10 patienten 
met de ziekte van Alzheimer (hoofdstuk 5.2). Er werd een twee-fasen 
onderzoeksopzet gebruikt met 11Verrijking11 , gebaseerd op de karakteristieke dosis-
respons curve in de vorm van een omgekeerde-U bij preklinische modellen voor leren 
en geheugen. Acht patienten hadden een "beste-dosis" (gedefinieerd als de grootste 
reductie op de ADAS schaal van tenminste 4 punten) bij dosis-titratie, echter in de 
navolgende replicatie fase verbeterden slechts 2 patienten in dezelfde mate. 
Onderzoek met positron emission tomography bij 2 patienten liet geen duidelijke 
veranderingen zien. Het is daarom onwaarschijnlijk dat pramiracetam in doseringen 
tot 4000 mg symptomatische verbetering geeft bij Alzheimer patienten. 
In hoofdstuk 5.3 werd de hypothese getest dat remming van serotonerge 
neurotransmissie met lisuride in !age doseringen een positief effect heeft op de 
symptomen van de ziekte van Alzheimer, gebaseerd op de hoge affiniteit van lisuride 
voor de 5-HT1a receptor. Zestien patienten met de ziekte van Alzheimer namen deel 
aan een trial met een dubbel-blinde parallelle opzet met dosis-titratie van lisuride in 
doseringen tot 0.3 mg/dag. Uitkomstmaten waren globale klinische impressie, 
alsmede enkele testen van cognitieve en non-cognitieve functies. Hoewel een 
significante verbetering optrad in een test van verbaal geheugen bij patienten 
behandeld met lisuride in vergelijking met de placebo groep, werden geen consistente 
verschillen tussen beide behandelingsgroepen gevonden in deze preliminaire studie. 
De globale klinische impressie was in overeenstemming met bet uitblijven van een 
klinisch effect van lisuride. Het is derhalve onwaarschijnlijk dat modulatie van 
serotonerge activiteit bij patienten met de ziekte van Alzheimer leidt tot klinische 
verbetering. 
Enkele methodologische aspecten alsmede de interpretatie van in dit proefschrift 
gepresenteerde onderzoeksresultaten, worden besproken vanuit een epidemiologisch 
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gezichtspunt in hoofdstuk 6. Tevens worden de resultaten van deze studies besproken 
in relatie tot het huidige en toekomstige SPECT onderzoek bij degeneratieve 
dementie en in relatie tot therapeutische strategieen bij de ziekte van Alzheimer. 
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